<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003449.pub4" GROUP_ID="FERTILREG" ID="966101011710090956" MERGED_FROM="" MODIFIED="2013-10-16 14:02:36 +0100" MODIFIED_BY="Anja Helmerhorst" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;/p&gt;&lt;p&gt;Old title: Treatment of vaginal bleeding irregularities induced by progestin only contraceptives&lt;/p&gt;" NOTES_MODIFIED="2013-10-16 15:00:24 +0200" NOTES_MODIFIED_BY="Anja Helmerhorst" REVIEW_NO="0011" REVMAN_SUB_VERSION="5.2.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2013-10-16 14:02:36 +0100" MODIFIED_BY="Anja Helmerhorst">
<TITLE MODIFIED="2011-01-13 10:44:50 +0100" MODIFIED_BY="[Empty name]">Treatment of vaginal bleeding irregularities induced by progestin only contraceptives</TITLE>
<CONTACT MODIFIED="2013-10-16 14:02:36 +0100" MODIFIED_BY="Anja Helmerhorst"><PERSON ID="13618" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Hany</FIRST_NAME><LAST_NAME>Abdel-Aleem</LAST_NAME><EMAIL_1>hany.abdelaleem@yahoo.com</EMAIL_1><EMAIL_2>haleem@aun.edu.eg</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology, Faculty of Medicine</DEPARTMENT><ORGANISATION>Assiut University Hospital</ORGANISATION><CITY>Assiut</CITY><ZIP>71511</ZIP><REGION>Assiut</REGION><COUNTRY CODE="EG">Egypt</COUNTRY><PHONE_1>+ 2088 2414672</PHONE_1><FAX_1>+2088 2373899</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-10-16 14:02:36 +0100" MODIFIED_BY="Anja Helmerhorst"><PERSON ID="13618" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Hany</FIRST_NAME><LAST_NAME>Abdel-Aleem</LAST_NAME><EMAIL_1>hany.abdelaleem@yahoo.com</EMAIL_1><EMAIL_2>haleem@aun.edu.eg</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology, Faculty of Medicine</DEPARTMENT><ORGANISATION>Assiut University Hospital</ORGANISATION><CITY>Assiut</CITY><ZIP>71511</ZIP><REGION>Assiut</REGION><COUNTRY CODE="EG">Egypt</COUNTRY><PHONE_1>+ 2088 2414672</PHONE_1><FAX_1>+2088 2373899</FAX_1></ADDRESS></PERSON><PERSON ID="13627" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Catherine</FIRST_NAME><LAST_NAME>d'Arcangues</LAST_NAME><POSITION>Independent Consultant</POSITION><EMAIL_1>darcangues@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Own Consultancy</ORGANISATION><CITY>Prevessin-Moens</CITY><COUNTRY CODE="FR">France</COUNTRY></ADDRESS></PERSON><PERSON ID="13667" ROLE="AUTHOR"><PREFIX>Dr.</PREFIX><FIRST_NAME>Kirsten</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Vogelsong</LAST_NAME><EMAIL_1>kirsten.vogelsong@gatesfoundation.org</EMAIL_1><ADDRESS><ORGANISATION>Bill and Melinda Gates Foundation</ORGANISATION><CITY>Seattle</CITY><REGION>Washington</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="47383698969855052584100929161910" ROLE="AUTHOR"><FIRST_NAME>Mary Lyn</FIRST_NAME><LAST_NAME>Gaffield</LAST_NAME><POSITION>Scientist</POSITION><EMAIL_1>gaffieldm@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>Avenue Appia 20</ADDRESS_1><CITY>Geneva 27</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 7911806</PHONE_1></ADDRESS></PERSON><PERSON ID="15905" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A Metin</FIRST_NAME><LAST_NAME>Gülmezoglu</LAST_NAME><POSITION>Scientist</POSITION><EMAIL_1>gulmezoglum@who.int</EMAIL_1><URL>http://www.who.int/reproductive-health/rhl/index.html</URL><ADDRESS><DEPARTMENT>UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 7913417</PHONE_1><FAX_1>+41 22 7914171</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-10-16 14:58:33 +0200" MODIFIED_BY="Anja Helmerhorst">
<UP_TO_DATE>
<DATE DAY="15" MONTH="5" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="5" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="4" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-10-16 15:00:24 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This update includes:&lt;/p&gt;&lt;p&gt;1. Women using LNG-IUS&lt;/p&gt;&lt;p&gt;2. Women using Jadelle&lt;/p&gt;&lt;p&gt;3. Jadelle users combined with Norplant users in comparisons&lt;/p&gt;&lt;p&gt;4. New treatment: Antiprogestin + MMPI (doxy)&lt;/p&gt;&lt;p&gt;5. New treatment: EE + MMPI (doxy)&lt;/p&gt;&lt;p&gt;6. new treatment Vitamin C&lt;/p&gt;&lt;p&gt;7. New estrogen treatment modality.delivery system: vag ring&lt;/p&gt;&lt;p&gt;8. new treatment tranexamic acid&lt;/p&gt;" NOTES_MODIFIED="2013-10-16 15:00:24 +0200" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-10-16 15:00:24 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>This update includes:</P>
<P>1. Women using LNG-IUS</P>
<P>2. Women using Jadelle</P>
<P>3. Jadelle users combined with Norplant users in comparisons</P>
<P>4. New treatment: Antiprogestin + MMPI (doxy)</P>
<P>5. New treatment: EE + MMPI (doxy)</P>
<P>6. new treatment Vitamin C</P>
<P>7. New estrogen treatment modality.delivery system: vag ring</P>
<P>8. new treatment tranexamic acid</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-10-16 14:58:37 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-10-16 14:58:37 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="28" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Obstetrics and Gynecology, Assiut University Hospital, Assiut</NAME>
<COUNTRY CODE="EG">Egypt</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>HRP-UNDP/UNFPA/WHO/World Bank Special Programme in Human Reproduction, Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-04-22 16:00:37 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-02-06 13:44:06 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Evaluation of treatments for vaginal bleeding induced by progestin-only contraceptives</TITLE>
<SUMMARY_BODY MODIFIED="2013-02-06 13:44:06 +0100" MODIFIED_BY="[Empty name]">
<P>As the use of progestin-only methods of contraception continues to increase worldwide, the problem of vaginal bleeding disturbances these methods induce is becoming of increasing public health relevance.Since this adverse effect limits method's acceptability, and leads to loss of compliance. Some women may benefit to some degree from some interventions tested. However the evidence reviewed is not strong enough to recommend routine use of any of the regimens included in the trials, particularly for long-term effects. Positive results need to be reproduced in larger scale trials.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-03-12 14:38:30 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Despite their high effectiveness, progestin-only contraceptives are considered less than ideal by the many women who experience irregular vaginal bleeding when using them. Current treatments to control these bleeding problems are not sufficiently effective.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>We evaluated preventive and therapeutic approaches to normalise bleeding irregularities associated with the use of progestin-only contraceptives.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-02-06 13:39:25 +0100" MODIFIED_BY="[Empty name]">
<P>Literature was identified through database searches, reference lists, organisations and individuals, covering the period until May-June 2012.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-03-12 14:38:30 +0100" MODIFIED_BY="[Empty name]">
<P>Trials with random or systematic allocation, testing interventions for the prevention or treatment of bleeding irregularities associated with the use of progestin-only contraceptives were eligible.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Results are expressed as relative risks (RR) with 95% confidence interval (CI) for categorical data and as weighted mean difference (WMD) with 95% CI for continuous data. When we encountered heterogeneity (visual or statistical) we used the random-effects model (quantitative) or did not produce a summary estimate (qualitative).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-02-08 08:45:04 +0100" MODIFIED_BY="[Empty name]">
<P>Thirty-three randomised controlled trials enrolling 3677 participants were included. Two thirds of the trials were determined to reflect low to moderate risk of bias.</P>
<P>Estrogen treatments reduced the number of days of an ongoing bleeding episode in DMPA and Norplant users. However, treatment frequently led to more discontinuation due to gastrointestinal upset.</P>
<P>Combinations of oral ethinyl estradiol and levonorgestrel improved bleeding patterns in Norplant users, but method discontinuation rates were unchanged. One trial reported successful use of combined oral contraceptives in treating amenorrhea among DMPA users.</P>
<P>Norplant users, but not Implanon users, administered the anti-progestin mifepristone reported fewer days of bleeding during treatment than those given placebo. Mifepristone used monthly by new Norplant acceptors reduced bleeding, when compared to placebo.</P>
<P>A variety of NSAIDS have been evaluated for their ability to treat abnormal bleeding, with mixed results.</P>
<P>Norplant users receiving SERM (tamoxifen) had less unacceptable bleeding after treatment and were more likely to continue using Norplant than those receiving placebo.</P>
<P>Tranexamic acid, mifepristone combined with an estrogen and doxycycline were more effective than placebo in terminating an episode of bleeding in women using progestin-only contraceptives, according to three small studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Some women may benefit from the interventions described, particularly with cessation of current bleeding. Several regimens offer promise in regulating bleeding, but findings need to be reproduced in larger trials. The results of this review do not support routine clinical use of any of the regimens included in the trials, particularly for long-term effect.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-04-22 16:00:37 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-03-14 17:42:27 +0100" MODIFIED_BY="[Empty name]">
<P>Description of the condition</P>
<P>Over the past 30 years, the number of users of progestin-only methods of contraception has been increasing steadily worldwide and is estimated to be over 20 million. The method most widely used is the injectable depot medroxy-progesterone acetate (DMPA), first registered in the late 1960s in some countries. Its approval for contraceptive use by the United States Food and Drug Administration in 1992 increased access to the method worldwide, through new registrations; approximately 13 million women worldwide use DMPA for contraception. The other progestin-only injectable contraceptive currently available, norethisterone enanthate, is estimated to be used by fewer than one million women.</P>
<P>Additional progestin-only contraceptive methods are based on several delivery systems: subcutaneous implants, intra-uterine systems, vaginal rings and oral preparations. Five implant systems are available to family planning programmes; the most widely-used of these was the six capsule levonorgestrel-releasing implantable system, Norplant. This method was introduced in 1983, and has been used by approximately six million women; post-registration studies have demonstrated that the method is highly effective over a period of seven years. Its manufacture was discontinued in 2002.The two-rod levonorgestrel-releasing implantable system, Jadelle, is effective for five years and was first registered for this length of use in the year 2000. Two generic products, designed to imitate the performance of these two implants, are made in China and are known as Sino-implant (I) and (II), respectively. A single-implant system that has been available since 1997, Implanon releases etonogestrel and is effective for a period of 3 years and is used by approximately six million women worldwide. The levonorgestrel-releasing intra-uterine system, Mirena, has been available since 1990 and is currently used by around ten million women worldwide. The progesterone-releasing vaginal ring, Progering, designed for use by breast feeding women, has been available in limited markets since the late 1990s. Use of progestin-only oral preparations remains limited, despite being appropriate for lactating women and others who do not tolerate estrogens. Other progestin-only methods are being developed, such as transdermal patches and new injectable, implantable and intra-uterine systems.</P>
<P>Progestin-only contraceptive methods are highly effective ,safe and the long-acting properties of several delivery systems facilitate their use. However, despite differences in their primary mechanisms of action, all induce major uterine bleeding disturbances in a significant number of users. Data from clinical trials demonstrate that, at one year of use, fewer than 10% of DMPA and Mirena users and only 25% of Norplant users experience regular monthly bleeding, while others experience a variety of patterns ranging from infrequent bleeding and amenorrhea to irregular, frequent or prolonged bleeding. These patterns are all classified as breakthrough bleeding and have been discussed in several publications (<LINK REF="REF-Newton-1994" TYPE="REFERENCE">Newton 1994</LINK>, <LINK REF="REF-Fan-1996" TYPE="REFERENCE">Fan 1996</LINK>, <LINK REF="REF-Suvisaari-1996" TYPE="REFERENCE">Suvisaari 1996</LINK>, <LINK REF="REF-Affandi-1998" TYPE="REFERENCE">Affandi 1998</LINK>, <LINK REF="REF-Fraser-1998" TYPE="REFERENCE">Fraser 1998</LINK>,). This side effect is the primary reason that women give for discontinuing use of these methods and accounts for 40-70% of termination from clinical trials (<LINK REF="REF-d_x0027_Arcangues-1992" TYPE="REFERENCE">d'Arcangues 1992</LINK>, <LINK REF="REF-Datey-1995" TYPE="REFERENCE">Datey 1995</LINK>,; <LINK REF="REF-Adeyemi-2012" TYPE="REFERENCE">Adeyemi 2012</LINK>). There seem to be great variations in the tolerance that women have for these disturbances. In a multicenter clinical trial of DMPA, for example, users in Egypt, Jamaica and Thailand reported similar rates of amenorrhea. In Egypt, 27% of women discontinued DMPA use for this reason, while none did so in Thailand or Jamaica (<LINK REF="REF-Said-1987" TYPE="REFERENCE">Said 1987</LINK>).</P>
<P>Individual women respond differently to the use of progestin-only methods. Bleeding effects may also vary according to the type of progestin and the dose. With Norplant use, prolonged and irregular breakthrough bleeding is usually at its worst during the first 12 months of use, becoming more regular thereafter. With DMPA, users also start by experiencing prolonged and irregular bleeding, but later on this pattern is replaced by increasing periods of amenorrhea. A reasonable clinical goal would be to provide an intervention to assist women in managing any irregularities in bleeding - thus continuing the use of their chosen contraceptive method - until the time when their bleeding becomes more regular or until they experience amenorrhea.</P>
<P>Description of the intervention</P>
<P>In the absence of complete understanding of the underlying mechanisms leading to vaginal bleeding irregularities, there are variations in clinical practice. In the early 1980s, a survey was conducted on the management of progestin-associated menstrual disturbances among physicians and organizations (<LINK REF="REF-Fraser-1983" TYPE="REFERENCE">Fraser 1983</LINK>). There were 35 responses from 20 countries, most reporting experience with DMPA, and three with additional experience with NET-EN. Fourteen years later, another survey (<LINK REF="REF-Nutley-1997" TYPE="REFERENCE">Nutley 1997</LINK>) was conducted among family planning providers and researchers on the treatment regimens they used for progestin-associated bleeding disturbances. Sixty four responses from 32 countries were received. The second survey collected information based on experience with injectable, implantable and oral progestin-only methods. Both surveys documented a wide variability of treatment regimens offered to women, ranging from estrogens, combined oral contraceptives, progestins, non-steroidal anti-inflammatory agents, to vitamins, iron and anxiolytic agents.</P>
<P>How the intervention might work</P>
<P>Because the exact etiology of vaginal bleeding irregularities associated/induced by progestin-only contraceptives is not completely elucidated, different interventions are targeting different possible mechanisms.For instance; estrogens may enhance those mechanisms that cause bleeding to cease, i.e. coagulation or tissue repair (<LINK REF="REF-Shaaban-1984" TYPE="REFERENCE">Shaaban 1984</LINK> and <LINK REF="REF-Viegas-1988" TYPE="REFERENCE">Viegas 1988</LINK>),the anti-progestin (mifepristone) may functionally inhibit progesterone, leading to up-regulation of endometrial estrogen receptors and a positive effect on bleeding patterns similar to exogenous estrogen treatment(<LINK REF="STD-Jain-2003" TYPE="STUDY">Jain 2003</LINK>), SERMs(tamoxifen) may improve bleeding patterns disrupted by the use of progestin-only contraceptives by antagonizing the angiogenic effect of estrogen (<LINK REF="REF-Grow-1998" TYPE="REFERENCE">Grow 1998</LINK>) and the antifibrinolytic agent(tranexamic acid) can reduce the amount of bleeding through slowing the process of dissolving the tiny clots that are formed as a result of bleeding (<LINK REF="REF-Lukes-2011" TYPE="REFERENCE">Lukes 2011</LINK>).</P>
<P>Why it is important to do this review</P>
<P>This wide variation in treatments given to women, and the uncertainty about the potential benefits or risks of individual treatments, highlight the importance of conducting a rigorous and comprehensive review of the different treatments for vaginal bleeding irregularities associated with progestin-only contraceptives.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The purpose of this review is to evaluate prophylaxis and treatment of bleeding irregularities associated with the use of progestin-only contraceptives.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-02-06 14:20:20 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-02-06 14:20:20 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Trials designed to test regimens to treat or prevent bleeding irregularities associated with the use of progestin-only contraceptive methods were considered for inclusion. Studies were required to use random or systematic (i.e. alternation) methods of allocation. Studies employing a cross-over design were not eligible for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women using progestin-only contraceptives were the participants of the studies included in this review. These comprise:</P>
<P>1. Women experiencing vaginal bleeding irregularities i.e. bleeding/spotting, irregular bleeding, prolonged bleeding, frequent bleeding or amenorrhoea. The trialists' definitions of these conditions were accepted.</P>
<P>2. Women not experiencing vaginal bleeding irregularities but accepting prophylactic treatment. These women would be likely to be enrolled as they start using the progestin-only contraceptive method.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-02-06 14:14:19 +0100" MODIFIED_BY="[Empty name]">
<P>Drugs used to prevent or treat bleeding irregularities in women using progestin-only contraceptives. These are likely to include:</P>
<P>1. Estrogens<BR/>2. Progestins<BR/>3. Combined oral contraceptives<BR/>4. Nonsteroidal anti-inflammatory drugs<BR/>5. Antioxidants<BR/>6. Antifibrinolytic agents<BR/>7. Antiprogestins/progesterone receptor modulators<BR/>8. Selective estrogen receptor modulators<BR/>9. Antiangiogenesis agents</P>
<P>10 Matrix metalloproteinase inhibitors</P>
<P>11. Others<BR/>12. Combinations of the above<BR/>
<BR/>The dose, duration and frequency of treatment and length of follow-up should be specified.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-02-06 14:20:20 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome of this review is the effectiveness of prophylactic or therapeutic interventions to prevent or treat bleeding irregularities, as defined by an improvement in irregular bleeding. Trials using objective or subjective methods for assessing bleeding were eligible.</P>
<P>Additional outcomes included:<BR/>1. Discontinuation of the contraceptive method<BR/>2. Discontinuation of the treatment<BR/> a. Discontinuation due to side-effects<BR/> b. Discontinuation due to lack of improvement<BR/>3. Any side-effect of treatment<BR/>4. Patient dissatisfaction with treatment<BR/>5. Blood loss during treatment</P>
<P>Outcome measures were assessed during treatment and/or at the end of treatment, to evaluate short-term effects, and at varying intervals following discontinuation of treatment, to evaluate long-term effectiveness, according to the study design.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-06 10:35:51 +0100" MODIFIED_BY="[Empty name]">
<P>The search included:</P>
<P>1. ELECTRONIC DATABASES</P>
<P>a. MEDLINE using OVID or SilverPlatter for the years 1966-2006; <B>
<I>searches were updated using Pubmed through May 2012.</I>
</B>
</P>
<P>b. EMBASE using OVID for the years 1980-2006; EMBASE through Elsevier for years 2006 &#8211; 2012.</P>
<P>The methodological search filter for high sensitivity in identifying randomised controlled trials in MEDLINE, parts I and II (11a.15 Appendix B, Cochrane Reviewers' Handbook 4.1, June 2000, p153) was added to the subject search strategy to identify reports of controlled trials in MEDLINE. This methodological search filter was adapted for use in searching EMBASE.</P>
<P>c. Popline was searched through<B>
<I> June 7, 2012</I>
</B>
</P>
<P>d. The Cochrane Central Register of Controlled Trials (CENTRAL), which includes controlled trials identified from electronic databases as well as hand searching of relevant journals.</P>
<P>e. LILACS ( Literatura Latino Americana e do Caribe em Ciências da Saúde) which covers Latin American and Caribbean literature in Spanish, Portugese and English was searched with the same search terms.</P>
<P>The drug classes and individual names for progestin-only contraceptives, including their proprietary names used in different countries where known, were combined with terms describing vaginal bleeding irregularities in order to identify treatment interventions.<BR/>
<BR/>The following subject search terms were combined:</P>
<P>#1 explode PROGESTATIONAL-HORMONES-SYNTHETIC<BR/>#2 explode PROGESTERONE<BR/>#3 explode CONTRACEPTIVES-ORAL-SYNTHETIC<BR/>#4 CONTRACEPTIVES-ORAL-HORMONAL<BR/>#5 PROGESTATIONAL-HORMONES<BR/>#6 gestagen<BR/>#7 progestogen only contracep* OR progestin only contracep*<BR/>#8 progesterone OR progestogen* OR norgestrienone OR norgestrel OR ogyline OR microlut OR microval OR mirena OR norplant OR levonova OR microluton OR follistrel OR neogest OR norgeston OR postinor-2 OR ovrette OR levonorgestrel OR norgestimate OR nomegestrol acetate OR norethisterone acetate OR norethisterone enanthate OR norethisterone enantate OR micronovum OR primolut-nor OR locilan OR micronor OR noriday OR norlutate OR milligynon OR norfor OR noristerat OR norluten OR gestakadin OR sovel OR conludag OR nur-isterate OR mini-pe OR menzol OR primolut-N OR sh420 OR utovlan OR aygestin OR nor-qd OR medroxyprogesterone acetate OR depo-provera OR depocon OR farlutal OR prodafem OR provera OR depo-ralovera OR ralovera OR depo-prodasone OR gestoral OR prodasone OR clinofem OR clinovir OR depo-clinovir OR g-farlutal OR lutoral OR perlutex OR petogen OR depo-progevera OR progevera OR cykrina OR gestapuran OR prodafem OR amen OR curretab OR cycrin OR lynoestrenol OR lynestrenol OR orgametril OR exluton OR exlutona OR exlutena OR gestodene OR etonogestrel OR implanon OR ethynodiol diacetate OR etynodiol diacetate OR lutometrodiol OR luteonorm OR femulen OR drospirenone OR desogestrel OR dienogest OR demegestone OR lutionex OR cyproterone acetate OR andro-diane OR androcur OR cyprone OR cyprostat OR chlormadinone acetate OR luteran OR gestafortin OR prostal OR algestone acetophenide OR neolution depositum OR levonorgestrel OR lng ius<BR/>#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8<BR/>#10 explode UTERINE-HEMORRHAGE<BR/>#11 AMENORRHEA<BR/>#12 vagina* NEAR (bleed* OR haemorrhag* OR hemorrhag* OR blood loss)<BR/>#13 uter* NEAR (bleed* OR haemorrhag* OR hemorrhag* OR blood loss)<BR/>#14 spotting<BR/>#15 (irregular OR prolonged OR frequent OR persistent OR unpredictable OR unscheduled OR abnormal OR breakthrough) NEAR (bleed* OR menstrual* OR menses OR blood loss OR period OR periods OR haemorrhag* OR hemorrhag*)<BR/>#16 menstrual disturbance*<BR/>#17 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16<BR/>#18 #9 AND #17<BR/>
<BR/>(N.B. Upper case denotes controlled vocabulary, which comprise Thesaurus terms applied by the database indexers, and lower case denotes free-text terms, which are used by the authors of the studies).</P>
<P>The search strategies of the different data bases are shown in Appendix A.</P>
<P>2. Reference lists of trials identified and relevant review articles were scrutinized for any additional trials not retrieved with the database searches listed above.</P>
<P>3. Researchers active in the field were contacted for possible unpublished studies or data.</P>
<P>The searches included all languages.</P>
<P>
<BR/>
<BR/>
</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-12-29 17:01:11 +0100" MODIFIED_BY="[Empty name]">
<P>Two reviewers (HAA and KV) initially assessed the results of the search by checking the titles and the abstracts where available. When unsure about the relevance or the methodology, they requested and reviewed full reports. Reports of studies using a random or quasi-random allocation and evaluating the interventions described here were critically appraised for inclusion.</P>
<P>A data extraction form was developed, as described in the Cochrane Handbook, for standardisation of the data extraction. Trials were reviewed for methodological quality based on concealment of allocation, outcome assessment blinding and drop out rates. If all of the criteria were met, there was considered to be a low risk of bias (validity criteria score A). In cases where one or more criteria were partly met, for example if the trialists reported that the study was double blind, but didn't report any concealment approach, there was considered to be a moderate risk of bias (validity criteria score B). If one or more of the criteria was not met, if allocation concealment or outcome assessment were not blinded, or if the study participant drop-out rate was more than 10%, studies were given a validity criteria score of C.</P>
<P>There were no language restrictions for inclusion of trials. Abstracted data were entered into Review Manager software and analysed. Studies that enrolled women who were using any levonorgestrel-releasing subcutaneous implant (either the 2-rod Jadelle system or the 6-rod Norplant system) were combined, since these methods release the same hormone at the same daily rate. Otherwise, studies that enrolled women who were using different contraceptive methods were not combined, due to the different primary mechanisms of contraceptive action of the various methods, and their differing effects on bleeding patterns. Since the types and mechanisms of pharmaceutical agents used were different and the desired outcomes of treatment differed between trials (for example induction of regular menses or of amenorrhoea), different groups of agents were not combined in a single analysis. Therefore, three main variables were identified in the comparison plan: the contraceptive method, the intervention, and the prophylactic or therapeutic nature of the intervention. Few trials could be combined and we conducted the analyses with this consideration in mind.</P>
<P>Data regarding participant drop out rates, loss to follow up and reasons for early discontinuations were recorded and presented in the table of included studies. Study participant characteristics, treatment interventions, length of follow-up and outcome measures were recorded. Trial characteristics such as type of trial, study duration and setting where the trials were conducted were also recorded.</P>
<P>The data were extracted separately by two reviewers (HAA and KV) and discrepancies or disagreements were resolved by discussion and consultation with a third reviewer (MEG). Data were entered for analysis by KV and MEG. The results are expressed as relative risks (RR) with 95% confidence interval (CI) in case of categorical data and as weighted mean difference (WMD) with 95% confidence interval (CI) for continuous data, using a fixed-effect approach where possible. When we encountered heterogeneity (visual or statistical) we used the random-effects model (quantitative) or did not produce a summary estimate (qualitative).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-04-22 15:52:58 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-03-12 14:54:18 +0100" MODIFIED_BY="[Empty name]">
<P>This review included 33 randomised (n=32) or systematically allocated (n=1) controlled trials (RCTs), conducted in 17 countries (China, Indonesia, Iran, Pakistan, the Philippines and Thailand in Asia; Tunisia and Egypt in Africa; France, the Netherlands, Sweden, Switzerland and the United Kingdom in Europe; the United States of America in North America; Chile and the Dominican Republic in Latin America; and Australia). Studies were conducted at family planning clinics, hospitals and university research centres.<BR/>
<B>
<BR/>
</B>Contraceptives used:<BR/>Twelve of the included studies enrolled women using Norplant as their contraceptive method. New Norplant users, as well as women using the method for one to 43 months were enrolled; most of the studies limited enrolment to women using the method for less than one year. Twelve studies were conducted to evaluate interventions in women using the injectable DMPA. Two of these enrolled new users, with the aim of evaluating interventions to prevent bleeding irregularities; the remaining studies enrolled women who had been using the method for one to 18 months. In three trials, women used progestin-only pills; the duration of use was at least one month in one study and was not defined in the other two studies. Three trials recruited women who had been using Implanon for a period of more than two months. Two studies enrolled new users of the Mirena LNG-IUS. One study was conducted to evaluate treatment of irregular bleeding in Jadelle users.</P>
<P>
<B>
<BR/>
</B>
</P>
<P>
<B>Characteristics of participants: </B>
</P>
<P>The age of women included in these trials generally was in the range of 20 to 30 years; however, many of the studies' inclusion criteria allowed for the enrolment of women up to age 45.. Two studies (<LINK REF="STD-Subakir-2000" TYPE="STUDY">Subakir 2000</LINK>, and <LINK REF="STD-Weisberg-2006" TYPE="STUDY">Weisberg 2006</LINK>) included women 18 to 40 years old. One study (<LINK REF="STD-Harel-2002" TYPE="STUDY">Harel 2002</LINK>) specifically enrolled adolescent girls; the mean age of participants in this trial was 16 ± 1 years. The parity of women recruited in the trials was reported in only 13 trials and ranged between zero and five. The body weight of study participants was reported in 11 trials and mean body weights were reported in the range between 44 and 73 kg. Height was not mentioned in the majority of the trials, but nine studies reported the body mass index; in these trials BMI ranged from 21 to <U>&gt;</U> 30 kg/m2.</P>
<P>Interventions:</P>
<P>There were 18 types of interventions tested in the trials. Fourteen interventions were tested as therapeutic treatments. These included <B>estrogens</B> alone in various formulations (ethinyl estradiol,17-beta estradiol, diethylstilbestrol, oestrone sulphate, quinesterol), as used in seven trials (<LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK>, <LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>, <LINK REF="STD-Boonkasemsanti-1996" TYPE="STUDY">Boonkasemsanti 1996</LINK>, <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>, <LINK REF="STD-Johannisson-1982" TYPE="STUDY">Johannisson 1982</LINK>, <LINK REF="STD-Said-1996" TYPE="STUDY">Said 1996</LINK> and <LINK REF="STD-Witjaksono-1996" TYPE="STUDY">Witjaksono 1996</LINK>). <B>Estrogen - progestin combinations</B> were used therapeutically in three trials (<LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK>, <LINK REF="STD-Sadeghi_x002d_Bazargani-2006" TYPE="STUDY">Sadeghi-Bazargani 2006</LINK> and <LINK REF="STD-Witjaksono-1996" TYPE="STUDY">Witjaksono 1996</LINK>). A <B>progestin</B> was used therapeutically in a single trial (<LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>). <B>Anti-progestins</B> were used therapeutically in two trials (<LINK REF="STD-Cheng-2000" TYPE="STUDY">Cheng 2000</LINK> and <LINK REF="STD-Weisberg-2006" TYPE="STUDY">Weisberg 2006</LINK>). An <B>antiprogestin was combined with an estrogen</B> as a method to treat irregular bleeding in two trials (<LINK REF="STD-Weisberg-2006" TYPE="STUDY">Weisberg 2006</LINK>, <LINK REF="STD-Weisberg-2009" TYPE="STUDY">Weisberg 2009</LINK>). A <B>capillary protecting venotonic drug</B> (registered in France as Cyclo 3, containing extract of <I>Ruscus aculeatus </I>with ascorbic acid and hesperidin methyl chalcone) was used therapeutically in one trial (<LINK REF="STD-Monteil_x002d_Seurin-1985" TYPE="STUDY">Monteil-Seurin 1985</LINK>). In two trials (<LINK REF="STD-Subakir-2000" TYPE="STUDY">Subakir 2000</LINK> and <LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>), <B>vitamin E</B> was used therapeutically. <B>Non-steroidal anti-inflammatory drugs (NSAIDs</B>) were used therapeutically in eight trials (<LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>, <LINK REF="STD-Buasang-2009" TYPE="STUDY">Buasang 2009</LINK>, <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>, <LINK REF="STD-Kaewrudee-1999" TYPE="STUDY">Kaewrudee 1999</LINK>, <LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>, <LINK REF="STD-Nathirojanakun-2006" TYPE="STUDY">Nathirojanakun 2006</LINK>, <LINK REF="STD-Phaliwong-2004" TYPE="STUDY">Phaliwong 2004</LINK> and <LINK REF="STD-Tantiwattanakul-2004" TYPE="STUDY">Tantiwattanakul 2004</LINK>). The therapeutic effects of combined <B>Vitamin E and NSAIDs</B> were evaluated in a single trial (<LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>). <B>A selective estrogen receptor modulator (SERM)</B> was used therapeutically in one trial (<LINK REF="STD-Abdel_x002d_Aleem-2005" TYPE="STUDY">Abdel-Aleem 2005</LINK>). An <B>antifibrinolytic agent</B> was used in two trials (<LINK REF="STD-Phupong-2006" TYPE="STUDY">Phupong 2006</LINK>, <LINK REF="STD-Senthong-2009" TYPE="STUDY">Senthong 2009</LINK>). <B>A matrix metalloproteinase inhibitor (MMPI)</B> alone was used in three trials (<LINK REF="STD-Abdel_x002d_Aleem-2012" TYPE="STUDY">Abdel-Aleem 2012</LINK>, <LINK REF="STD-Weisberg-2006" TYPE="STUDY">Weisberg 2006</LINK>, <LINK REF="STD-Weisberg-2009" TYPE="STUDY">Weisberg 2009</LINK>). One trial evaluated the effects of <B>combined MMPI and estrogen</B> treatment ( <LINK REF="STD-Weisberg-2009" TYPE="STUDY">Weisberg 2009</LINK>); this same study also evaluated <B>MMPI combined with an antiprogestin.</B>
</P>
<P>Four types of interventions were tested for their effects to prevent bleeding irregularities in users of progestin-only contraceptives. These included <B>estrogens alone</B> (estradiol acetate, diethylstilbestrol, 17-beta estradiol, quinesterol) as used prophylactically in five trials (<LINK REF="STD-Dempsey-2010" TYPE="STUDY">Dempsey 2010</LINK>, <LINK REF="STD-El_x002d_Habashy-1970" TYPE="STUDY">El-Habashy 1970</LINK>, <LINK REF="STD-Goldberg-2002" TYPE="STUDY">Goldberg 2002</LINK>; <LINK REF="STD-Madden-2012" TYPE="STUDY">Madden 2012</LINK> and <LINK REF="STD-Parker-1980" TYPE="STUDY">Parker 1980</LINK>). <B>Anti-progestins</B> were used prophylactically in four trials (<LINK REF="STD-Gemzell_x002d_Danielsson-2002" TYPE="STUDY">Gemzell-Danielsson 2002</LINK> , <LINK REF="STD-Jain-2003" TYPE="STUDY">Jain 2003</LINK>, and <LINK REF="STD-Massai-2004" TYPE="STUDY">Massai 2004</LINK> and <LINK REF="STD-Warner-2010" TYPE="STUDY">Warner 2010</LINK>). The effects of <B>vitamin C</B> in preventing bleeding irregularities in new DMPA users were evaluated in a single four-arm trial (<LINK REF="STD-Harel-2002" TYPE="STUDY">Harel 2002</LINK>). In addition, a trial of new LNG-IUS users provided an <B>NSAID</B> for prophylaxis (<LINK REF="STD-Madden-2012" TYPE="STUDY">Madden 2012</LINK>).</P>
<P>All trials except (<LINK REF="STD-Dempsey-2010" TYPE="STUDY">Dempsey 2010</LINK>) were placebo-controlled. Twenty four trials included a single intervention arm, while nine trials were designed to test the effects of more than one intervention, singly or in combination. In two trials (<LINK REF="STD-El_x002d_Habashy-1970" TYPE="STUDY">El-Habashy 1970</LINK> and <LINK REF="STD-Parker-1980" TYPE="STUDY">Parker 1980</LINK>) the interventions tested, diethylstilbestrol and quinesterol, respectively, are no longer used in clinical practice, for any indication. In addition to the range of types of interventions, the treatments were used in different doses and according to different dosing schedules, and study participants were followed according to diverse schedules, for varying lengths of time.</P>
<P>Duration of Follow-Up:<BR/>The duration of follow-up varied among the trials, from less than three months to eighteen months. Most trials were designed to test the short-term effects of the interventions, with only eight trials treating or following participants for longer than six months (<LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>, <LINK REF="STD-Parker-1980" TYPE="STUDY">Parker 1980</LINK>, <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>, <LINK REF="STD-Said-1996" TYPE="STUDY">Said 1996</LINK>, <LINK REF="STD-Cheng-2000" TYPE="STUDY">Cheng 2000</LINK>, <LINK REF="STD-Goldberg-2002" TYPE="STUDY">Goldberg 2002</LINK>, <LINK REF="STD-Massai-2004" TYPE="STUDY">Massai 2004</LINK> and <LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>). The longest duration of follow-up, as reported in two studies (<LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>, <LINK REF="STD-Said-1996" TYPE="STUDY">Said 1996</LINK>) was one year and up to 18 months, respectively ; however, the long-term results were not reported.</P>
<P>Outcome measures:<BR/>Although nearly all trials were designed to evaluate the effects of treatment on bleeding episodes as a primary outcome, the authors reported the outcome in different ways, including cessation of bleeding, number of bleeding days during treatment, number of bleeding days after treatment, number of days of treatment required before bleeding stopped, percent of women with bleeding free intervals of more than a given number of days, percent of women with acceptable bleeding, and others. Moreover, the data were presented in different ways including means, medians, and percentages. Other types of outcome measures included discontinuation of the treatment, discontinuation of the contraceptive method, side effects due to treatment, dissatisfaction with treatment and, in a few studies, blood loss during treatment.</P>
<P>Due to the lack of consistency in study design, outcome measures, and statistical reporting, very few studies could be combined in the analyses.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-03-13 21:32:15 +0100" MODIFIED_BY="[Empty name]">
<P>This review included 33 trials. The methodological quality was assessed as mentioned above, in the methods section, with validity criteria scores based on allocation concealment, outcome assessment blinding and number/percent of study discontinuations. The overall assessment of risk of bias is shown in (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). According to these criteria, 10 of the trials were assigned "A" validity criteria scores with low risk of bias ( <LINK REF="STD-Abdel_x002d_Aleem-2005" TYPE="STUDY">Abdel-Aleem 2005</LINK>,<LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>, <LINK REF="STD-Buasang-2009" TYPE="STUDY">Buasang 2009</LINK>, <LINK REF="STD-Cheng-2000" TYPE="STUDY">Cheng 2000</LINK>, <LINK REF="STD-Kaewrudee-1999" TYPE="STUDY">Kaewrudee 1999</LINK>, <LINK REF="STD-Nathirojanakun-2006" TYPE="STUDY">Nathirojanakun 2006</LINK>, <LINK REF="STD-Phaliwong-2004" TYPE="STUDY">Phaliwong 2004</LINK>, <LINK REF="STD-Phupong-2006" TYPE="STUDY">Phupong 2006</LINK>, <LINK REF="STD-Senthong-2009" TYPE="STUDY">Senthong 2009</LINK> and <LINK REF="STD-Weisberg-2006" TYPE="STUDY">Weisberg 2006</LINK>). In these trials, allocation concealment was considered to be adequate, outcome assessment blinding was achieved and fewer than 10% of the enrolled women discontinued prior to the end of the study(<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). There were 12 trials that were considered to be at moderate risk of bias and were therefore given validity criteria scores of "B". In many of these studies, the allocation concealment was unclear ( <LINK REF="STD-Boonkasemsanti-1996" TYPE="STUDY">Boonkasemsanti 1996</LINK>, <LINK REF="STD-Jain-2003" TYPE="STUDY">Jain 2003</LINK>, <LINK REF="STD-Johannisson-1982" TYPE="STUDY">Johannisson 1982</LINK>, <LINK REF="STD-Massai-2004" TYPE="STUDY">Massai 2004</LINK>, <LINK REF="STD-Subakir-2000" TYPE="STUDY">Subakir 2000</LINK>). The outcome assessment blinding was unclear or inadequate in three of these trials ( <LINK REF="STD-El_x002d_Habashy-1970" TYPE="STUDY">El-Habashy 1970</LINK>, <LINK REF="STD-Jain-2003" TYPE="STUDY">Jain 2003</LINK>, <LINK REF="STD-Johannisson-1982" TYPE="STUDY">Johannisson 1982</LINK> ).In two trials the drop out rate was &gt;10% but less than 15%(<LINK REF="STD-Abdel_x002d_Aleem-2012" TYPE="STUDY">Abdel-Aleem 2012</LINK>,<LINK REF="STD-Weisberg-2009" TYPE="STUDY">Weisberg 2009</LINK>). Eleven trials were given a validity criteria score of "C", meaning that the study may be subject to a high risk of bias (<LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK>, <LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>, <LINK REF="STD-Dempsey-2010" TYPE="STUDY">Dempsey 2010</LINK>,<LINK REF="STD-Gemzell_x002d_Danielsson-2002" TYPE="STUDY">Gemzell-Danielsson 2002</LINK>, <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>, <LINK REF="STD-Goldberg-2002" TYPE="STUDY">Goldberg 2002</LINK>,<LINK REF="STD-Madden-2012" TYPE="STUDY">Madden 2012</LINK>, <LINK REF="STD-Monteil_x002d_Seurin-1985" TYPE="STUDY">Monteil-Seurin 1985</LINK>, <LINK REF="STD-Parker-1980" TYPE="STUDY">Parker 1980</LINK>, <LINK REF="STD-Said-1996" TYPE="STUDY">Said 1996</LINK> and <LINK REF="STD-Witjaksono-1996" TYPE="STUDY">Witjaksono 1996</LINK>).In all these trials at least two of the criteria were unmet or not clear or the drop out rate was markedly high. Overall, two thirds of the trials were of high to moderate quality , with 34% being considered "poor." The 10 trials (30% of all included studies) that were considered to be of good quality recruited 855 (23%) of 3,677 women enrolled in all included trials.</P>
<P>
<B>
<BR/>
</B>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-04-22 15:52:58 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>1. Estrogen versus placebo (therapeutic treatment for LNG subcutaneous implant users; n=5 studies)<BR/>
</B>In five of the included studies, women reporting bleeding irregularities while using Norplant were administered an estrogen formulation and followed for resolution of symptoms (<LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK>, <LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>, <LINK REF="STD-Boonkasemsanti-1996" TYPE="STUDY">Boonkasemsanti 1996</LINK>, <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>, and <LINK REF="STD-Witjaksono-1996" TYPE="STUDY">Witjaksono 1996</LINK>). Together, these studies recruited 166 women in the respective estrogen treatment arms and 185 women in placebo groups; of these, data from 147 estrogen-treated women and 173 placebo-treated women were included in the analyses. Treatments included ethinyl estradiol (EE) tablets in four studies (<LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK>, <LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>, <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK> and <LINK REF="STD-Witjaksono-1996" TYPE="STUDY">Witjaksono 1996</LINK>) and an estradiol patch in the fifth (<LINK REF="STD-Boonkasemsanti-1996" TYPE="STUDY">Boonkasemsanti 1996</LINK>).</P>
<P>The efficacy of the various treatments was reported in different manners in these studies. In <LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK>, the primary outcomes included whether or not bleeding stopped within three days of the initiation of treatment and the number of bleeding days during the 20-day treatment interval. Archer et al (<LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>) reported the main study outcomes as being the mean duration (number of days) of bleeding and/or spotting during various intervals throughout the one-month follow up period; however, the effect of EE treatment was inestimable, since standard deviations were not published. The <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK> study reported mean and total numbers of bleeding and spotting days during all treatment intervals throughout the entire year and did not separate individual treatment intervals. Women receiving estradiol reported shorter episodes of bleeding and spotting throughout the year and fewer days of bleeding and spotting. However, it is not clear how many treatment cycles were included in the analysis. But it is reported that the mean number of treatments per year per treated subject ranged from 2.2 to 3.1, with no differences between groups. <LINK REF="STD-Witjaksono-1996" TYPE="STUDY">Witjaksono 1996</LINK> reported on the number of bleeding or spotting days and episodes in 90-day reference periods prior to and following the treatment, and the number of bleeding or spotting days per episode. The study results from the individual trials generally suggest that the estrogen treatment had a beneficial effect in stopping bleeding. Two of the included studies (<LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK> and <LINK REF="STD-Boonkasemsanti-1996" TYPE="STUDY">Boonkasemsanti 1996</LINK>) reported the number of women who experienced irregular bleeding during treatment; according to our combined analysis, the use of estrogen reduced irregular bleeding during the treatment interval [RR 0.43, 95% CI 0.30-0.61 ). In addition, the <LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK> data support the conclusion that women receiving EE report a lower incidence of unacceptable bleeding patterns after treatment, as defined by the length of the post-treatment bleeding-free interval. Fewer women reported a bleeding-free interval of less than 11 days after receiving the oral EE regimen than after receiving placebo [RR 0.28, 95% CI 0.14 ,0.58]. In contrast, no differences in the number of bleeding and/or spotting days within the 20 days following a 10-day EE treatment period were reported by Archer et al (<LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>). </P>
<P>Based on our analysis of data reported by <LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK>, women receiving estrogen treatment appeared to be less likely to discontinue the use of Norplant for bleeding irregularities than were those receiving placebo, though the overall effect was not significant, as only one woman discontinued for this reason. <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK> did not report any method discontinuations for bleeding irregularities. Nausea or gastrointestinal discomfort was commonly reported in the former study: only two of 46 participants receiving placebo reported such side effects, whereas 17 of 43 receiving estrogen complained of gastric upset [RR 9.09, 95% CI 2.23, 37.06]. In the <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK> study, 5 of 13 study discontinuations in the estrogen group were associated with gastric intolerance, while none of the women in the placebo group discontinued from the study for this reason. <LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK> reported discontinuation of treatment due to gastralgia or nausea in 2 of 50 women receiving treatment and none of the women in the placebo group. When the data for these studies were combined, it was clear that women receiving estrogen tended to be more likely to discontinue their participation in the trial due to side effects of the treatment than were women receiving placebo [RR 8.1, 95% CI 1.04, 63.40].</P>
<P>
<B>2. Estrogen versus placebo (therapeutic treatment for DMPA users; n= 1 study)<BR/>
</B>Only one of the included studies (<LINK REF="STD-Said-1996" TYPE="STUDY">Said 1996</LINK>) was designed to evaluate the effects of an estrogen on bleeding irregularities in women using DMPA for family planning. This was one of the largest included studies, having randomised 278 DMPA users with irregular bleeding to receive either EE 50 µg, oestrone sulfate 2.5 mg or placebo for 14 days. This study was also designed to report on both short- and long-term success, with follow-up at 14 days (the duration of the treatment) and 12-18 months; unfortunately, there was a high rate of discontinuation (over 40% in each group), giving the study a high risk of bias.</P>
<P>Ethinyl Estradiol was effective in stopping bleeding during treatment [RR 0.26, 95%CI 0.11, 0.60] and to a lesser extent after three months [RR 0.06, 95%CI 0.00, 1.00] . Oestrone sulphate was ineffective in stopping bleeding during treatment [RR 1.03, 95%CI 0.41, 2.59] and after three months.</P>
<P>The authors reported discontinuations and their causes among the study participants who presented at the study centres. But due to the high numbers of study participants who were lost to follow-up and who dropped out of the study prematurely, without giving a reason, it was impossible to determine the true discontinuation rates, particularly as related to bleeding irregularities and side effects, respectively.</P>
<P>
<B>3. Estrogen versus placebo (prophylactic treatment for DMPA users; n= 4 studies</B>)<BR/>Four studies were identified in which estrogen was administered to new acceptors of DMPA, with the goal of preventing or reducing bleeding irregularities. Two of these (<LINK REF="STD-El_x002d_Habashy-1970" TYPE="STUDY">El-Habashy 1970</LINK> and <LINK REF="STD-Parker-1980" TYPE="STUDY">Parker 1980</LINK>) examined the effects of orally administered estrogens, diethylstilbestrol (DES) and quinesterol, respectively, the third (<LINK REF="STD-Goldberg-2002" TYPE="STUDY">Goldberg 2002</LINK>) evaluated the effects of a 17-beta estradiol-containing transdermal patch and the most recent study evaluated the use of a vaginal ring releasing estradiol acetate (<LINK REF="STD-Dempsey-2010" TYPE="STUDY">Dempsey 2010</LINK>).</P>
<P>Two of the studies reported efficacy of the treatment in terms that could be incorporated into the present analysis. <LINK REF="STD-El_x002d_Habashy-1970" TYPE="STUDY">El-Habashy 1970</LINK> reported that women administered DES 1 mg daily exhibited more acceptable bleeding patterns (defined as bleeding episodes of less than 8 days) than women receiving placebo [RR 0.45, 95% CI 0.21, 0.96]. The trial of the vaginal ring (<LINK REF="STD-Dempsey-2010" TYPE="STUDY">Dempsey 2010</LINK>) reported that the mean number of days of bleeding during treatment was reduced in women using the ring; however this finding was not statistically significant, with a weighted mean difference of -8.30 days in the treatment group (95% CI -20.2, 3.6). <LINK REF="STD-Parker-1980" TYPE="STUDY">Parker 1980</LINK> reported the percent of women with acceptable bleeding patterns in terms of numbers of bleeding episodes throughout 3-month intervals, following either one or three doses of quinestrol per DMPA injection segment (12 weeks). The primary outcome of the (<LINK REF="STD-Goldberg-2002" TYPE="STUDY">Goldberg 2002</LINK>) study was DMPA continuation rates and (<LINK REF="STD-Dempsey-2010" TYPE="STUDY">Dempsey 2010 </LINK>also reported on this outcome. The combined analysis demonstrated that estrogen treatment is ineffective as a means to improve DMPA continuation [RR 1.00, 95% CI 0.78, 1.28]. Three of the studies in this category suffered from very high discontinuation and non-compliance rates, in both treatment and placebo groups</P>
<P>
<BR/>
<B>4. Estrogen versus placebo (therapeutic treatment for minipill users; n= 1 study)</B>
<BR/>One small (n=12) study (<LINK REF="STD-Johannisson-1982" TYPE="STUDY">Johannisson 1982</LINK>) was designed to evaluate the effects of estrogen treatment on bleeding irregularities experienced by minipill (300 µg norethisterone) users. The bleeding data could not be used in the current analysis, as confidence intervals, rather than standard deviations, were presented in the descriptions of bleeding during the treatment interval.</P>
<P>
<B>5. Combined estrogen and progestin versus placebo (therapeutic treatment for LNG subcutaneous implant users; n= 2 studies)<BR/>
</B>There were two studies (<LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK>; <LINK REF="STD-Witjaksono-1996" TYPE="STUDY">Witjaksono 1996</LINK>) in which a combination of oral ethinyl estradiol and oral levonorgestrel was tested as a means to treat bleeding irregularities in Norplant users. The two studies together randomised 66 women to receive the treatment regimen and 64 to receive placebo; of these 61 and 60, respectively, were included in the analyses. As above, <LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK> reported efficacy in terms of the percentage of women who experienced a cessation of bleeding within 3 days of treatment; the <LINK REF="STD-Witjaksono-1996" TYPE="STUDY">Witjaksono 1996</LINK> paper reported the number of bleeding days and episodes in 90-day reference periods. According to the reports of the author and to our analyses, in the former study, the combined approach significantly reduced continued irregular bleeding during treatment, when compared with placebo [RR 0.08, 95% CI 0.03, 0.24] and reduced unacceptable bleeding after treatment (as defined by the number of women experiencing bleed-free intervals of less than 11 days) [RR 0.02, 95% CI 0.00, 0.29].</P>
<P>
<LINK REF="STD-Witjaksono-1996" TYPE="STUDY">Witjaksono 1996</LINK> did not report discontinuations or side effects in the study results; (<LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK>) reported that the discontinuation of Norplant due to bleeding disturbances was not significantly different between women in the combined hormone treatment and placebo groups, which was supported by our analysis [RR 0.33, 95% CI 0.01, 7.99]. Discontinuation due to the side effects of the treatment did not differ between groups; however, our analysis of the Alvarez-Sanchez data revealed a higher incidence of reported side effects (nausea or gastralgia) in the treatment group than in the placebo group [RR 7.16, 95% CI 1.72, 29.71].</P>
<P>
<B>6. Combined estrogen and progestin versus placebo (therapeutic treatment for DMPA users; n= 1 study)<BR/>
</B>One small trial (<LINK REF="STD-Sadeghi_x002d_Bazargani-2006" TYPE="STUDY">Sadeghi-Bazargani 2006</LINK> ) recruited DMPA users who had cessation of menstruation for two months. Twenty four women received low dose combined oral contraceptives (COCs) and 22 received placebo. Significantly fewer women in the treatment group than in the placebo group continued to experience amenorrhea [RR 0.38, 95% CI 0.19, 0.73]. The number of women who discontinued use of DMPA was less in the group assigned to receive low dose pills [RR 0.60, 95% CI 0.40, 0.88].</P>
<P>
<B>7. Progestin versus placebo (therapeutic treatment for LNG subcutaneous implant users; n= 1 study)</B>
<BR/>One study (<LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>) evaluated the effect of administering an additional progestin to Norplant users experiencing bleeding episodes of eight or more days. These women received 0.03 mg levonorgestrel tablets, twice a day for 20 days, starting on the eighth consecutive day of bleeding. Women could treat extended bleeding up to five times in the year-long study. The authors described a significant decrease in the total number of bleeding days and bleeding and spotting days over the entire year in women who ever used the levonorgestrel, compared with those who ever used the placebo, even when the untreated bleeding cycles were included in the analysis; however, the numbers of women in the final analysis were small (21 per group).</P>
<P>Three of the 47 women enrolled in the levonorgestrel group elected to have their Norplant system removed, though none for reasons related to bleeding; only one woman in the placebo group asked to discontinue the contraceptive method [RR 2.94, 95% CI 0.32, 27.21].</P>
<P>
<B>8. Antiprogestin versus placebo (therapeutic treatment for LNG subcutaneous implant users; n= 1 study)</B>
<BR/>One of the included studies (<LINK REF="STD-Cheng-2000" TYPE="STUDY">Cheng 2000</LINK>) was designed to evaluate the effects of the anti-progestin mifepristone on bleeding irregularities experienced by users of levonorgestrel-containing subdermal contraceptive implants equivalent to Norplant. The study results stated that the women treated with mifepristone reported significantly shorter episodes of bleeding during the treatment than prior to the study; however, both the treatment and control groups demonstrated a decrease in the frequency of bleeding in the one year of follow up. In the current analysis, we found no significant difference between the groups with respect to the number of days of bleeding during treatment when reported 3 months after study initiation; at 6 months, however, women using the anti-progestin reported fewer days of bleeding than did those receiving placebo [WMD -8.00, 95% CI -12.41, -3.59]. No difference in the number of days of bleeding after the treatment was noted. No women in either group discontinued the use of the contraceptive method due to bleeding irregularities. There was a significant effect of mifepristone to decrease patient dissatisfaction with the treatment [RR 0.46; 95% CI 0.23, 0.91].</P>
<P>
<B>9. Antiprogestin versus placebo (prophylactic treatment for LNG subcutaneous implant users; n= 1 study)<BR/>
</B>A single study (<LINK REF="STD-Massai-2004" TYPE="STUDY">Massai 2004</LINK>) was designed to evaluate the effect of two subsequent daily oral doses of 100 mg mifepristone in preventing bleeding irregularities in new users of Norplant. Of the 120 women enrolled, 116 completed 6 months of treatment and 115 were included in the analysis. The mean number of bleeding or spotting days during the course of the 180 days of the treatment period of the trial was significantly lower in women who had taken mifepristone for 2 days at 30 day intervals than in women given placebo [WMD -18.0; 95% CI -26.93, -9.07]. However, the improvement in bleeding patterns did not continue past the time of discontinuation of treatment and, by 6 months after treatment, there were no differences in reported acceptable bleeding patterns between the two groups. None of the women in the treatment group discontinued use of Norplant for continued irregular bleeding. Of importance, one woman who received the anti-progestin did become pregnant during the course of the study. Two women in the placebo group elected to have their implants removed due to continued irregular bleeding. This difference was not found to be significant, nor was the difference between groups with respect to discontinuation from the study due to side effects of the treatments, in the current analysis.</P>
<P>
<B>10. Antiprogestin versus placebo (therapeutic treatment for Implanon users; n=1 study)<BR/>
</B>One pilot study (<LINK REF="STD-Weisberg-2006" TYPE="STUDY">Weisberg 2006</LINK>) randomised women who used Implanon implant and had bleeding irregularities to receive mifepristone (25 mg twice/day for one day) then placebo for four days or placebo only for five days. The authors reported that mifepristone alone was similar to placebo in stopping an episode of bleeding. Unfortunately, the results were presented in a way not suitable for our analysis. A similar proportion of women in both groups reported any side effect [0.93, 95% CI 0.61, 1.42] or, specifically, nausea and vomiting [0.64, 95% CI 0.23, 1.80]. <B>
<BR/>
</B>
<BR/>
<B>11. Antiprogestin versus placebo (prophylactic treatment for DMPA users; n= 1 study)</B>
<BR/>Results of one small study (<LINK REF="STD-Jain-2003" TYPE="STUDY">Jain 2003</LINK>) suggest that a single tablet of 50 mg mifepristone, taken orally every 14 days, can lessen bleeding irregularities in new users of DMPA, in terms of percent days with breakthrough bleeding and percent cycles with bleeding intervals of more than 8 days.</P>
<P>
<B>12. Antiprogestin versus placebo (prophylactic treatment for minipill users; n= 1 study)</B>
<BR/>In one study (<LINK REF="STD-Gemzell_x002d_Danielsson-2002" TYPE="STUDY">Gemzell-Danielsson 2002</LINK>), 103 women were randomised to take either 150 mg of a novel antiprogestogen (Org 31710) or placebo tablets once every 28 days, for a maximum of seven treatment cycles. Although the study authors report an improvement in the bleeding patterns of women who received the antiprogestin, our analysis did not reveal any differences between groups in terms of efficacy, discontinuation of the contraceptive method due to bleeding irregularities or side effects, or the incidence of side effects or adverse events.</P>
<P>
<B>13. Combined antiprogestin and estrogen versus placebo (therapeutic treatment for Implanon users; n= 1 study)<BR/>
</B>One pilot study (<LINK REF="STD-Weisberg-2006" TYPE="STUDY">Weisberg 2006</LINK>) and a larger follow-on trial (<LINK REF="STD-Weisberg-2009" TYPE="STUDY">Weisberg 2009</LINK>) randomised women using Implanon and experiencing bleeding irregularities to take either mifepristone 50 mg for one day, followed by EE 20 µg/day for four days, or placebo for five days. The efficacy results were presented in a way not suitable for our analysis but the authors reported in both trials that mifepristone followed by EE was significantly more effective than placebo in stopping an episode of bleeding. Data extracted from the more recent trial<LINK REF="STD-Weisberg-2009" TYPE="STUDY">Weisberg 2009</LINK> reflect the number of women who experienced continued irregular bleeding during treatment; none of the 40 women randomized to receive the active treatment reported continued bleeding, compared with 11 of the 37 women who received placebo [RR 0.04, 95% CI 0.00, 0.66]. The analysis of the pilot study demonstrated no significant differences between the two groups of women in reporting any side effects [RR 1.22, 95% CI 0.84, 1.75]. The 2009 trial reported no difference between treatment groups with respect to the number of women who experienced headache; a combined analysis of both trials revealed no effect of treatment group on the number of women experiencing nausea or vomiting [RR 0.5, 95% CI 0.18, 1.38]. The more recent trial reported on discontinuation of the contraceptive method at 90 and 180 days following initiation of treatment. Treatment with mifepristone followed by EE did not result in a favourable effect on method continuation rates at either time point.</P>
<P>
<B>14. Venotonic versus placebo (therapeutic treatment for minipill users; n= 1 study</B>)<BR/>In one of the included studies (<LINK REF="STD-Monteil_x002d_Seurin-1985" TYPE="STUDY">Monteil-Seurin 1985</LINK>), women using a norethisterone acetate-containing minipill and complaining of bleeding irregularities were administered either a capillary protecting venotonic drug (registered in France as Cyclo 3, containing extract of <I>Ruscus aculeatus</I> with ascorbic acid and hesperidin methyl chalcone) or placebo. The treatment schedule was cyclic, with drug exposure for 20 continuous days, followed by a drug-free period during the expected time of menses. The mean number of bleeding days during treatment was lower in the group using the venotonic drug in comparison to the placebo group [WMD -2.0, CI -2.78, -1.22]. This was the only one of the included studies that attempted to quantify the amount of blood lost during treatment, as a listed endpoint, and the study authors indicated that women who received the Cyclo 3 needed less menstrual protection than did women in the placebo group. There were no study drop outs reported and no data were presented on side effects due to the treatment. According to the study authors, treated women subjectively reported less discomfort due to bleeding after 3 treatment cycles than did women who received placebo.</P>
<P>
<B>15. Vitamin E versus placebo (therapeutic treatment for LNG subcutaneous implant users; n= 2 studies)<BR/>
</B>Two of the included studies (<LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK> and <LINK REF="STD-Subakir-2000" TYPE="STUDY">Subakir 2000</LINK>) were conducted to evaluate the effectiveness of vitamin E, 200 mg/day for 10 days, in the treatment of bleeding irregularities experienced by women using Norplant implants. In Subakir study, the mean number of bleeding days after the first treatment cycle was significantly less among the 38 women taking vitamin E than among the 34 women assigned to the placebo group [WMD -4.4, CI -5.02, -3.78]. However, in the second, larger study (<LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>), with more than 100 women in each group, there were no statistically significant differences between the groups in terms of the length of bleeding/spotting episodes and the length of bleeding-free intervals that followed cessation of bleeding. <LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK> reported median numbers of days of bleeding, rather than means, given the non-normal distribution of the data. In this study, discontinuation rates were high but did not differ between groups, nor did the incidence of side effects.</P>
<P>
<B>16. Non-steroidal anti-inflammatory drug versus placebo (therapeutic treatment for LNG subcutaneous implant users; n=5 studies)<BR/>
</B>Five of the included studies (<LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>, <LINK REF="STD-Buasang-2009" TYPE="STUDY">Buasang 2009</LINK>, <LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>, <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK> and <LINK REF="STD-Kaewrudee-1999" TYPE="STUDY">Kaewrudee 1999</LINK>) were designed to evaluate the effects of non-steroidal anti-inflammatory drugs (NSAIDS) on bleeding irregularities experienced by women using LNG-releasing sub-cutaneous implants (either Norplant or Jadelle). The regimens included oral ibuprofen 800 mg, three times/day for five days (<LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>); oral ibuprofen 800 mg, two times/day for five days (<LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>); oral mefenamic acid 500 mg, twice daily for 5 days (<LINK REF="STD-Kaewrudee-1999" TYPE="STUDY">Kaewrudee 1999</LINK>); and oral aspirin, 80 mg/day for 10 days (<LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>) and celecoxib 200 mg/day for five days (<LINK REF="STD-Buasang-2009" TYPE="STUDY">Buasang 2009</LINK>).</P>
<P>The earliest paper reported that women taking ibuprofen experienced a decrease in the mean number of bleeding days after initiating treatment in all treated bleeding intervals over the course of a year and fewer bleeding and spotting days during the year (<LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>). Of data from Kaewrudee and Buasang , 14 of the 54 women taking an NSAID continued to experience irregular bleeding during the treatment, compared with 44 of 53 women in the placebo group [RR 0.32; 95% CI 0.2, 0.51]. In addition, Kaewrudee et al reported that women randomized to the mefenamic acid group experienced fewer days of bleeding during the treatment [WMD -5.6; 95% CI -10.04, -1.16]. The percentage of women with unacceptable bleeding after treatment was significantly less in the treated group as reported by both( <LINK REF="STD-Kaewrudee-1999" TYPE="STUDY">Kaewrudee 1999</LINK> and <LINK REF="STD-Buasang-2009" TYPE="STUDY">Buasang 2009</LINK> )and confirmed in the present combined analysis [RR 0.38; 95% CI 0.25, 0.6]. In the <LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK> trial, the median duration of bleeding/spotting episodes after treatment and the median lengths of the bleed-free intervals were not significantly different in the drug and placebo groups, as reported by the authors. Archer et al (<LINK REF="STD-Archer-2008" TYPE="STUDY">Archer 2008</LINK>) reported the main study outcomes as being the mean duration (number of days) of bleeding and/or spotting during various intervals throughout the one-month follow up period; however, the effect of ibuprofen treatment was inestimable, since standard deviations were not published. No differences in the number of bleeding and/or spotting days within the 25 days following a five-day ibuprofen treatment period were reported by these authors. </P>
<P>In the <LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK> trial none of the women receiving ibuprofen requested removal of the Norplant system, while one woman in the placebo group requested removal, though not for bleeding-associated reasons. No differences in discontinuation rates or incidence of side effects (headache and gastrointestinal upset) were noted in the single studies or in the combined analyses (where combinations were feasible). Patient dissatisfaction with treatment was significantly lower as reported by Jadelle users taking celecoxib for bleeding irregularities, in comparison with the placebo group (<LINK REF="STD-Buasang-2009" TYPE="STUDY">Buasang 2009</LINK>) [RR 0.29; 95% CI 0.11, 0.72].</P>
<P>
<B>17. Combined non-steroidal anti-inflammatory drug and vitamin E versus placebo (therapeutic treatment for LNG subcutaneous implant users; n= 1 study)</B>
<BR/>In the large study reported in <LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>, over 120 women using Norplant were randomly assigned to receive a combination of aspirin and vitamin E, while the same number received placebo. The efficacy data were reported as medians, and no benefit of the treatment was demonstrated in the original analysis. In addition, our analyses indicated that there were no differences between the groups with respect to study discontinuation or side effects related to the treatment .</P>
<P>
<B>18. Non-steroidal anti-inflammatory drugs versus placebo (therapeutic treatment for DMPA users; n= 2 studies)<BR/>
</B>Two trials (<LINK REF="STD-Tantiwattanakul-2004" TYPE="STUDY">Tantiwattanakul 2004</LINK> and <LINK REF="STD-Nathirojanakun-2006" TYPE="STUDY">Nathirojanakun 2006</LINK>) evaluating the therapeutic effect of an NSAID on bleeding patterns in women using DMPA were included in the analysis. In the first, women were randomised to receive mefenamic acid (n=23) or placebo (n=25). In the second trial, 46 women were randomised to receive either valdecoxib or placebo. . In a combined analysis, fewer women receiving NSAID treatment continued bleeding during or just after the treatment period, versus in the placebo group [RR 0.42; 95% CI 0.25, 0.72]. In the first trial gastrointestinal discomfort was reported by six women in the treatment group and by none in the control group; this difference was not found to be significant in our analysis. In the second trial no adverse effects were reported.</P>
<P>
<B>19. Selective estrogen receptor modulator versus placebo (therapeutic treatment for LNG subcutaneous implant users; n= 1 study)</B>
<BR/>
<LINK REF="STD-Abdel_x002d_Aleem-2005" TYPE="STUDY">Abdel-Aleem 2005</LINK> was the only included trial to examine the efficacy of a selective estrogen receptor modulator (SERM), in this case tamoxifen, on bleeding irregularities experienced by women using progestin-only methods of fertility regulation. The study was limited to women using Norplant. women received tamoxifen, 10 mg tablets twice daily for 10 days or placebo. Women randomised to the treatment arm were significantly less likely to experience irregular bleeding during treatment [RR 0.41; 95% CI 0.21, 0.80] or unacceptable bleeding after treatment [RR 0.38; 95% CI 0.18, 0.88] or to discontinue the use of Norplant for any reason [RR 0.20; 95% CI 0.05, 0.87]. The effect of the SERM in reducing Norplant discontinuation for bleeding-related reasons bordered on significance [RR 0.22; 95% CI 0.05, 0.98]. Women receiving tamoxifen were more likely to report satisfaction with their treatment regimen [RR 0.22; 95% CI 0.11, 0.45] and were no more likely to report side effects.</P>
<P>
<B>20. Antifibrinolytic versus placebo (therapeutic treatment for LNG subcutaneous implant users; n= 1 study)<BR/>
</B>One randomised trial (<LINK REF="STD-Phupong-2006" TYPE="STUDY">Phupong 2006</LINK>) evaluated the effects of an antifibrinolytic agent on bleeding patterns in women using Norplant and reporting irregular bleeding. Sixty-eight Norplant users were enrolled; half received tranexamic acid 500 mg twice/day for five days and the other half received similar placebo. The percentage of women whose irregular bleeding stopped at 7 days after the initiation of treatment was significantly higher in the tranexamic acid group than the placebo group [RR 0.55, 95 % CI 0.32, 0.92]. The percentage of women with unacceptable bleeding by four weeks after the initiation of treatment was higher in the treatment group (41%) than in the control group (24%) [RR 1.75, 95% CI 0.85, 3.62].</P>
<P>
<B>21. Matrix metalloproteinase inhibitor versus placebo (therapeutic treatment for Implanon users; n= 2 studies)<BR/>
</B>In a pilot study (<LINK REF="STD-Weisberg-2006" TYPE="STUDY">Weisberg 2006</LINK>) and a larger follow-on trial (<LINK REF="STD-Weisberg-2009" TYPE="STUDY">Weisberg 2009</LINK>), Implanon users who experienced prolonged or frequent bleeding patterns were randomised to receive doxycycline 100 mg/twice daily or similar placebo, for five days. Follow up was for a period of 90 days in the pilot study; the larger trial implemented a 90-day treatment period, then a 90 day follow-up period. In the earlier study, the authors reported that doxycycline was more effective than placebo in stopping an episode of bleeding; this finding was not replicated in the larger trial. Data extracted from the 2009 trial showed no treatment benefit with respect to continued irregular bleeding during treatment; 11 of the 32 women randomized to receive the active treatment reported continued bleeding, compared with 11 of the 37 women who received placebo [RR 1.16, 95% CI 0.58, 2.3]. </P>
<P>At 90 and 180 days following initiation of treatment, there were no differences in Implanon discontinuation rates between women receiving doxycycline and those receiving placebo [RR 0.98; 95% CI 0.26, 3.64] and [RR 0.76; 95% CI 0.31, 1.84], respectively.</P>
<P>There were no differences in the reporting of any side effects between the two groups [RR 0.83, 95% CI 0.53, 1.29]. The side effect of nausea/vomiting was reported in both trials; a combined analysis demonstrated no benefit of the treatment, though results were inconsistent between the studies. In the 2009 trial, fewer women reported headache in the treatment group; however, this finding was not significant.The authors reported that there was good compliance with treatment intake, with only 10% of study participants reporting having missed any tablet.</P>
<P>.</P>
<P>22. <B>Matrix metalloproteinase inhibitor versus placebo (therapeutic treatment for DMPA users; n=1 study)</B>
</P>
<P>In a recently published trial (<LINK REF="STD-Abdel_x002d_Aleem-2012" TYPE="STUDY">Abdel-Aleem 2012</LINK>), 68 women using DMPA who experienced prolonged or frequent bleeding and/or spotting patterns were randomised to receive doxycycline 100 mg/twice daily or an identical placebo, for five days. Trial participants were followed for three months after the initial treatment to compare patterns of bleeding and spotting. When compared with a placebo, doxycycline treatment showed no benefit in stopping an episode of bleeding within 10 days of treatment (RR 0.88, 95% CI 0.64, 1.21). Moreover, during the follow-up of two cycles post treatment, no differences in either the mean number of bleeding or spotting days recorded by study participants were observed. Two women in doxycycline arm (2/34) and three women taking placebo (3/34) discontinued using DMPA during the trial (RR 0.67, 95% CI 0.12, 3.74). Several women reported side effects due to their treatments: in the doxycycline arm, two women experienced nausea and one complained of diarrhoea; whereas one woman who received placebo reported nausea.</P>
<P>
<BR/>
</P>
<P>
<B>23. Antifibrinolytic versus placebo (therapeutic treatment for DMPA users; n= 1 study)</B>
</P>
<P>One randomized trial (<LINK REF="STD-Senthong-2009" TYPE="STUDY">Senthong 2009</LINK>) evaluated the effects of tranexamic acid for treatment of irregular bleeding secondary to use of DMPA. One hundred women were enrolled and randomized to receive either tranexamic acid (1000 mg per day for five days) or placebo, and were followed for four weeks after the initial treatment. Current analysis of the study results showed that six out of the 50 women who were assigned the treatment group, and 45 of the 49 women in the placebo group, experienced continued irregular bleeding during the first week of treatment [RR 0.13, 95% CI 0.06, 0.28]. There was also a significant effect of tranexamic acid on unacceptable bleeding after treatment; women in the treatment group experienced fewer days of bleeding and spotting in the four week follow-up period [mean number of days: 5.7 ± 2.5 days vs 17.5 ± 7.2 days, respectively].</P>
<P>
<B>24. Non-steroidal anti-inflammatory drug versus placebo (therapeutic treatment for Implanon users; n= 1 study)</B>
</P>
<P>A single trial (<LINK REF="STD-Phaliwong-2004" TYPE="STUDY">Phaliwong 2004</LINK>) evaluated the effects of mefenamic acid for treatment of irregular bleeding secondary to use of Implanon. Fifty women were enrolled and randomized to receive either 1500 mg mefenamic acid per day for five days or placebo. They were followed for four weeks after the initial treatment. Eight out of 23 women who were assigned to the treatment group, and 18 of the 23 women in the placebo group, experienced continued irregular bleeding during the first week following initiation of treatment [RR 0.44, 95% CI 0.24, 0.81, current analysis]. Duration of bleeding and spotting during the 28 days of follow-up was reported by the authors to be significantly less among women taking mefenamic acid compared with women assigned to the placebo group [mean number of days: 10.5 days vs 16.8 days, respectively]; however, we were unable to estimate the mean difference in continued irregular bleeding because the standard deviations were not published.</P>
<P>Due to the small number of women enrolled in the trial, and wide confidence intervals surrounding the point estimate of effect, in the current analysis of the results, there were no observed differences in side effects experienced by women taking mefenamic acid compared with placebo. Abdominal discomfort was reported by three women in the treatment group, compared with none in the placebo group. Headache was reported by one woman in each group and breast tenderness was experienced by two women in the mefenamic acid group, but none in the placebo group.</P>
<P>
<B>25. Antiprogestin versus placebo (prophylactic treatment for LNG IUS users; n= 1 study)</B>
</P>
<P>One randomized trial (<LINK REF="STD-Warner-2010" TYPE="STUDY">Warner 2010</LINK>) evaluated the prophylactic effect of the use of an antiprogestin to reduce bleeding irregularities among new users of the LNG IUS. 136 women were enrolled; 69 were randomized to receive CDB-2914 (150 mg per day for three days, starting on days 21, 49 and 77 after device insertion) and 67 received placebo. Follow up visits were scheduled at 1, 3 and 6 months after device insertion. According to current analysis,during the first 28 days following the initial treatment (i.e. initiation on day 21 following LNG IUS insertion), there was a significant difference in the percentage of days in which women experienced bleeding and/or spotting. Women taking anti-progestins reported, on average, bleeding and/or spotting on 46.7% ± 20.6 days during the 28 day period, whereas women in the placebo group recorded irregular bleeding on 57.3% ± 24.8 days during the first 28-day cycle. However, any beneficial effect of treatment with this antiprogestin disappeared by the third treatment cycle (i.e. the 28 days following initiation of treatment on day 77 after insertion). Women taking antiprogestin reported, on average, bleeding and/or spotting on 38.2% ± 23.7 days during the 28 day period, whereas women in the placebo group recorded irregular bleeding on 28.7% ± 20.7 days during the third 28 day cycle. In fact, women in the placebo group reported a significantly lower percentage of days of bleeding and/or spotting during the third cycle.</P>
<P>Twenty-three percent (14/61) of women taking CDB-2914 reported a tendency to gain weight during the trial, compared with only 4% (2/25) of women in the control group. While this difference is statistically significant, according to patient characteristics collected at baseline, women who were randomized to the treatment group were more likely to have discontinued use of a previous contraceptive method due to weight gain.</P>
<P>There was no significant difference with regards to patient dissatisfaction with treatment, as implied by drug noncompliance. Further reports of blood loss improvement did not differ between the two groups. Similar numbers of women in each group requested removal of their LNG IUS during the trial.</P>
<P>
<B>26. Vitamin C supplementation versus placebo (prophylactic treatment for DMPA users; n= 1 study)</B>
</P>
<P>A single trial (<LINK REF="STD-Harel-2002" TYPE="STUDY">Harel 2002</LINK>) evaluated the effects of oral vitamin C supplementation on bleeding patterns among adolescents initiating DMPA use. Fifty-five adolescent girls (age 16 ± 1 years) were randomly assigned to one of four groups (three treatment groups and a placebo group); only one of the treatment groups was included as a possible prophylactic treatment for bleeding irregularities, the other two treatment groups were not included in the present analysis. The treatment group received 500 mg vitamin C plus placebo per day and the placebo group received 2 placebo tablets per day. Follow-up visits were scheduled at three and six months after the initial injection. There was no significant difference in the number of days of bleeding during the follow up period experienced by women in the treatment group, versus the placebo.</P>
<P>
<B>27. Antiprogestin and matrix metalloproteinase inhibitor versus placebo (therapeutic treatment for Implanon users; n= 1 study)</B>
</P>
<P>In a single trial (<LINK REF="STD-Weisberg-2009" TYPE="STUDY">Weisberg 2009</LINK>), Implanon users who experienced prolonged or frequent bleeding patterns were randomised to receive doxycycline 100 mg/twice daily for five days, with the addition of 25 mg mifepristone on the first day, or similar placebo. The trial implemented a 90-day treatment period, with a 90 day post-treatment follow-up period. Extracted data demonstrated a significant treatment benefit with respect to continued irregular bleeding during treatment; 1 of the 35 women randomized to receive the active treatment reported continued bleeding, compared with 11 of the 37 women who received placebo [RR 0.10; 95% CI 0.01, 0.71].</P>
<P>At 90 and 180 days following initiation of treatment, there were no differences in Implanon discontinuation rates between women receiving doxycycline and mifepristone and those receiving placebo, despite a tendency for improved continuation rates at 180 days in the treatment group [RR 0.49; 95% CI 0.09, 2.52] and [RR 0.33; 95% CI 0.09, 1.11], respectively.</P>
<P>The side effect of nausea/vomiting was reported slightly more frequently by women in the treatment group; however, this difference was not significant. Alternatively, fewer women in the treatment group reported headaches; again, this finding was not significant.</P>
<P>
<B>28. Estrogen and matrix metalloproteinase inhibitor versus placebo (therapeutic treatment for Implanon users; n= 1 study)</B>
</P>
<P>In a single trial (<LINK REF="STD-Weisberg-2009" TYPE="STUDY">Weisberg 2009</LINK>), Implanon users who experienced prolonged or frequent bleeding patterns were randomised to receive doxycycline 100 mg/twice daily combined with EE 20 &#956;g/day for five days, or similar placebo. The trial implemented a 90-day treatment period, with a subsequent 90 day follow-up period. Extracted data demonstrated no treatment benefit with respect to the number of women reporting continued irregular bleeding during treatment; 14 of the 35 women randomized to receive the active treatment reported continued bleeding, compared with 11 of the 37 women who received placebo [RR 1.35; 95% CI 0.71, 2.55].</P>
<P>At 90 and 180 days following initiation of treatment, there were no differences in Implanon discontinuation rates between women receiving doxycycline and EE and those receiving placebo.</P>
<P>The number of women reporting the side effects of nausea/vomiting or headache was not different between treatment groups.</P>
<P>
<B>29. Estrogen versus placebo (prophylactic treatment for LNG IUS users; n= 1 study)</B>
</P>
<P>One recently published trial (<LINK REF="STD-Madden-2012" TYPE="STUDY">Madden 2012</LINK>) evaluated whether the application of a transdermal 0.1 mg estradiol patch decreased bleeding and spotting among new users of the LNG IUS. Overall, the trial enrolled 129 women initiating the use of the LNG IUS and randomly assigned them to three arms for twelve weeks of treatment (84 days). Forty-four women were assigned to the transdermal estradiol arm, 42 women received a 500 gm NSAID, and 43 women received a placebo identical to the NSAID. Comparisons between the NSAID and placebo arms are presented and analysed elsewhere in this review.</P>
<P>Women assigned to the transdermal estradiol group applied their patch the day following IUS insertion and used it continuously, changing the patch on a weekly basis, for the 12 week treatment period. Beginning the day after IUS insertion, the placebo group took their study medication twice daily for the first five days of each four week period during the 12 weeks of treatment. Trial participants were asked to complete study diaries to record the occurrence of bleeding and spotting as well as compliance with the study's protocol. Telephone follow-up was conducted at 4, 8 and 16 weeks, and an in-person follow-up visit was scheduled at 12 weeks.</P>
<P>Because the results were reported as medians , range and quartiles, current analysis could not be done , and the results presented as reported by the authors.During the entire treatment period of the trial, women using the estradiol patch reported a greater number bleeding/spotting days than the placebo group [median and range: 44 days (2-82 days) for estradiol patch arm versus 32 days (9-84 days) for placebo arm], however the difference was not statistically different (p-value = 0.15). The distribution of bleeding and spotting over the 12-week treatment period showed that women in the estradiol patch arm were significantly more likely to experience patterns of bleeding/spotting within the highest quartile (i.e., 54-84 days) compared with women who received placebo (40.9% versus 18.l %, p-value = 0.02). During the four week post-treatment period, there were no reported differences in bleeding/spotting between women in the estradiol patch or placebo groups.</P>
<P>Over the 12 treatment period, one woman in each group discontinued the use of the LNG-IUS due to dissatisfaction with the demands of the trial (patch arm) and IUS expulsion (placebo arm). One woman in the patch group discontinued her treatment due to headache complaints. A greater proportion of women in the estradiol patch arm reported dissatisfaction with their treatment compared with the placebo group both at 4 weeks (39.5% versus 11.6%, p-value=0.01) and 12 weeks follow-up (13.5% versus 0).</P>
<P>
<B>30. Non-steroidal anti-inflammatory drug versus placebo (prophylactic treatment for LNG IUS users; n= 1 study)</B>
</P>
<P>A recently published trial (<LINK REF="STD-Madden-2012" TYPE="STUDY">Madden 2012</LINK>) evaluated the prophylactic effect of naproxen in decreasing bleeding and spotting irregularities among new users of the LNG IUS. The trial enrolled 129 new users of the LNG IUS, and randomly assigned them to three arms for twelve weeks of treatment (84 days). Forty-two women were assigned to receive naproxen (500 gm), 43 women received a placebo identical to naproxen, and 44 women were assigned to a transdermal estradiol arm. Comparisons between the estradiol patch and the placebo arms are presented and analysed elsewhere in this review.</P>
<P>Beginning the day after IUS insertion, the naproxen and placebo group took their 500 gm study medication twice daily for the first five days of each four week period during the 12 weeks of treatment. Trial participants were asked to complete study diaries to record the occurrence of bleeding and spotting as well as compliance with the study's protocol. Telephone follow-up was conducted at 4, 8 and 16 weeks, and an in-person follow-up visit was scheduled at 12 weeks.</P>
<P>Because the results were presented as means, range and quartiles, current analysis could not be done per review methodology. The authors reported that over the entire treatment period, women who received naproxen reported fewer bleeding/spotting days than the placebo group [median and range: 27.5 days (5-83 days) naproxen arm versus 32 days (9-84 days) placebo arm], however the difference was not statistically different (p-value = 0.1). The distribution of bleeding and spotting over the 12-week treatment period showed that women taking naproxen were more likely to experience patterns of bleeding/spotting within the lowest quartile (i.e., 2-21 days) compared with women who received placebo (42.9% versus 16.3 %). During the four week post-treatment period, there were no reported differences in bleeding/spotting between women in either group.</P>
<P>Over the 12 week treatment period, two women who received naproxen discontinued use of the LNG IUS due to pregnancy and chest pain. A woman in the placebo group discontinued using her LNG-IUS due to IUS expulsion. Reports of dissatisfaction with treatment differed minimally between the naproxen or placebo groups at 4 weeks (9.5% versus 11.6%); however, more women taking naproxen were dissatisfied with the treatment at 12 weeks (11.4% versus 0).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-04-22 15:59:03 +0200" MODIFIED_BY="[Empty name]">
<P>In performing the original review it became clear that clinical trial authors reported efficacy outcomes in such divergent manners so as to make comparison of the outcomes across studies difficult or impossible; this remains the case at the time of this update. Due to the methodological differences among trials, very few could be combined in our analysis; therefore our findings primarily describe the results from analyses of individual studies. Data for some of the outcomes selected for the review were difficult to extract or interpret. In many studies discontinuation of the contraceptive method for bleeding reasons was not differentiated from discontinuation for other reasons. And, finally, the numbers of women in many of the trials were small, making the results difficult to interpret.</P>
<P>Several of the included studies were designed to evaluate the effects of <B>estrogen </B>administration on bleeding irregularities associated with Norplant or DMPA use. Estrogens may enhance those mechanisms that cause bleeding to cease, i.e. coagulation or tissue repair (<LINK REF="REF-Shaaban-1984" TYPE="REFERENCE">Shaaban 1984</LINK> and <LINK REF="REF-Viegas-1988" TYPE="REFERENCE">Viegas 1988</LINK>). Results were inconsistent, with ethinyl estradiol showing beneficial effects in stopping a current bleeding episode as reported in several of the studies, and significant improvements in a combined analysis of two trials among Norplant users (<LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK> and <LINK REF="STD-Boonkasemsanti-1996" TYPE="STUDY">Boonkasemsanti 1996</LINK>). According to Said (<LINK REF="STD-Said-1996" TYPE="STUDY">Said 1996</LINK>), among DMPA users, intake of ethinyl estradiol stopped bleeding better than placebo during the treatment period; however, part of the data was reported as medians and therefore could not be incorporated into our analyses. The higher rates of study discontinuation related to side effects of estrogenic compounds (<LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>, <LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK>) should encourage providers to exercise caution in recommending these regimens to their patients with bleeding irregularities, particularly those with known sensitivity to estrogens.</P>
<P>It is difficult to draw any firm conclusions from the data related to the prophylactic use of estrogens to prevent bleeding irregularities in DMPA users. While the first of the three studies (<LINK REF="STD-El_x002d_Habashy-1970" TYPE="STUDY">El-Habashy 1970</LINK>) demonstrated a reduction in unacceptable bleeding during treatment with diethylstilbestrol, the study included only small numbers of women and was found to be of only moderate quality, due to possible inadequacies in allocation concealment and outcome assessment binding. In fact, all of the trials in this category suffer from weaknesses in design or implementation, with high rates of discontinuations (23-38%) in two of the trials (<LINK REF="STD-Parker-1980" TYPE="STUDY">Parker 1980</LINK> and <LINK REF="STD-Goldberg-2002" TYPE="STUDY">Goldberg 2002</LINK>, respectively). In two of the trials (<LINK REF="STD-El_x002d_Habashy-1970" TYPE="STUDY">El-Habashy 1970</LINK> and <LINK REF="STD-Parker-1980" TYPE="STUDY">Parker 1980</LINK>) therapies were tested that are no longer available for clinical use. The high rates of discontinuation and of non-compliance with the study protocol in the Goldberg study (<LINK REF="STD-Goldberg-2002" TYPE="STUDY">Goldberg 2002</LINK>) not only confuse the interpretation of the results so that they could not be incorporated into the present analysis, they also suggest that the tested therapy (transdermal estrogen delivered by means of a daily patch) would not be accepted by a large proportion of women.In the recent trial of Madden(<LINK REF="STD-Madden-2012" TYPE="STUDY">Madden 2012</LINK>)A greater proportion of women in the estradiol patch arm reported dissatisfaction with their treatment compared with the placebo group both at 4 weeks (39.5% versus 11.6%, p-value=0.01) and 12 weeks follow-up (13.5% versus 0).,</P>
<P>
<B>Combined oral contraceptives </B>(ethinyl estradiol and levonorgestrel) were used to treat bleeding irregularities among Norplant users in two trials, with the rationale being that most family planning service delivery facilities would have such a therapy readily available (<LINK REF="STD-Alvarez_x002d_Sanchez-1996" TYPE="STUDY">Alvarez-Sanchez 1996</LINK> and <LINK REF="STD-Witjaksono-1996" TYPE="STUDY">Witjaksono 1996</LINK>). The two studies reported a beneficial effect of treatment in stopping bleeding, though the endpoints and data in the latter study were reported in such a way as to make incorporation in our analysis impossible. We might presume to conclude that the addition of a progestin to the treatment regimen offered no benefit over and above the effects of an estrogen alone, but that it did not compromise the safety or effectiveness of an estrogen-only therapy. One study evaluated the role of combined oral contraceptives in treating amenorrhea associated with the use of DMPA (<LINK REF="STD-Sadeghi_x002d_Bazargani-2006" TYPE="STUDY">Sadeghi-Bazargani 2006</LINK> ). These investigators reported that more women resumed menstruation with the use of this therapy, and fewer women discontinued the use of DMPA in comparison to placebo; these positive results were confirmed in the present analysis. However, it is difficult to draw any conclusion about this regimen as the type, dose and duration of use of the combined oral contraceptive was not reported; in addition, the sample size was small, with fewer than 25 women in each study group.</P>
<P>The use of an <B>additional progestin </B>to resolve bleeding irregularities in Norplant users met with limited success in a single study (<LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>). While the study reported moderate improvements in bleeding in women using levonorgestrel compared with placebo, it suffered from high discontinuation rates, high rates of non-use of the treatment, even when required by the protocol, and other potential sources of bias. Because of the natural changes in bleeding patterns over the first year of Norplant use, the data describing the overall mean number of bleeding days in every treated bleeding interval (up to five in the year, but with a mean range of 2.2 to 3.1 treated cycles per woman per year) could not be included in our analyses. We could not compare these mean data with data on single intervals of treatment.</P>
<P>An <B>anti-progestin</B> (mifepristone) was used to treat bleeding among Norplant users in one trial (<LINK REF="STD-Cheng-2000" TYPE="STUDY">Cheng 2000</LINK>). According to our analysis, users of mifepristone reported a significant decrease in bleeding during treatment at six months following initiation of treatment, but not before. This supports the authors' report that all women experienced a decrease in the frequency of bleeding over the course of the one-year study, but that the decrease was more gradual in the placebo group than for those women receiving mifepristone.</P>
<P>Anti-progestins have also been shown to be somewhat promising in the prevention of bleeding irregularities in DMPA (<LINK REF="STD-Jain-2003" TYPE="STUDY">Jain 2003</LINK>), minipill (<LINK REF="STD-Gemzell_x002d_Danielsson-2002" TYPE="STUDY">Gemzell-Danielsson 2002</LINK> ), Norplant (<LINK REF="STD-Massai-2004" TYPE="STUDY">Massai 2004</LINK>) and LNG IUS users (<LINK REF="STD-Warner-2010" TYPE="STUDY">Warner 2010</LINK>). In the first two studies, the authors reported that women taking antiprogestins reported fewer cycles with extended periods (more than 14 days) of breakthrough bleeding or better cycle control, respectively, than did placebo users; however, these outcomes were not identified for the present review, and therefore the data could not be included in this analysis. Massai et al (<LINK REF="STD-Massai-2004" TYPE="STUDY">Massai 2004</LINK>) demonstrated acute, but not long-term, improvements in bleeding patterns in new Norplant users taking mifepristone.<LINK REF="STD-Warner-2010" TYPE="STUDY">Warner 2010</LINK> reported similar results with the use of antiprogestin(CDB-2914) to reduce bleeding irregularities among new users of the LNG IUS. In contrast, mifepristone was not effective in stopping an episode of bleeding in women using Implanon (<LINK REF="STD-Weisberg-2006" TYPE="STUDY">Weisberg 2006</LINK>). In this trial, the addition of an estrogen to mifepristone was more effective than placebo in stopping an episode of bleeding. The data were presented in terms of 90-day reference periods, before and after the treatment; our analysis was not able to capture the data presented in this manner.</P>
<P>Glasier et al (<LINK REF="STD-Glasier-2002" TYPE="STUDY">Glasier 2002</LINK>) and Jain et al (<LINK REF="STD-Jain-2003" TYPE="STUDY">Jain 2003</LINK>) have suggested that mifepristone may functionally inhibit progesterone, leading to up-regulation of endometrial estrogen receptors and a positive effect on bleeding patterns similar to exogenous estrogen treatment. In contrast, Grow and co-workers (<LINK REF="REF-Grow-1998" TYPE="REFERENCE">Grow 1998</LINK>) have demonstrated, primarily in non-human primates, that even though estrogen receptors are increased following mifepristone exposure, the receptors may not be transcriptionally active.</P>
<P>While anti-progestins have been shown in some trials to improve bleeding. The results of these studies need to be substantiated in larger, well-controlled trials; an effective dose and regimen need to be defined. In addition, the safety of such a regimen needs to be established, as the approach to antagonize the effect of the contraceptive progestin to achieve better bleeding patterns may potentially compromise the efficacy of the contraceptive method. In fact, one pregnancy was reported in the trial using the highest dose of mifepristone (<LINK REF="STD-Massai-2004" TYPE="STUDY">Massai 2004</LINK>).</P>
<P>The results of the single trial that was designed to evaluate the effects of a <B>SERM</B> (tamoxifen) on bleeding patterns in women using progestin-only contraceptive methods were quite promising in terms of effectiveness, safety, continuation of the contraceptive method and compliance with treatment (<LINK REF="STD-Abdel_x002d_Aleem-2005" TYPE="STUDY">Abdel-Aleem 2005</LINK>). This was the only regimen that demonstrated an effect that lasted longer than the period of treatment. Again, this result needs to be substantiated in larger trials, with longer periods of follow-up, before any clinical recommendation can be made. Grow et al hypothesized that SERMs may improve bleeding patterns disrupted by the use of progestin-only contraceptives by antagonizing the angiogenic effect of estrogen (<LINK REF="REF-Grow-1998" TYPE="REFERENCE">Grow 1998</LINK>).</P>
<P>Several <B>other types of treatments </B>have been shown to be somewhat effective in small trials, but the results have not been reproduced in larger studies, possibly demonstrating a overestimation of the beneficial effects of drugs in small studies. <B>Vitamin E</B>, for example, was effective in reducing the number of bleeding days during treatment in a pilot study conducted in Indonesia (<LINK REF="STD-Subakir-2000" TYPE="STUDY">Subakir 2000</LINK>); these results were not replicated in a large multi-centre study of the same regimen, even in the same Indonesian centre (<LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>). The d'Arcangues et al study (<LINK REF="STD-d_x0027_Arcangues-2004" TYPE="STUDY">d'Arcangues 2004</LINK>) also failed to demonstrate the positive results of <B>NSAIDs</B> on bleeding patterns reported by Diaz et al (<LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>), Kaewrudee et al (<LINK REF="STD-Kaewrudee-1999" TYPE="STUDY">Kaewrudee 1999</LINK>) , Nathirojanakun et al (<LINK REF="STD-Nathirojanakun-2006" TYPE="STUDY">Nathirojanakun 2006</LINK>) and Madden (<LINK REF="STD-Madden-2012" TYPE="STUDY">Madden 2012</LINK>). These different results may be related to the use of different treatments - the studies that reported a positive effect of the treatment tested ibuprofen, as used by 21 women (<LINK REF="STD-Diaz-1990" TYPE="STUDY">Diaz 1990</LINK>), mefenamic acid, in 34 women (<LINK REF="STD-Kaewrudee-1999" TYPE="STUDY">Kaewrudee 1999</LINK>) or the COX-2 inhibitor, valdecoxib, in 22 women (<LINK REF="STD-Nathirojanakun-2006" TYPE="STUDY">Nathirojanakun 2006</LINK>); and naproxen in 42 new users of LNG IUS. In the larger trial, in which an NSAID was not effective, over 100 women who received aspirin were included in the analysis. On the other hand, the rationale for testing both Vitamin E and NSAIDs is scientifically compelling. As the angiogenic response in the endometrium of Norplant users has been found to be lower than in women with normal menstrual cycles (<LINK REF="STD-Subakir-2000" TYPE="STUDY">Subakir 2000</LINK>), the disturbance in the angiogenic process, as well as an imbalance of pro- and antioxidant processes in the endometrium, may contribute to irregular bleeding in Norplant users. Supplementation with vitamin E may serve as an effective method of preventing membrane damage caused by oxygen radicals (<LINK REF="REF-Halliwell-1992" TYPE="REFERENCE">Halliwell 1992</LINK>) or of increasing endometrial angiogenic activity(<LINK REF="STD-Subakir-2000" TYPE="STUDY">Subakir 2000</LINK> ).<BR/>
<BR/>One small study have suggested that <B>the antifibrinolytic compound</B>, tranexamic acid, can have a short-term therapeutic effect on bleeding disturbances in Norplant users (<LINK REF="STD-Phupong-2006" TYPE="STUDY">Phupong 2006</LINK>) .Tranexamic acid has been used around the world for over 20 years to treat heavy menstrual bleeding. Tranexamic acid, a synthetic lysine derivative, is an antifibrinolytic drug that prevents the breakdown of fibrin by competitively blocking binding sites of plasminogen.By slowing the process of dissolving the tiny clots that are formed as a result of bleeding, tranexamic acid can reduce the amount of bleeding (<LINK REF="REF-Lukes-2011" TYPE="REFERENCE">Lukes 2011</LINK>). Small studies evaluated the effect of the matrix metalloproteinase inhibitor, doxycycline (DOX), in terminating an episode of prolonged bleeding in Implanon users. One pilot study showed a beneficial effect of DOX (<LINK REF="STD-Weisberg-2006" TYPE="STUDY">Weisberg 2006</LINK>). But these results were not replicated in a trial done in the same centre(<LINK REF="STD-Weisberg-2009" TYPE="STUDY">Weisberg 2009</LINK>) and in a more recent trial testing DOX to treat bleeding episodes among DMPA users (<LINK REF="STD-Abdel_x002d_Aleem-2012" TYPE="STUDY">Abdel-Aleem 2012</LINK>).The three trials used the same dose and regimen of DOX.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-04-22 16:00:37 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-02-07 20:53:56 +0100" MODIFIED_BY="[Empty name]">
<P>Based on the results of this review, women may benefit to a degree from the interventions described, particularly with regard to cessation of an ongoing bleeding episode. Several regimens offer promise in regulating bleeding in the short term, but positive results need to be reproduced in larger scale trials. The results of the review do not support the routine clinical use of any of the treatment or preventive regimens to exert anything other than a short-term effect on the current bleeding episode; no medium- or long-term beneficial effects were described in any of the studies. The review was focused on pharmacologic interventions; however, it is acknowledged that proper counseling at the time of method initiation can help to prepare women for the bleeding irregularities that they may experience and improves method continuation rates.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-04-22 16:00:37 +0200" MODIFIED_BY="[Empty name]">
<P>Many women using progestin-only methods experience unacceptable bleeding disturbances, discontinue use, and are left without contraceptive protection or switch to a less effective method. It is essential that the family planning research community develop standardized methodologies for research and reporting in this field of study. If a common set of outcomes could be developed and widely utilized, studies could be more easily and effectively interpreted and compared, and the findings would more readily make their way into evidence-based practice, as appropriate. It is recommended that future studies attempt to collect data on blood loss using objective and validated measurement tools, such as the pictorial blood assessment scores.</P>
<P>Through the process of performing the review, it became clear to the authors that additional research directed towards the possible underlying mechanisms of bleeding among users of these products is required. Results from such studies would not only help to further identify potential therapeutic interventions, but would help to ensure that clinical studies and, eventually, treatments can be based on etiological findings.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-01-02 09:19:57 +0100" MODIFIED_BY="[Empty name]">
<P>The statistical advice and assistance of Barts J.A. Mertens, Department of Medical Statistics, Leiden University, the Netherlands and Dr Gilda Piaggio, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction are gratefully acknowledged, for their contributions to the original review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>CDA and HAA have conducted research in this area and have authored papers included in the review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-02-07 21:03:42 +0100" MODIFIED_BY="[Empty name]">
<P>HAA, CDA, AMG had the idea. HAA prepared the protocol with comments from CDA, KV and AMG. KV. In this updated review,KV, MG and HAA extracted the data. HAA, MG and KV prepared and updated the review. CDA reviewed the updated review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-02-08 14:30:58 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-02-08 14:30:58 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-02-08 14:30:58 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdel_x002d_Aleem-2005" NAME="Abdel-Aleem 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdel-Aleem H, Shaaban OM, Amin AF, Abdel-Aleem AM</AU>
<TI>Tamoxifen treatment of bleeding irregularities associated with Norplant use</TI>
<SO>Contraception</SO>
<YR>2005</YR>
<VL>72</VL>
<PG>432-437</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 16307966"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abdel_x002d_Aleem-2012" MODIFIED="2013-01-02 09:21:35 +0100" MODIFIED_BY="[Empty name]" NAME="Abdel-Aleem 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-12-29 18:07:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdel-Aleem H, Shaaban OM, Abdel-Aleem MA, Fetih GN</AU>
<TI>Doxycycline in the treatment of bleeding with DMPA: a double-blinded randomized controlled trial</TI>
<SO>Contraception</SO>
<YR>2012</YR>
<VL>86</VL>
<PG>224-230</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1016/j.contraception.2012.01.003"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-01-02 09:21:35 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez_x002d_Sanchez-1996" NAME="Alvarez-Sanchez 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A</AU>
<TI>Hormonal treatment for bleeding irregularities in Norplant implant users</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>174</VL>
<PG>919-922</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Archer-2008" MODIFIED="2009-09-30 11:18:30 +0200" MODIFIED_BY="[Empty name]" NAME="Archer 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-09-30 11:18:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Archer DF, Philput CB,Levine AS,Cullins V,Stoval TG,Bacon J,Weber ME</AU>
<TI>Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in Levonorgestrel subcutaneous implant users.</TI>
<SO>Contraception</SO>
<YR>2008</YR>
<VL>78</VL>
<PG>106-112</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boonkasemsanti-1996" NAME="Boonkasemsanti 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boonkasemsanti W, Reinprayoon D, Pruksananonda K, Niruttisard S, Triratanachat S, Leepipatpaiboon S, Wannakrairot P</AU>
<TI>The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users</TI>
<SO>Human Reproduction</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>115-123</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buasang-2009" MODIFIED="2009-09-28 11:08:18 +0200" MODIFIED_BY="[Empty name]" NAME="Buasang 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-09-28 11:08:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Buasang K,Taneepanichskul S</AU>
<TI>Efficacy of Celecoxib on controlling irregular uterine bleeding secondary to Jadelle use</TI>
<SO>J Med Assoc Thai</SO>
<YR>2009</YR>
<VL>92</VL>
<PG>301-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2000" NAME="Cheng 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng L, Zhu H, Wang A, Ren F, Chen J, Glasier A</AU>
<TI>Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel</TI>
<SO>Human Reproduction</SO>
<YR>2000</YR>
<VL>15</VL>
<PG>1969-1972</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-d_x0027_Arcangues-2004" MODIFIED="2013-02-08 14:30:58 +0100" MODIFIED_BY="[Empty name]" NAME="d'Arcangues 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>d'Arcangues C, Piaggio G, Brache V, Aissa RB, Hazelden C, Massai R, Pinol A, Subakir SB, Su-juan G; Study Group on Progestogen-induced Vaginal Bleeding Disturbances</AU>
<TI>Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, in Norplant-induced prolonged bleeding</TI>
<SO>Contraception</SO>
<YR>2004</YR>
<VL>70</VL>
<PG>451-462</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 15541406"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dempsey-2010" MODIFIED="2010-09-19 18:36:59 +0200" MODIFIED_BY="[Empty name]" NAME="Dempsey 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-09-19 18:36:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dempsey A,Roca C, westhoff C</AU>
<TI>Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial.</TI>
<SO>Contraception</SO>
<YR>2010</YR>
<VL>82</VL>
<PG>250-255</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diaz-1990" NAME="Diaz 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diaz S, Croxatto HB, Pavez M, Belhadj H, Stern J, Sivin I</AU>
<TI>Clinical assessment of treatments for prolonged bleeding in users of Norplant implants</TI>
<SO>Contraception</SO>
<YR>1990</YR>
<VL>42</VL>
<PG>97-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Habashy-1970" NAME="El-Habashy 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Habashy MA, Mishell DR Jr, Moyer DL</AU>
<TI>Effect of supplementary oral estrogen on long-acting injectable progestogen contraception</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1970</YR>
<VL>35</VL>
<PG>51-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gemzell_x002d_Danielsson-2002" MODIFIED="2011-02-07 11:12:50 +0100" MODIFIED_BY="[Empty name]" NAME="Gemzell-Danielsson 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gemzell-Danielsson K, van Heusden AM, Killick SR, Croxatto HB, Bouchard P, Cameron S, Bygdeman M</AU>
<TI>Improving cycle control in progestogen -only contraceptive pill users by intermittent treatment with a new anti-progestogen</TI>
<SO>Human Reproduction</SO>
<YR>2002</YR>
<VL>17</VL>
<PG>2588-2593</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-2002" NAME="Goldberg 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg AB, Cardenas LH, Hubbard AE, Darney PD</AU>
<TI>Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol</TI>
<SO>Contraception</SO>
<YR>2002</YR>
<VL>66</VL>
<PG>215-220</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harel-2002" MODIFIED="2009-10-07 12:33:59 +0200" MODIFIED_BY="[Empty name]" NAME="Harel 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-10-07 12:33:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harel Z,Biro F, Kollar L, Riggs S, Flangan P, Vaz R.</AU>
<TI>Supplementation with vitamin C and/or vitamin B6 in the prevention of Depo-Provera side effects in adolescents.</TI>
<SO>J Pediatr Gynecol</SO>
<YR>2002</YR>
<VL>15</VL>
<PG>153-158</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jain-2003" NAME="Jain 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jain JK, Nicosia AF, Nucatola DL, Lu JJ, Felix JC</AU>
<TI>Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate</TI>
<SO>Steroids</SO>
<YR>2003</YR>
<VL>68</VL>
<PG>1115-1119</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 14668006"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johannisson-1982" NAME="Johannisson 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johannisson E , Landgren BM, Diczfalusy E</AU>
<TI>Endometrial morphology and peripheral steroid levels in women with and without intermenstrual bleeding during contraception with 300 mcg Norethisterone (NET) Minipill</TI>
<SO>Contraception</SO>
<YR>1982</YR>
<VL>25</VL>
<PG>13-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaewrudee-1999" NAME="Kaewrudee 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaewrudee S, Taneepanichskul S, Jaisamraun U, Reinprayoon D</AU>
<TI>The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use</TI>
<SO>Contraception</SO>
<YR>1999</YR>
<VL>60</VL>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madden-2012" MODIFIED="2013-01-06 15:08:12 +0100" MODIFIED_BY="[Empty name]" NAME="Madden 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-01-06 15:08:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madden T, Proehl S, Allsworth JE, Secura GM, Peipert JE.  </AU>
<TI>Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>2012</YR>
<VL>206</VL>
<NO>2</NO>
<PG>129.e 1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massai-2004" NAME="Massai 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massai MR, Pavez MR, Fuentealba B, Croxatto H, d'Arcangues C</AU>
<TI>Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users</TI>
<SO>Contraception</SO>
<YR>2004</YR>
<VL>70</VL>
<PG>442-450</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monteil_x002d_Seurin-1985" NAME="Monteil-Seurin 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monteil-Seurin J, Bernard-Fernier MF, Martinaggi P, Demarez JP, Cauquil J, Lafont A</AU>
<TI>Evaluation of the efficacy of a ventonic capillary protector in the treatment of metrorrhagia due to IUD or micropill contraception</TI>
<TO>Appreciation de l'efficacite d'une association veinotonique protecteur capillaire comme traitment des metrorragies de la contraception par D.I.U. ou par micropilule</TO>
<SO>Contraception-fertilité-sexualité</SO>
<YR>1985</YR>
<VL>13</VL>
<PG>721-725</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nathirojanakun-2006" NAME="Nathirojanakun 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nathirojanakun P, Taneepanichskul S, Sappakitkumjorn N</AU>
<TI>Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users</TI>
<SO>Contraception</SO>
<YR>2006</YR>
<VL>73</VL>
<PG>584-587</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parker-1980" NAME="Parker 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parker RA</AU>
<TI>The use of Quinesterol for the control of vaginal bleeding irregularities caused by DMPA</TI>
<SO>Contraception</SO>
<YR>1980</YR>
<VL>22</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phaliwong-2004" MODIFIED="2013-01-06 15:09:18 +0100" MODIFIED_BY="[Empty name]" NAME="Phaliwong 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-06 15:09:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phaliwong P, Taneepanichskul S</AU>
<TI>The effect of Mefenamic acid on controlling irregular uterine bleeding second to Implanon use.</TI>
<SO>J Med Assoc Thai</SO>
<YR>2004</YR>
<VL>87(Suppl 3)</VL>
<PG>S64-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phupong-2006" NAME="Phupong 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phupong V, Sophonsritsuk A, Taneepanichskul S</AU>
<TI>The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use</TI>
<SO>Contraception</SO>
<YR>2006</YR>
<VL>73</VL>
<PG>253-256</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sadeghi_x002d_Bazargani-2006" MODIFIED="2011-02-07 11:14:12 +0100" MODIFIED_BY="[Empty name]" NAME="Sadeghi-Bazargani 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadeghi-Bazargani H, Ehdaeivand F, Arshi S, Eftekhar H, Sezavar H, Amanati L</AU>
<TI>Low-dose oral contraceptive to re-induce menstrual bleeding in amenorrheic women on DMPA treatment: A randomized clinical trial</TI>
<SO>Medical Science Monitor</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>CR420-CR425</PG>
<MD>Amanati L. Sadeghi-Bazargani H. Ehdaeivand F. Arshi S. Eftekhar H. Sezavar H. Amanati L.</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Said-1996" NAME="Said 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Said S, Sadek W, Rocca M, Koetsawang S, Kirwat O, Piya-Anant M, Dusitsin N, Sethavanich S, Affandi B, Hadisaputra W, Kazi A, Ramos RM, d'Arcangues C, Belsey EM, Noonan E, Olayinka I, Pinol A; World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents For Fertility Regulation</AU>
<TI>Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception</TI>
<SO>Human Reproduction</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>1-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 8982739"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Senthong-2009" MODIFIED="2009-09-28 11:14:37 +0200" MODIFIED_BY="[Empty name]" NAME="Senthong 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-09-28 11:14:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Senthong A, Taneepanichskul S</AU>
<TI>The effect of Tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use</TI>
<SO>J Med Assoc Thai</SO>
<YR>2009</YR>
<VL>92</VL>
<PG>461-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subakir-2000" NAME="Subakir 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subakir SB, Setiadi E, Affandi B, Pringgoutomo, Freisleben HJ</AU>
<TI>Benefits of vitamin E supplementation to Norplant users - in vitro and in vivo studies</TI>
<SO>Toxicology</SO>
<YR>2000</YR>
<VL>148</VL>
<PG>173-8</PG>
<ED>Freisleben HJ and Deisinger B</ED>
<PB>Gardez! Verlag, St. Augustin</PB>
<CY>Germany</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISBN 3-928624-98-9"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tantiwattanakul-2004" NAME="Tantiwattanakul 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tantiwattanakul P, Taneepanichskul S</AU>
<TI>Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users</TI>
<SO>Contraception</SO>
<YR>2004</YR>
<VL>70</VL>
<PG>277-279</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warner-2010" MODIFIED="2010-08-09 09:52:54 +0200" MODIFIED_BY="[Empty name]" NAME="Warner 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-08-09 09:52:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warner P,Guttinger A, Glasier AF,Lee RJ,Nickerson S,Brenner RM,Crtichley HOD.</AU>
<TI>Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding</TI>
<SO>Human Reproduction</SO>
<YR>2010</YR>
<VL>25</VL>
<PG>345-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weisberg-2006" NAME="Weisberg 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weisberg E, Hickey M, Palmer D, O&#8217;Connor V, Salamonsen L, Findlay JK, Fraser IS</AU>
<TI>A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>295&#8211;302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weisberg-2009" MODIFIED="2013-01-06 19:25:44 +0100" MODIFIED_BY="[Empty name]" NAME="Weisberg 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-10-03 11:56:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weisberg E, Hickey M, Plamer D, O'Connor V,Salamonsen LA,Findlay JK,Fraser IS.</AU>
<TI>A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users</TI>
<SO>Human Reproduction</SO>
<YR>2009</YR>
<VL>24</VL>
<PG>1852-1861</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witjaksono-1996" NAME="Witjaksono 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Witjaksono J, Lau TM , Affandi B, Rogers PA</AU>
<TI>Oestrogen treatment for increased bleeding in Norplant users: preliminary results</TI>
<SO>Human Reproduction</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>109-114</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-02-07 10:36:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Archer-1996" NAME="Archer 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Archer DF, Philput CA, Weber ME</AU>
<TI>Management of irregular uterine bleeding and spotting associated with Norplant</TI>
<SO>Human Reproduction</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>24-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cseffalvay-1965" NAME="Cseffalvay 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cseffalvay T and Klose S</AU>
<TI>(Estrogen-gestagen therapy with hormonally induced uterine bleeding.11.Therapeutic use of Klimovan)</TI>
<SO>Deutsche gesundheitswesen</SO>
<YR>1965</YR>
<VL>20</VL>
<PG>1334-1339</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-d_x0027_Arcangues-2000" NAME="d'Arcangues 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>d'Arcangues C</AU>
<TI>Management of vaginal bleeding irregularities induced by progestin-only contraceptives</TI>
<SO>Human Reproduction</SO>
<YR>2000</YR>
<VL>15</VL>
<PG>24-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glasier-2002" NAME="Glasier 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glasier AF, Wang H, Davie JE, Kelly RW, Critchley HO</AU>
<TI>Administration of antiprogesterone up-regulates estrogen receptors in the endometrium of women using norplant: a pilot study</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>77</VL>
<PG>366-372</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piya_x002d_Anant-1998" NAME="Piya-Anant 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piya-Anant M, Koetsawang S, Patrasupapong N, Dinchuen P, d'Arcangues C, Piaggio G, Pinol A</AU>
<TI>Effectiveness of cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea</TI>
<SO>Contraception</SO>
<YR>1998</YR>
<VL>57</VL>
<NO>1</NO>
<PG>23-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sapire-1991" MODIFIED="2011-02-07 10:36:42 +0100" MODIFIED_BY="[Empty name]" NAME="Sapire 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-02-07 10:36:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sapire KE</AU>
<TI>A study of bleeding patterns with two injectable contraceptives given postpartum and the effect of two non-hormonal treatments</TI>
<SO>Advances in Contraception</SO>
<YR>1991</YR>
<VL>7</VL>
<PG>379-387</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-05-29 15:13:28 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-01-06 15:14:18 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-01-06 15:14:18 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adeyemi-2012" MODIFIED="2013-01-02 09:23:43 +0100" MODIFIED_BY="[Empty name]" NAME="Adeyemi 2012" TYPE="JOURNAL_ARTICLE">
<AU>Adeyemi, A. S. and D. A. Adekanle</AU>
<TI>Progestogen-only injectable contraceptive: experience of women in Osogbo, southwestern Nigeria</TI>
<SO>Ann Afr Med </SO>
<YR>2012</YR>
<VL>11</VL>
<PG>27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Affandi-1998" NAME="Affandi 1998" TYPE="JOURNAL_ARTICLE">
<AU>Affandi B</AU>
<TI>An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon</TI>
<SO>Contraception</SO>
<YR>1998</YR>
<VL>58</VL>
<PG>99s-107s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-d_x0027_Arcangues-1992" NAME="d'Arcangues 1992" TYPE="BOOK_SECTION">
<AU>d'Arcangues C, Odlind V, Fraser IS</AU>
<TI>Dysfunctional uterine bleeding induced by exogenous hormones</TI>
<SO>Steroid hormones and uterine bleeding</SO>
<YR>1992</YR>
<PG>81-105</PG>
<ED>Alexander NJ, d'Arcangues C</ED>
<PB>AAAS Press</PB>
<CY>Washington</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISBN 0-87168-508-6"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Datey-1995" NAME="Datey 1995" TYPE="JOURNAL_ARTICLE">
<AU>Datey S, Gaur LN, Saxena BN</AU>
<TI>Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills) - an Indian experience. An ICMR Task Force Study. Indian Council of Medical Research</TI>
<SO>Contraception</SO>
<YR>1995</YR>
<VL>51</VL>
<PG>155-165</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID 7621684 UI 95347181"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fan-1996" NAME="Fan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Fan M, Sujuan G</AU>
<TI>Menstrual bleeding patterns in Chinese women using the Norplant subdermal implant</TI>
<SO>Human Reproduction</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>14-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fraser-1983" NAME="Fraser 1983" TYPE="JOURNAL_ARTICLE">
<AU>Fraser IS</AU>
<TI>A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives</TI>
<SO>Contraception</SO>
<YR>1983</YR>
<VL>28</VL>
<PG>385-397</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fraser-1998" NAME="Fraser 1998" TYPE="JOURNAL_ARTICLE">
<AU>Fraser IS, Tiitinen A, Affandi B, Brache V, Croxatto H, Diaz S, Ginsburg J, Gu S, Holma P, Johansson E, Meirik O, Mishell DR Jr, Nash HA, von Schoultz B, Sivin I</AU>
<TI>Norplant consensus statement and background review</TI>
<SO>Contraception</SO>
<YR>1998</YR>
<VL>57</VL>
<PG>1-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9554244"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grow-1998" NAME="Grow 1998" TYPE="JOURNAL_ARTICLE">
<AU>Grow DR, Reece MT, Hsiu JG, Adams L, Newcomb PM, Williams RF, Hodgen GD</AU>
<TI>Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroplast growth factor: a 1-year primate study in contraception and amenorrhea</TI>
<SO>Fertility and Sterility</SO>
<YR>1998</YR>
<VL>69</VL>
<NO>5</NO>
<PG>936-943</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 9591506"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Halliwell-1992" NAME="Halliwell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Halliwell B, Gutteridge JM, Cross CE</AU>
<TI>Free radical, antioxidants and human disease: where are we now?</TI>
<SO>Journal of Laboratory and Clinical Medicine</SO>
<YR>1992</YR>
<VL>119</VL>
<PG>598-620</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lukes-2011" MODIFIED="2013-01-06 11:40:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lukes 2011" TYPE="JOURNAL_ARTICLE">
<AU>Lukes AS, Kouides PA, Moore KA.</AU>
<TI>Tranexamic acid: a novel oral formulation for the treatment of heavy menstrual bleeding</TI>
<SO>Womens Health (Lond Engl).</SO>
<YR>2011</YR>
<VL>7</VL>
<NO>2</NO>
<PG>151-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newton-1994" NAME="Newton 1994" TYPE="JOURNAL_ARTICLE">
<AU>Newton JR, d'Arcangues C, Hall PE</AU>
<TI>A review of "once-a-month" combined injectable contraceptives</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1994</YR>
<VL>4</VL>
<PG>S1- S34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nutley-1997" NAME="Nutley 1997" TYPE="JOURNAL_ARTICLE">
<AU>Nutley T, Dunson TR</AU>
<TI>Treatment of bleeding problems associated with progestin-only contraceptives: survey results</TI>
<SO>Advances in Contraception</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>419-428</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Said-1987" NAME="Said 1987" TYPE="JOURNAL_ARTICLE">
<AU>Said S, Omar K, Koetsawang S, Kiriwat O, Srisatayapan Y, Kazi A, Ajmal F, Wynter HH, Pretnar-Darovec A, Benitez IB; World Health Organization, Task Force on Long-Acting Systemic Agents for Fertility Regulation, Special Programme of Research, Development and Research Training in Human Reproduction</AU>
<TI>A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns</TI>
<SO>Contraception</SO>
<YR>1987</YR>
<VL>35</VL>
<PG>591-610</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 2959448"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shaaban-1984" NAME="Shaaban 1984" TYPE="JOURNAL_ARTICLE">
<AU>Shaaban MM, Elwan SI, el-Kabsh MY, Farghaly SA, Thabet N</AU>
<TI>Effect of levonorgestrel contraceptive implants, Norplant, on blood coagulation</TI>
<SO>Contraception</SO>
<YR>1984</YR>
<VL>30</VL>
<PG>421-430</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 6440738"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Suvisaari-1996" NAME="Suvisaari 1996" TYPE="JOURNAL_ARTICLE">
<AU>Suvisaari J, Lahteenmaki P</AU>
<TI>Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortion insertion of a copper IUD or a levonorgestrel-releasing intrauterine system</TI>
<SO>Contraception</SO>
<YR>1996</YR>
<VL>54</VL>
<PG>201-208</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Viegas-1988" NAME="Viegas 1988" TYPE="JOURNAL_ARTICLE">
<AU>Viegas OA, Singh K, Koh S, Singh P, Ratnam SS</AU>
<TI>The effects of Norplant on clinical chemistry in Singaporean acceptors after 1 year of use: I. Haemostatic changes</TI>
<SO>Contraception</SO>
<YR>1988</YR>
<VL>38</VL>
<PG>313-323</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 3139360"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2012-05-29 15:13:04 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abdel_x002d_Aleem-2012" MODIFIED="2012-05-29 15:13:04 +0200" MODIFIED_BY="[Empty name]" NAME="Abdel-Aleem 2012" TYPE="JOURNAL_ARTICLE">
<AU>Abdel-Aleem H, Shaaban OM, Abdel-Aleem MA, Fetih GN</AU>
<TI>Doxycycline in the treatment of bleeding with DMPA: a double-blinded randomized controlled trial</TI>
<SO>Contraception</SO>
<YR>2012</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1016/j.contraception.2012.01.003"/>
</IDENTIFIERS>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-04-24 11:23:08 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-04-24 11:23:08 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-04-22 16:01:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdel_x002d_Aleem-2005">
<CHAR_METHODS>
<P>Randomized trial<BR/>Study duration: 3 months<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: yes<BR/>Drop outs: 7 (7%)<BR/>Validity criteria: A</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 16:01:20 +0200" MODIFIED_BY="[Empty name]">
<P>100 women in the first year of Norplant use, complaining of increased bleeding<BR/>Age:<BR/>Tamoxifen: 32.48 ± 5.6<BR/>Pl: 32.28 ± 6.1<BR/>Education level:<BR/>Tamoxifen: 26/50 illiterate; 24/50 some education<BR/>Pl: 24/50 illiterate; 26/50 some education<BR/>Setting: Family planning clinic, university hospital<BR/>Diagnostic criteria:<BR/>Abnormal/increased bleeding defined as current episode of bleeding/spotting longer than 8 days OR bleeding-free interval less than 15 days.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 16:01:29 +0200" MODIFIED_BY="[Empty name]">
<P>Agents:<BR/>Tamoxifen (n=50): 10 mg twice a day, for 10 days, oral;<BR/>Placebo (n=50): twice a day, for 10 days, oral.<BR/>Treatment length: 10 days<BR/>Follow up: 3 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 16:01:56 +0200" MODIFIED_BY="[Empty name]">
<P>Percent of women who stopped bleeding during the treatment:<BR/>Overall, within 3 days, within 7 days, within 10 days.</P>
<P>Bleeding, spotting or bleeding/spotting days during follow up:<BR/>First month, second month, third month</P>
<P>Bleed-free interval post-treatment (days)</P>
<P>B/S episodes in 90 day reference period</P>
<P>Discontinuation of contraceptive method due to bleeding</P>
<P>Discontinuation of treatment due to lack of improvement</P>
<P>Side effects related to treatment:<BR/>Headache, GI disturbance, dizziness, fatigue, hot flush, other</P>
<P>Patient satisfaction with treatment, over time:<BR/>First month, second month, third month - data not given (no difference between groups)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 16:04:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdel_x002d_Aleem-2012">
<CHAR_METHODS MODIFIED="2012-11-22 08:23:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial</P>
<P>Study duration: three months</P>
<P>Type of trial: parallel</P>
<P>Outcome assessment blinding: yes</P>
<P>Drop outs: 5/34 (14.7%) .Doxycyclin 8.9%, Control 5.9%</P>
<P>Validity criteria: B (moderate risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 16:04:10 +0200" MODIFIED_BY="[Empty name]">
<P>68 women using DMPA as a contraception for at least one month and having bleeding episode,defined as [&#8805;8 bleeding or spotting days or bleeding-free interval less than15days) and were expected to be able to keep an accurate menstrual diary. Lactating women were excluded for fear of the effect of DOX on the breast fed infant.Women who had been diagnosed to have any local gynecological abnormality or those who were receiving any other treatment for bleeding within the last 1month prior to the study were also excluded.</P>
<P>Setting: family planning clinic in a University Hospital</P>
<P>Age:DOX 29.6±7.3 years .Placebo 30.0±5.7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 15:34:29 +0200" MODIFIED_BY="[Empty name]">
<P>Doxycyclin (DOX) 100 mg capsules PO/ twice daily for 5 days.</P>
<P>Placebo one capsule PO/ twice daily for 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 15:48:42 +0200" MODIFIED_BY="[Empty name]">
<P>The primary outcome of the study was the cessation of the current bleeding episode within 10 days.Other outcome measures included the number of days needed to stop a current episode of bleeding,the length of the next bleeding-free intervals,uterine bleeding patterns in the 3 months after<BR/>treatment, women's satisfaction with the treatment,side effects encountered during treatment and discontinuation of theDMPA and its reason.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 15:13:28 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-30 11:08:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996">
<CHAR_METHODS MODIFIED="2012-12-30 11:08:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Study duration: 8 weeks<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: inadequate<BR/>Drop outs: 16 (10.66%)<BR/>Validity criteria: C (High risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>150 Norplant users in the first year of use enrolled; 134 included in analysis<BR/>Age (years): <BR/>EE (n=43) 23±4.2<BR/>LNG+EE (n=45): 24.6±3.8<BR/>Pl (n=46): 25.0±4.5<BR/>Setting: Family planning clinic<BR/>Diagnostic criteria:<BR/>Prolonged bleeding: (bleeding or spotting 8 days or more)<BR/>Irregular bleeding (bleeding-free interval &lt;15 days)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>EE: 50 mcg/day x 20 days, orally; <BR/>LNG: 250 mcg/day + EE 50 mcg/day x 20 days orally;<BR/>Pl: 1/day x 20 days, orally<BR/>Treatment length: 20 days<BR/>Follow-up 8 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Effectiveness of treatment, as measured by a cessation of B/S in 3 days of treatment or less</P>
<P>Mean number of bleeding days during treatment interval</P>
<P>Percentage of women with bleeding-free interval of 20 days or more</P>
<P>Percentage of women with bleeding-free interval of less than 11 days</P>
<P>Discontinuation of contraceptive method because of bleeding</P>
<P>Side-effects related to treatment (stomach pain, nausea)</P>
<P>Discontinuation rate because of side-effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 16:09:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Archer-2008">
<CHAR_METHODS MODIFIED="2009-10-03 10:56:29 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Study duration: 30 days<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: adequate<BR/>Drop outs: 1 (1/107)<BR/>Validity criteria: A (low risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 16:09:06 +0200" MODIFIED_BY="[Empty name]">
<P>107 women using LNG subcutaneous implant for more than one month</P>
<P>Age (years):<BR/>EE (n=20) not mentioned<BR/>IBU (n=42): not mentioned<BR/>Pl (n=44): not mentioned<BR/>Setting: Five university hospital Ob/Gyn departments in the United States of America<BR/>Diagnostic criteria:<BR/>Bleeding or spotting lasting 8 or more consecutive days<BR/>S/B for more than 10 days out of 14 days within the preceding three weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-13 11:03:41 +0100" MODIFIED_BY="[Empty name]">
<P>EE: 20 mcg/day x 10 days, orally; with 5 days IBU Pl given twice a day.<BR/>IBU: 800 mg/ twice a day x 5 days, with 10 days of a daily EE Pl orally;<BR/>Pl: 1/day x 10 days orally and the other taken twice/day x five days orally.<BR/>Treatment length: 10 days<BR/>Follow-up 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-13 11:02:10 +0100" MODIFIED_BY="[Empty name]">
<P>The number of days of bleeding and/or spotting during treatment</P>
<P>The number of days of bleeding and/or spotting within the first 30 days following treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-13 09:58:05 +0100" MODIFIED_BY="[Empty name]">
<P>The dose of IBU administered is described inconsistently in the publication; dose has been confirmed with first author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-13 11:06:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boonkasemsanti-1996">
<CHAR_METHODS>
<P>Randomized trial<BR/>Study duration: 10 weeks<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: yes<BR/>Drop-outs: 0<BR/>Validity criteria: B (moderate risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-13 11:06:25 +0100" MODIFIED_BY="[Empty name]">
<P>64 Norplant users in the first year of use.</P>
<P>Age (years):<BR/>Estradiol patch (E) 27±3;<BR/>Pl 25±4.</P>
<P>Setting: University Ob/Gyn Department, Bangkok, Thailand</P>
<P>Diagnostic criteria:<BR/>Bleeding problems as defined by bleeding more than 8 days, and/or bleeding-free interval less than 10 days.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents:<BR/>Estradiol patch (n=33) releasing 100 mcg/24 hours x 6 weeks;<BR/>Pl patch (n=31) x 6 weeks.</P>
<P>Follow-up: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>"Clinical improvement" refers to women with an initially abnormal pattern, who develop a normal pattern (bleeding less than 8 days and/or bleeding free interval more than 20 days.</P>
<P>Continued irregular bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-13 11:12:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buasang-2009">
<CHAR_METHODS MODIFIED="2009-11-14 10:45:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial</P>
<P>Study duration: 28 days</P>
<P>Type of trial: parallel</P>
<P>Outcome assessment blinding: yes<BR/>Drop-outs: 0<BR/>Validity criteria: A (low risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-13 11:10:49 +0100" MODIFIED_BY="[Empty name]">
<P>40 women using Jadelle for 9-13 months.</P>
<P>Age (years):<BR/>Celecoxib 34.1±7.4<BR/>Placebo 29.5±9.8</P>
<P>Setting: Family planning clinic, university hospital, Bangkok, Thailand</P>
<P>Diagnostic criteria:Bleeding problems as defined by bleeding/spotting more than 8 days, or current bleeding episode initiated after a bleeding-free interval less than 14 days.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-13 11:08:01 +0100" MODIFIED_BY="[Empty name]">
<P>Agents:<BR/>Celecoxib (n=20) 200 mg/day x 5 days, oral;<BR/>Pl (n=20) 1/day x 5 days, oral.</P>
<P>Follow-up: 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-13 11:12:50 +0100" MODIFIED_BY="[Empty name]">
<P>Percent of women who stopped bleeding during the treatment (within 7 days).</P>
<P>The length of bleeding-free interval in 28 days.</P>
<P>The number of bleeding days after initial treatment.<BR/>
</P>
<P>Patient satisfaction with treatment.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cheng-2000">
<CHAR_METHODS>
<P>Randomized trial<BR/>Study duration: 360 days<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: yes<BR/>Drop-outs: 0<BR/>Validity criteria: A (low risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 women using Norplant for 3-43 months.</P>
<P>Age (years): <BR/>Mifepristone 29.5; <BR/>Placebo 30</P>
<P>Setting: Family planning clinic</P>
<P>Diagnostic criteria: <BR/>Frequent vaginal bleeding, defined as bleeding episode occurring more often than once every 24 days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents:<BR/>Mifepristone (n=50) 50 mg (2x25 mg tablets) once, orally.<BR/>Pl (n=50) 2 tablets once, orally.</P>
<P>Treatment started on the third day after the start of a B/S episode.<BR/>After the first treatment, women were given a date to return to the clinic once/28 days for 5 months (a total of 6 treatments in all).</P>
<P>Follow-up: 12 months<BR/>Reference period 1: 90 days before the first treatment;<BR/>Reference periods 2 and 3 cover 180 days from the first treatment, and together include 6 treatment months and the first 12 days of the seventh month.<BR/>Reference period 4 started 39 days after the last treatment and ended 90 days later.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of bleeding days over time:<BR/>Reference period 1, reference period 2, reference period 3, reference period 4</P>
<P>Average duration of bleeding episodes (days):<BR/>Reference period 1, after treatment</P>
<P>Women rating their treatment as satisfactory</P>
<P>Discontinuation rate because of bleeding</P>
<P>Side effects related to treatment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-d_x0027_Arcangues-2004">
<CHAR_METHODS>
<P>Randomized trial<BR/>Study duration: 1 year, with follow up at end of treatment, 3 months and 6 months<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: yes<BR/>Drop outs: <BR/>Total: 139/486 (28.6%)<BR/>Aspirin: 30/122 (25%);<BR/>Vitamin E: 38/120 (32%);<BR/>Combined aspirin and vitamin E: 40/121 (33%);<BR/>Pl: 31/123 (25%).<BR/>Validity criteria: C (high risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>486 women in the first 6 months of Norplant use<BR/>347 women completed the study<BR/>Age: all groups: 29.0 ± 5.0<BR/>Setting: Developing country research institutes, University Ob/Gyn department; family planning clinic<BR/>Diagnostic criteria:<BR/>Prolonged bleeding: 8 or more days; <BR/>Clinically important bleeding patterns in 90-day reference period:<BR/>Amenorrhea: no bleeding<BR/>Infrequent: fewer than 2 B/S episodes in ref. pd<BR/>Frequent: more than 4 B/S episodes in ref pd<BR/>Irregular: a range of lengths of bleeding-free intervals greater than 17 days<BR/>Prolonged: at least one B/S episode lasting more than 10 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents:<BR/>Aspirin 80 mg/day x 10 days, orally<BR/>Vitamin E 200 mg/day x 10 days, orally<BR/>Combined aspirin + vitamin E x 10 days, orally<BR/>Pl x 10 days, orally<BR/>Treatment length: 10 days; repeated up to 5 times in year, if 20 days have passed between treatment cycles<BR/>Follow up: 1 year, with visits after each treatment period and at 3 and 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Efficacy in management of 1-5 episodes of prolonged bleeding:<BR/>Number of B/S days in episode;<BR/>Number of B/S days from the first day of treatment;<BR/>Number of B/S days following the treatment episode.</P>
<P>Discontinuation of treatment due to lack of improvement</P>
<P>Discontinuation of treatment due to side effects</P>
<P>Side effects related to treatment:<BR/>Headache, GI discomfort</P>
<P>Patient dissatisfaction with treatment at 3 months:<BR/>Improved pattern, unchanged pattern, worse pattern, no answer/unknown</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-30 11:11:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dempsey-2010">
<CHAR_METHODS MODIFIED="2011-01-13 11:25:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Study duration: 6 months, with follow up at end of 3 months and 6 months<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: No<BR/>Drop outs: At three months DMPA: 13/36 (36%), Vaginal ring: 9/35 (26%);<BR/>At 6 months: DMPA 20/36 (56%), Vaginal ring 18/35 (51%)<BR/>Validity criteria: C (high risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-13 11:43:38 +0100" MODIFIED_BY="[Empty name]">
<P>71 women who initiated DMPA<BR/>
</P>
<P>Age:</P>
<P>Untreated: n=14 of 36 randomized (39%) age 18-20 years; n=22 of 36 randomized (61%) age 21 years or older</P>
<P>Vaginal ring: n=14 of 35 randomized (40%) age 18-20 years; n=21of 35 randomized (60%) age 21 years or older</P>
<P>Setting: Family Planning Clinic in New York City, USA.<BR/>Diagnostic criteria:</P>
<P>Inclusion criteria: at least 18 years old, had not used DMPA or Lng IUS in the preceding 120 days.</P>
<P>Exclusion criteria: oligomenorrhoea (fewer than 4 periods in the last 6 months), amenorrhoea, or contraindications to either DMPA or estrogen</P>
<P>Education:</P>
<P>Untreated: n=11 of 36 randomized (31%) less than high school; n=25 of 36 randomized (69%) high school or greater</P>
<P>Vaginal ring: n= 12 of 35 randomized (34%) less than high school; n=23 of 35 randomized (66%) high school or greater</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-13 11:35:40 +0100" MODIFIED_BY="[Empty name]">
<P>Each participant received DMPA 150 mg IM injection for contraception</P>
<P>Estradiol vaginal ring (n=26 included in 3-month analysis): 24.8 mg of estradiol acetate which releases ar a rate equivalent to 0.1 mg of estradiol per day for 3 months</P>
<P>Untreated controls (n=23 included in 3-month analysis): no placebo ring available</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-24 11:16:46 +0100" MODIFIED_BY="[Empty name]">
<P>Days of bleeding and spotting</P>
<P>Number of bleeding/spotting episodes</P>
<P>Discontinuation of the contraceptive method</P>
<P>Discontinuation of treatment due to lack of improvement</P>
<P>Discontinuation of treatment due to side effects </P>
<P>Side effects related to treatment (data not shown)</P>
<P>Patient satisfaction with treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-30 11:11:20 +0100" MODIFIED_BY="[Empty name]">
<P>Several of the outcomes described above were stated outcomes of the trial; however, data were not presented for all outcomes. For others, data were not disaggregated by treatment group. Data extracted for the purposes of the current review included the number of days of bleeding during treatment and discontinuation of the contraceptive method. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-24 11:23:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diaz-1990">
<CHAR_METHODS MODIFIED="2013-04-24 11:23:08 +0200" MODIFIED_BY="[Empty name]">
<P>Quasi-randomized trial <BR/>Study duration:<BR/>one year<BR/>Type of trial:<BR/>Parallel<BR/>Outcome assessment blinding: Yes<BR/>Drop outs:<BR/>Total: 43/183 (24%)<BR/>LNG 13/47 (28%)<BR/>EE 12/45 (27%)<BR/>Ibuprofen 10/45 (22%)<BR/>Pl 8/46 (17%).<BR/>Validity criteria: C (High risk of bias)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>183 women using Norplant for 3-43 months.</P>
<P>Age (years; mean ± SD): <BR/>LNG 26 ± 4; <BR/>EE 27 ± 4;<BR/>Ibuprofen 27 ± 4;<BR/>Pl 27 ± 4. </P>
<P>Setting: Family planning clinic</P>
<P>Diagnostic criteria: <BR/>Frequent vaginal bleeding, defined as bleeding episode occurring more often than once every 24 days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents:<BR/>LNG 0.03 mg tablets, twice daily x 20 days, orally;<BR/>EE 0.05 mg tablets once daily x 20 days, orally;<BR/>Ibuprofen 800 mg, three times daily x 5 days, orally;<BR/>Pl once daily, x 20 days, orally.<BR/>Schedule:<BR/>Treatment began on the 8th consecutive day of each B/S episode, as needed throughout the year, but no more than five treatments in the year.<BR/>Follow-up:<BR/>Each time a B/S episode lasted more than 7 days, and at three month intervals.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean number of bleeding days per woman in intervals of days 1-20, 1-5, and 6-20 of treatment. </P>
<P>Mean number of B/S days per woman in intervals of days 1-20, 1-5, and 6-20 of treatment</P>
<P>Mean number of B/S days per treated woman in the year:</P>
<P>DIscontinuation of contraceptive method because of lack of improvement at the end of the year</P>
<P>Discontinuation of treatment due to side effects (gastric intolerance)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-El_x002d_Habashy-1970">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 3 months<BR/>Outcome assessment blinding: unclear<BR/>Drop-outs: 2/63 (3.2%)<BR/>validity criteria: B (moderate risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>63 post-partum women who chose DMPA as their method of contraception<BR/>Age: data not given<BR/>Setting: Hospital<BR/>Diagnostic criteria: Prophylactic prevention of bleeding problems. No definition of normal or abnormal bleeding patterns provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Diethylstilbestrol (DES; n=32): 1mg tablet/daily x 90 days, orally;<BR/>Pl (n=31) 1 vitamin tablet/daily x 90 days.</P>
<P>Follow-up: monthly</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of women experiencing bleeding episodes of less than 8 days (including 0 days):<BR/>First month, second month, third month</P>
<P>Compliance, as defined as taking the agent 25 days/month or more:<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-30 10:06:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gemzell_x002d_Danielsson-2002">
<CHAR_METHODS MODIFIED="2012-12-30 10:06:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Study duration: 16-28 weeks<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: yes<BR/>Drop-outs: 12/103 (12%)<BR/>Anti-progesterone: 3/52 (5.8%)<BR/>Placebo: 9/51(17.6%)<BR/>Validity criteria: C (high risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>103 women using 75 mcg desogestrel pill daily<BR/>Age (mean): <BR/>Antiprogestogen 31.6; <BR/>Placebo 32.8<BR/>Setting: Research institutes<BR/>Diagnostic criteria, within a 90-day reference period: <BR/>Amenorrhea: no B/S<BR/>Infrequent bleeding: fewer than three B/S episodes, excluding amenorrhea<BR/>Frequent bleeding: more than five B/S episodes<BR/>Prolonged bleeding: one or more B/S episode lasting more than 14 days<BR/>Irregular bleeding: range of the length of bleeding-free intervals less than 17 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents:<BR/>Org 31710 (antiprogesterone) 150 mg (three tablets x 50 mg), once/28 days, orally<BR/>Placebo three similar tablets, once/28 days, orally<BR/>Schedule: One dose every 28 days for a maximum of seven treatments.<BR/>Follow-up: 16-28 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Effectiveness of treatment:</P>
<P>Number (percentage) of days with recorded B/S, cycle day 8-28:<BR/>Cycle 1, cycle 3, cycle 6</P>
<P>Number (percent) of subjects with B/S episodes starting day 8-28:<BR/>Cycle 1, cycle 3, cycle 6</P>
<P>Discontinuation rate because of bleeding</P>
<P>Side effects related to treatment (headache, emotional lability, acne, breast pain)</P>
<P>Discontinuation of the study because of side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goldberg-2002">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 12 months<BR/>Outcome assessment blinding: adequate<BR/>Drop-outs: 50/132 (38%) <BR/>Estradiol 30/66 (45%);<BR/>Pl: 20/66 (30%)<BR/>Validity criteria: C (high risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>132 post-abortion DMPA users in the first year of use<BR/>Age (years): <BR/>Estradiol patch 24±5.2; <BR/>Pl 23±5.9.<BR/>Education: No significant difference between groups<BR/>Setting: Hospital-based research unit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents and schedule:<BR/>17-beta Estradiol patch (0.1 mg/day, brand name Climara)/weekly x 3 patches per month (3 weeks on + 1 week off/month), transdermal.<BR/>Pl patch 1 patch/weekly x 3 patches per month (3 weeks on + 1 week off/month), transdermal.<BR/>Duration of treatment: 3 months.</P>
<P>Follow-up: at months 4, 8 and 12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Effectiveness of treatment as defined by association between use of estrogen patches and regular bleeding patterns, over time:</P>
<P>Discontinuation of the contraceptive method over time:<BR/>At 4 months, 8 months, 12 months</P>
<P>Discontinuation of the contraceptive method due to bleeding:</P>
<P>Non-compliance with treatment due to side effects (inconvenience and skin irritation):<BR/>(Compliance defined as using 6 out of 9 treatment patches)</P>
<P>Reasons for non-compliance</P>
<P>Side effects related to treatment (skin irritation, inconvenience)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>High rate of DMPA discontinuation.<BR/>High rate of non-compliance with the study protocol.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-12 14:52:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harel-2002">
<CHAR_METHODS MODIFIED="2009-10-07 12:55:26 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 6 months<BR/>Outcome assessment blinding: unclear<BR/>Drop-outs: unclear<BR/>
<BR/>Validity criteria: B (Moderate risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-12 14:52:59 +0100" MODIFIED_BY="[Empty name]">
<P>55 DMPA users<BR/>Age (years):<BR/>
</P>
<P>Vit C+Pl : 16<U>+</U>1</P>
<P>
<BR/>Pl :16±1.<BR/>
<BR/>Setting: Hospital-based adolescent clinics in the United States.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-30 11:14:57 +0100" MODIFIED_BY="[Empty name]">
<P>Group 1: Vit. C 500 mg plus Pl x daily, oral x 6 months</P>
<P>Group 2 : Control Pl 2 tab daily, oral x 6 months</P>
<P>Follow up: at 3 and 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-07 13:16:25 +0200" MODIFIED_BY="[Empty name]">
<P>Days of bleeding during the first interval (first 3 months)</P>
<P>Days of bleeding during second interval (months 4-6)</P>
<P>Discontinuation of the contraceptive method.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-30 11:15:38 +0100" MODIFIED_BY="[Empty name]">
<P>Vitamin B6 was included as an intervention to prevent weight gain; however outcomes related to bleeding were reported for the VitamIn B6 alone group. Because this was not identified and tested as an intervention to affect bleeding, the results of the Vitamin B6 groups are not included in the analysis. .</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jain-2003">
<CHAR_METHODS>
<P>Randomized trial<BR/>Study duration: 6 treatment cycles of 28 days each<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: not clear<BR/>Drop-outs: 0<BR/>Validity criteria: B (moderate risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 new users of DMPA<BR/>Age: not described<BR/>Setting: University Ob/Gyn department<BR/>Diagnostic criteria: not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents:<BR/>Mifepristone: 50 mg, every 14 days, orally<BR/>Pl: similar tablet every 14 days, orally<BR/>Treatment length: six cycles (6 x 28 days)<BR/>Follow-up: six cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Percent days with breakthrough bleeding (median)<BR/>Cycles 1-3, cycles 4-6, total cycles 1-6</P>
<P>Number (percent) cycles with bleeding intervals 8 or more days<BR/>Cycles 1-3, cycles 4-6, total cycles 1-6</P>
<P>Number (percent) cycles with bleeding intervals 14 or more days <BR/>Cycles 1-3, cycles 4-6, total cycles 1-6</P>
<P>Ovulation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Johannisson-1982">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 4 months (1 month control + 3 months treatment)<BR/>Outcome assessment blinding: unclear<BR/>Drop-outs: 0<BR/>Validity criteria: B (moderate risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 minipill users (300 µg norethisterone (Net))<BR/>Age: 25-30 years<BR/>Setting: clinical research settings<BR/>Diagnostic criteria: Intermenstrual bleeding in second month of Net use.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents and schedule:<BR/>EE (n=6) 50 µg/daily x 7 days, orally.<BR/>Pl (n=6) once/daily x 7 days, orally.</P>
<P>Treatment started in case of intermenstrual bleeding, after endometrial biopsy.<BR/>Follow-up: 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of days with bleeding during 7 days treatment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kaewrudee-1999">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 4 weeks<BR/>Outcome assessment blinding: yes<BR/>Drop-outs: 2/69 (2.9%)<BR/>Validity criteria: A (low risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>69 women using Norplant for 3-36 months recruited; 67 included in analysis..<BR/>Age (years):<BR/>Mefenamic acid (MEF n=34) 27.2±9.4; <BR/>Pl (n=33) 25.0±5.9.</P>
<P>Setting: Family planning clinic in hospital Ob/Gyn Department</P>
<P>Diagnostic criteria: <BR/>Prolonged bleeding defined as 8 or more continuous days of bleeding or spotting;<BR/>Irregular bleeding defined as a current bleeding episode following a bleeding-free interval of less than 15 days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents and schedule:<BR/>MEF 500 mg/twice daily x 5 days, orally;<BR/>Pl 2 capsules/twice daily x 5 days, orally.</P>
<P>Follow-up: One and four weeks after treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Percentage of women who stopped bleeding within 7 days after initiation of treatment</P>
<P>Bleeding free interval more than 20 days at 28 days follow-up</P>
<P>Number of B/S days within the 28 day follow up period (Mean+SD)</P>
<P>Side effects related to treatment (headache, dysmenorrhea, breast tenderness and leukorrhea)</P>
<P>Discontinuation rate due to side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-30 10:14:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madden-2012">
<CHAR_METHODS MODIFIED="2012-12-30 10:09:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Study duration: 16 weeks<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: two arms blinded from subjects and investigators (naproxen and placebo); estradiol patch arm not blinded<BR/>Drop-outs: 23/129 = 17.8% overall. Differential loss within trial arms: placebo = 6/43 (14%); estradiol patch = 10/44 (23%); naproxen = 7/42 (17%)</P>
<P>Validity criteria: C (high risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-12-30 10:11:21 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 129 women randomised</P>
<P>Age:     &lt; 21 years:      11.4 (estradiol)           11.9 (naproxen)          9.3 (placebo)</P>
<P>            21 - 29 years  68.2 (estradiol)           66.7 (naproxen)          69.8 (placebo)</P>
<P>            &#8805; 30 years       20.5 (estradiol)           21.4 (naproxen)          20.9 (placebo)</P>
<P>Education level:</P>
<P>Some high school        25.6 (estradiol)           14.6 (naproxen)          14.6 (placebo)</P>
<P>High school                 46.5 (estradiol)           56.1 (naproxen)          41.5 (placebo)</P>
<P>College/grad               27.9 (estradiol)           29.3 (naproxen)          43.9 (placebo)</P>
<P> BMI:    &lt;25                  27.3 (estradiol)           35.7 (naproxen)          51.2 (placebo)</P>
<P>            25-29.9            22.7 (estradiol)           35.7 (naproxen)          20.9 (placebo)</P>
<P>            &#8805; 30                 50 (estradiol)              29.3 (naproxen)          27.9 (placebo)</P>
<P>Diagnostic criteria used to define the condition of interest:</P>
<P>Bleeding = 1 panty liner, tampon, or pad/day</P>
<P>Spotting = &lt; 1 panty liner, tampon or pad/day</P>
<P>Setting: University research clinic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-12-30 10:12:56 +0100" MODIFIED_BY="[Empty name]">
<P>Agents:</P>
<P>Naproxen (N=42): 500 mg oral naproxen.  Days 1-5, twice daily for 4 week period starting the day after LNG-IUS insertion.</P>
<P>Estradiol (N=44): 0.1 mg transdermal patch. Placed day after insertion, and used continuously, changing weekly. </P>
<P>Placebo (N=43): Identical pill to Naproxen. Days 1-5, twice daily for 4 week period starting the day after LNG-IUS insertion.</P>
<P>Treatment duration: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-12-30 10:14:55 +0100" MODIFIED_BY="[Empty name]">
<P>Effectiveness of treatment (i.e., reduction in bleeding/spotting): median bleeding/spotting days and range for entire treatment period</P>
<P>Discontinuation of the contraceptive method:</P>
<P>Discontinuation of treatment due to lack of improvement:    Not reported.</P>
<P>Discontinuation of treatment due to side effects:</P>
<P>Side effects related to treatment:</P>
<P>Patient dissatisfaction with treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 16:26:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Massai-2004">
<CHAR_METHODS>
<P>Randomized trial<BR/>Study duration: 13 months<BR/>Type of trial: parallel<BR/>Outcome assessment blinding: yes<BR/>Drop-outs: 5/120 (4%)<BR/>Validity criteria: B (moderate risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>120 new Norplant users enrolled<BR/>116 completed 6 months of treatment<BR/>115 included in analysis</P>
<P>Age (Mean ± SD): <BR/>Mifepristone (n=58): 30.1 ± 4.1; <BR/>Pl (n=57): 28.3 ± 4.8.</P>
<P>Setting: Research institute</P>
<P>Diagnostic criteria: <BR/>Prolonged bleeding episode: more than 8 consecutive days of B/S.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 16:26:23 +0200" MODIFIED_BY="[Empty name]">
<P>Agents:<BR/>Mifepristone 100 mg/day x 2 days at 30 day intervals, orally<BR/>Placebo: pill/day x 2 days at 30 day intervals, orally.</P>
<P>Treatment duration:<BR/>2 days, repeated at 30 day intervals for 6 months (months 2-7 of implant use)<BR/>Start 30 days after implant insertion.</P>
<P>Follow-up:<BR/>Monthly during treatment and for 6 additional months.<BR/>Additional follow up after treatment, for 6 months (total 13 months).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The number of B/S days per woman during the 180-day treatment (Mean+SD), over time;<BR/>At end of treatment, 6 months after end of treatment</P>
<P>Number of bleeding episodes in treatment period:<BR/>Number (%) of women with 5-8 bleeding episodes during 6 months treatment, number (%) of women with more than 8 bleeding episodes during treatment</P>
<P>Mean length of B/S episodes (days)</P>
<P>Women with 1 or more episode of prolonged bleeding, number (%), over time<BR/>At the end of treatment, 6 months after end of treatment</P>
<P>Total number B/S episodes</P>
<P>Number of prolonged bleeding episodes</P>
<P>Total number of B/S days at 6 months and post-treatment</P>
<P>Proportion of bleeding episodes that were prolonged</P>
<P>Mean length (days) of B/S episodes longer than 8 days</P>
<P>Discontinuation of the contraceptive method</P>
<P>Discontinuation of the contraceptive method due to bleeding</P>
<P>Discontinuation of treatment due to lack of improvement</P>
<P>Side effects (headache, weight loss, acne, nervousness, abdominal pain, lichen sclerosus)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Monteil_x002d_Seurin-1985">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 3 months<BR/>Outcome assessment blinding: no<BR/>Drop-outs: 0<BR/>Validity criteria: C (high risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 Minipill (Norethisterone acetate - NET) users for at least one month.</P>
<P>Age: average 25 years.</P>
<P>Setting: Clinical practice</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents and schedule:<BR/>Cyclo 3 (Capillary protecting venotonic drug containing Ruscus aculeatus) 4 capsules daily x 20 days<BR/>Pl 4 capsules daily x 20 days<BR/>Duration: 20 days, stopped during menses, repeated for 3 months.<BR/>Follow-up: 3 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Duration of bleeding in intermenstrual bleeding episodes (days), over time:<BR/>Pre-treatment, at 1-month, at 3 cycles</P>
<P>Number of days pads or tampons used<BR/>Pre-treatment, at 1-month, at 3 cycles</P>
<P>Subjective assessment of discomfort caused by bleeding:<BR/>Pre-treatment, during treatment (after 1 cycle), after 3 cycles</P>
<P>Tolerance to drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nathirojanakun-2006">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 28 days<BR/>Outcome assessment blinding: yes<BR/>Drop outs: 5/51 (9.8%)<BR/>Validity criteria: A (low risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>51 DMPA users (3-12 months) reporting abnormal bleeding<BR/>Age (years):<BR/>Valdecoxib (n=25) 24.1 ± 6.6;<BR/>Pl (n=26) 25.1 ± 7.3.<BR/>Setting: Family planing clinic in hospital Ob/Gyn department <BR/>Diagnostic criteria: 8 or more days of bleeding or spotting prior to bleeding on the day of admission<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents and schedule:<BR/>Valdecoxib (Cox-2 inhibitor): two tablets (20 mg /tablet) daily x 5 days, orally;<BR/>Pl 2 tablets daily x 5 days, orally.<BR/>Follow-up: 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of treatment days required to stop bleeding<BR/>Percentage of women who stopped bleeding within 7 days following initiation of treatment<BR/>Total number of bleeding-free days in 28 day follow-up period<BR/>Length of the bleeding-free interval in the 28 day follow up period</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Parker-1980">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 12 months<BR/>Outcome assessment blinding: yes<BR/>Drop-outs: 55/236 (23%).<BR/>Validity criteria: C (high risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>236 women who used DMPA for 90 days;<BR/>214 women included in analysis.<BR/>Age: Varying from 24.0±3.84 to 26.0±5.43, with no differences between groups.<BR/>Setting: Clinic<BR/>Diagnostic criteria: <BR/>Acceptable bleeding pattern: 2-4 bleeding episodes in a 12 week injection segment, with no episode longer than 8 days;<BR/>Prolonged bleeding pattern: a bleeding episode longer than 8 days;<BR/>Amenorrhea: no bleeding;<BR/>Irregular bleeding: one bleeding episode or more than 4 bleeding episodes in a 12 week injection segment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents.<BR/>Quinestrol (Quin) 400 ug, orally.<BR/>Placebo, orally</P>
<P>Doses:<BR/>One capsule Quin or Pl/injection segment;<BR/>Three capsules Quin or Pl/injection segment.</P>
<P>Regimens:<BR/>One capsule Quin of Pl with DMPA injection;<BR/>One capsule Quin or Pl two weeks after DMPA injection;<BR/>One capsule Quin or Pl at 0, 4, and 8 weeks after DMPA injection (total 3 capsules);<BR/>One capsule Quin or Pl at 2, 6, and 10 weeks after DMPA injection (total 3 capsules).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Acceptable bleeding, over time<BR/>First injection segment, all segments combined:</P>
<P>Discontinuation because of bleeding</P>
<P>Discontinuation because of amenorrhea</P>
<P>Discontinuation due to side effects (headache, weight change, palpitations, sickness)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 16:29:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Phaliwong-2004">
<CHAR_METHODS MODIFIED="2009-10-08 11:29:04 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 4 weeks<BR/>Outcome assessment blinding: yes<BR/>Drop-outs: 4/50 (8%).<BR/>Validity criteria: A (low risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-08 11:37:39 +0200" MODIFIED_BY="[Empty name]">
<P>50 Implanon users for at least two months<BR/>
</P>
<P>Age (Mean ± SD):<BR/>Mefenamic acid (n=23): 31.2 ± 5.1;<BR/>Pl (n=23): 28.6 ± 5.4.</P>
<P>Setting: Family Planning Clinic, Bangkok ,Thailand</P>
<P>Diagnostic criteria:<BR/>Prolonged bleeding episode: more than 8 consecutive days of bleeding or spotting</P>
<P>Irregular bleeding defined as a current bleeding episode initiated after a bleeding-free interval of &lt;15 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-14 10:21:38 +0100" MODIFIED_BY="[Empty name]">
<P>Mefenamic acid (250 mg /capsule): 500 mg x tds, oral x5 days</P>
<P>Pl two capsules x tds , oral x 5 days</P>
<P>Follow up: 1 and 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 16:29:49 +0200" MODIFIED_BY="[Empty name]">
<P>Days of treatment required for stopping the bleeding episode</P>
<P>Total number of bleeding/spotting days.</P>
<P>The length of bleeding free interval after the initial treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 16:31:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Phupong-2006">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 4 weeks<BR/>Outcome assessment blinding: yes<BR/>Drop outs: 0<BR/>Validity criteria: A (low risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 16:31:23 +0200" MODIFIED_BY="[Empty name]">
<P>68 women using Norplant for 3-36 months and reporting irregular bleeding.<BR/>Age (years):<BR/>Tranexamic acid (n=34) 27.0 ± 5.7;<BR/>Pl (n=34) 29.1 ± 6.1<BR/>Setting: Family planning clinic in hospital Ob/Gyn Department<BR/>Diagnostic criteria:<BR/>Bleeding or spotting for eight or more continuous days, or a current bleeding episode initiated after a bleeding-free interval of 14 days or less</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents and schedule:<BR/>Tranexamic acid: two capsules (250 mg /capsule) 4 times daily x 5 days, orally;<BR/>Pl: two capsules 4 times daily x 5 days, orally<BR/>Follow up: one and four weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 16:31:40 +0200" MODIFIED_BY="[Empty name]">
<P>Percentage of women who stopped bleeding after one week</P>
<P>Percentage of women who stopped bleeding after four weeks</P>
<P>Mean duration of bleeding/spotting days during 28 days of follow up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sadeghi_x002d_Bazargani-2006">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: undefined<BR/>Outcome assessment blinding: yes<BR/>Drop outs: unclear<BR/>Validity criteria: B (moderate risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>46 DMPA users with amenorrhea<BR/>Combined oral contraceptive: n = 24<BR/>Pl: n = 22<BR/>Age: not given for trial population.<BR/>Setting:<BR/>District Health centres.<BR/>Education: not given for trial population.<BR/>Diagnostic criteria: Amenorrhea as defined as two months without menstrual bleeding following DMPA injection<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents:<BR/>Low dose combined oral contraceptives (components not reported), daily, orally.<BR/>Pl daily, orally.<BR/>Treatment duration: not reported<BR/>Follow up duration: not reported.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Effectiveness of combined oral contraceptive in comparison to Pl in resolving amenorrhea.<BR/>Discontinuation of the contraceptive.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Said-1996">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 18 months<BR/>Outcome assessment blinding: yes<BR/>Drop-outs:<BR/>Total: 117/278 (44%)<BR/>EE: 40/90 (44.4%);<BR/>Oestrone sulfate (OS): 37/91 (40.7%);<BR/>Pl: 40/97 (41.2%).<BR/>Validity criteria: C (high risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>278 women using DMPA for &lt;6 months<BR/>EE n=90, OS n=91, Pl n=97</P>
<P>Age: <BR/>EE 27.0±4.7; <BR/>OS 27.6±4.7;<BR/>Pl 27.0±4.9.</P>
<P>Settings: Hospitals, University Ob/Gyn Department, Research Institute, Family Planning Centre.</P>
<P>Diagnostic criteria: <BR/>Vaginal bleeding episode &gt;7 days, during first or second injection interval;<BR/>Prolonged bleeding: a bleeding episode lasting 10 days or more;<BR/>Amenorrhea: no bleeding within a 90 day reference period;<BR/>Frequent bleeding: more than 4 bleeding episodes in a 90 day reference period;<BR/>Infrequent bleeding: fewer than 2 B/S episodes in a 90 day reference period;<BR/>Irregular bleeding: bleeding-free intervals greater than 17 days in a 90 day reference period.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents:<BR/>EE (n=90) 50 µg/day x 14 days, orally.<BR/>OS (n=91) 2.5 mg/day x 14days, orally.<BR/>Pl (n=97) 1/day x 14 days, orally.</P>
<P>Follow-up<BR/>At the end of 14 days treatment (short-term success).<BR/>12 months follow-up (long-term success).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Bleeding stopped during the 14 day treatment course, with at least 2 days bleed-free interval</P>
<P>Continued irregular bleeding</P>
<P>Median time to cessation of bleeding and spotting (days)</P>
<P>The median number of B/S days during treatment</P>
<P>Number of B/S days in 90 day reference period after treatment (mean ± SD)</P>
<P>Number of B/S episodes in 90 day reference period following treatment</P>
<P>Discontinuation due to bleeding, at one year</P>
<P>Discontinuation due to amenorrhea, at one year</P>
<P>Discontinuation due to Oestrogen treatment failure, at one year</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-14 13:46:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Senthong-2009">
<CHAR_METHODS MODIFIED="2011-02-14 13:46:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 28 days<BR/>Outcome assessment blinding: yes<BR/>Drop-outs:<BR/>Total: 1/100</P>
<P>Validity criteria: A (low risk of bias)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-14 10:36:04 +0100" MODIFIED_BY="[Empty name]">
<P>100 DMPA users for a period of 1-18 months, with abnormal bleeding<BR/>Age:</P>
<P>Tranx:29.6+7.0</P>
<P>PL :28.6+7.6<BR/>Setting:<BR/>Family planning clinic.<BR/>Diagnostic criteria:Bleeding problems as defined by bleeding/spotting more than 8 days, or current bleeding episode initiated after a bleeding-free interval less than 14 days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-14 10:43:07 +0100" MODIFIED_BY="[Empty name]">
<P>Agents:<BR/>Tranexamic acid tablets (n=50) , containing 250 mg/tablet x 4 times daily, oral x5 days;<BR/>Pl tablets (n=49) x 4 tablets daily, oral x5 days.</P>
<P>Follow-up: 28days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-28 12:04:22 +0200" MODIFIED_BY="[Empty name]">
<P>Percent of women who stopped bleeding during the treatment:<BR/>( within 7 days).</P>
<P>The length of bleeding-free interval in the 28 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-07 21:54:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Subakir-2000">
<CHAR_METHODS>
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 2 months<BR/>Outcome assessment blinding: yes<BR/>Drop-outs: zero<BR/>Validity criteria: B (moderate risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-07 21:54:21 +0100" MODIFIED_BY="[Empty name]">
<P>72 women using Norplant for 3-12 months.<BR/>Age: 18-40 years.<BR/>Setting: University<BR/>Diagnostic criteria:<BR/>"Bleeding problems" presumably as reported by the study participants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents:<BR/>Vitamin E (Vit) (n=38) 200 mg /day x 10 days, oral;<BR/>Pl (n=34) 1/day x 10 days, oral.</P>
<P>Treatment repeated 30 days from Day 1 of first treatment.</P>
<P>Follow-up: 2 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of bleeding days before first treatment cycle</P>
<P>Number of bleeding days after first treatment cycle<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Diagnostic criteria are not reported.<BR/>No data given for second treatment cycle.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-30 09:43:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tantiwattanakul-2004">
<CHAR_METHODS MODIFIED="2012-12-30 09:43:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 28 days<BR/>Outcome assessment blinding: yes<BR/>Dropouts: 6/54 (11%)<BR/>Validity criteria: B ( moderate risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>54 women using DMPA for 3-12 months enrolled<BR/>48 women in analysis</P>
<P>Age (Mean ± SD): <BR/>Mefenamic acid (MEF; n=23): 30 ± 6.8;<BR/>Pl (n=25): 27 ± 5.8.</P>
<P>Setting: Family planning clinic at hospital Ob/GYN department </P>
<P>Diagnostic criteria: <BR/>Bleeding on day of admission, following 8 or more days of continuous B/S (Abnormal bleeding)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Mefenamic acid (MEF) 500 mg twice daily x 5 days, orally;<BR/>Pl: capsules 2X/day x 5 days, orally.</P>
<P>Treatment duration: 5 days</P>
<P>Follow-up duration 1 and 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women who stopped bleeding within 7 days of initiation of treatment (number, percent)</P>
<P>Women who did not stop bleeding within 7 days of initiation of treatment</P>
<P>Mean bleed-free interval during 28 days following initiation of treatment (days)</P>
<P>Other outcomes listed, but no data reported:<BR/>Total number of days B/S<BR/>Number of days of treatment required to stop bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No data reported for some of the listed outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 16:34:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warner-2010">
<CHAR_METHODS MODIFIED="2012-12-30 11:20:33 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 6 months<BR/>Outcome assessment blinding: yes<BR/>Dropouts: 20/136 (14.7%)<BR/>Validity criteria: B (moderate risk of bias) Drop out rate &gt;10 %</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 16:34:27 +0200" MODIFIED_BY="[Empty name]">
<P>136 new users of Levonorgestrel IUS</P>
<P>Age: Progesterone receptor modulator(PRM): 36.9+6.5</P>
<P>Placebo(PL): 35.8+7.0</P>
<P>Setting: Family Planning Clinic, University of Edinburgh,UK.</P>
<P>Inclusion criteria: women initiating the use of IUS, 19-49 years, regular menstruation (17-42 days cycle),period &lt;11 days.</P>
<P>Exclusion criteria: breast feeding within three months ,chronic medical or psychiatric disorder, gynaecological disorders, and long-term medications.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-09 10:29:53 +0200" MODIFIED_BY="[Empty name]">
<P>PRM 50 mg/day for 3 days start at days 21,49,77 after LNG IUS insertion.</P>
<P>PL the same schedule</P>
<P>Follow up: 6 months ( at 1,3 and 6 months) after LNG IUS </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-09 10:32:14 +0200" MODIFIED_BY="[Empty name]">
<P>Effectiveness of treatment</P>
<P>Discontinuation of the contraceptive method.</P>
<P>Patient dissatisfaction with treatment.</P>
<P>Blood loss during treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-05 10:18:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weisberg-2006">
<CHAR_METHODS MODIFIED="2009-10-05 10:18:26 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 180 days (90 days before and 90 days after treatment)<BR/>Outcome assessment blinding: yes<BR/>Drop outs: 17/179 (9.5%)<BR/>Validity criteria: A (low risk of bias)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>179 Implanon users<BR/>Age (years):<BR/>Mifepristone 29.9 ± 1.0;<BR/>Mifepristone+EE 27.6 ± 1.0;<BR/>Doxycycline 28.8 ± 1.0;<BR/>Pl 28.9 ± 1.0.<BR/>Setting: University women's health research centres<BR/>Diagnostic criteria: <BR/>Prolonged bleeding: B/S episode longer than 10 days in 90 day reference period (as per WHO);<BR/>Frequent bleeding: more than 4 B/S episodes in 90 day reference period (as per WHO).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents and schedule:<BR/>Mifepristone 25 mg twice daily x 1 day + Pl twice daily x 4 days, orally.<BR/>Mifepristone 25 mg twice daily x 1 day +EE 20 ug x 4 days, orally.<BR/>Doxycycline 100 mg twice daily x 5 days.<BR/>Placebo twice daily x 5 days.<BR/>Follow up: 90 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of days of B/S following start of treatment.<BR/>Duration of the first B/S interval after treatment.<BR/>Mean number of B/S episodes in the 90 day reference period.<BR/>Mean duration of first B/S episode in the 90 day reference period post-treatment.<BR/>Total number of B/S days during the pre- and post-treatment 90 day reference periods.<BR/>Number of bleed-free days post-treatment.<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 16:35:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weisberg-2009">
<CHAR_METHODS MODIFIED="2012-12-30 10:19:02 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 180 days (90 days treatment reference period and 90 days post- treatment)<BR/>Outcome assessment blinding: yes<BR/>Drop outs: 25/179 (13.9%)<BR/>Validity criteria: B (moderate risk of bias), drop out rate &gt; 10 %.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 16:35:19 +0200" MODIFIED_BY="[Empty name]">
<P>204 Implanon users<BR/>Age (years):</P>
<P>Doxycycline: 28.6 ± 6.8;</P>
<P>Doxycycline+EE : 28.8+6.0</P>
<P>Mifepristone+EE : 29.1 ± 7.2;</P>
<P>Mifepristone+Doxycycline: 29.0 ± 6.0;<BR/>Pl 28.8 ± 5.8.</P>
<P>Education:</P>
<P>High school or more:</P>
<P>Doxy : 40/41</P>
<P>Doxy+EE: 40/41</P>
<P>Mifepristone+EE: 41/41</P>
<P>Mifepristone+Doxy: 41/42</P>
<P>Placebo: 38/40</P>
<P>
<BR/>Setting: University women's health research centres in four sites at Australia<BR/>Diagnostic criteria:<BR/>Prolonged bleeding: B/S episode longer than 10 days in 90 day reference period (as per WHO);<BR/>Frequent bleeding: More than 4 B/S episodes in 90 day reference period (as per WHO</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-29 10:56:36 +0200" MODIFIED_BY="[Empty name]">
<P>Agents and schedule:</P>
<P>Doxycycline 100 mg twice daily x 5 days.</P>
<P>Doxycycline100 mg twice daily+ EE 20ug once daily x 5 days.</P>
<P>Placebo twice daily x 5 days.<BR/>Mifepristone 25 mg twice daily x 1 day + EE 20 ug once daily x4 days +Pl twice daily x 4 days, orally.<BR/>Mifepristone 25 mg twice daily x 1 day + Doxy 100 mg twice daily x 5 days, orally.<BR/>
<BR/>
<BR/>Follow up: 90 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 16:35:52 +0200" MODIFIED_BY="[Empty name]">
<P>Number of days of B/S following start of treatment.<BR/>The mean number of days of B/S immediately following treatment.<BR/>The duration (number of days) of the first B/S -free interval after the initiation of treatment.<BR/>Mean number of days of B/S during the 90 day treatment reference period.<BR/>The mean number of B/S episodes during the 90 day treatment reference period.</P>
<P>Discontinuation of the contraceptive method.</P>
<P>Discontinuation of treatment due to side effects</P>
<P>Side effects related to treatment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-30 09:56:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Witjaksono-1996">
<CHAR_METHODS MODIFIED="2012-12-30 09:56:02 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized trial<BR/>Type of trial: parallel<BR/>Study duration: 3 months<BR/>Outcome assessment blinding: unclear<BR/>Drop-outs: not given<BR/>Validity criteria: C (High risk of bias)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>91 women using Norplant for 3-12 months were recruited; 48 women included in analysis</P>
<P>Age (mean ± SE): <BR/>EE: (n=18) 30.2 ± 2.6; <BR/>EE + LNG: (n=16) 29.5 ± 2.8;<BR/>Pl: (n=38) 29.3 ± 3.2.</P>
<P>Setting: University Obstetric and Gynecology departments</P>
<P>Diagnostic criteria: <BR/>Prolonged bleeding, frequent bleeding, irregular bleeding as defined by WHO (1990)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Agents:<BR/>EE 50 ug/day x 21 days, orally;<BR/>EE 30 ug/day + LNG 150 ug/day x 21 days, orally;<BR/>Pl daily/21 days, orally</P>
<P>Follow-up: 90 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of B/S days in 90 day reference period pre-treatment (mean ± SD)</P>
<P>Number of B/S days in 90 day reference period post-treatment (mean ± SD)</P>
<P>Number of B/S episodes in 90 day reference period pre-treatment (mean ± SD)</P>
<P>Number of B/S episodes in 90 day reference period post-treatment (mean ± SD)</P>
<P>Number of B/S days per episode, pre-treatment (mean ± SD)</P>
<P>Number of B/S days per episode, post-treatment (mean ± SD)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>EE - Ethinyl Estradiol <BR/>LNG - Levonorgestrel<BR/>NSAID - Nonsteroidal antiinflammatory drug<BR/>Pl - Placebo<BR/>B/S - Bleeding/Spotting</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-02-07 10:40:23 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Archer-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Interim data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cseffalvay-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-d_x0027_Arcangues-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Glasier-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Piya_x002d_Anant-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment involved switching contraceptive methods.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-07 10:40:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sapire-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-07 10:40:23 +0100" MODIFIED_BY="[Empty name]">
<P>Unable to determine which treatment group results were associated with experimental and placebo intervention - data blinded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-05-29 15:13:28 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-04-22 16:07:33 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-02-07 21:51:18 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Abdel_x002d_Aleem-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 15:49:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abdel_x002d_Aleem-2012">
<DESCRIPTION>
<P>closed sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:19:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Archer-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Boonkasemsanti-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:36:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buasang-2009">
<DESCRIPTION>
<P>A - Adequate. Celecoxib and placebo were packed in opaque sealed envelopes with labeled number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cheng-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:33:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dempsey-2010">
<DESCRIPTION>
<P>A - adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Diaz-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Habashy-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gemzell_x002d_Danielsson-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Goldberg-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:39:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harel-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jain-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johannisson-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kaewrudee-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:51:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madden-2012">
<DESCRIPTION>
<P>A-Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Massai-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Monteil_x002d_Seurin-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nathirojanakun-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Parker-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:43:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phaliwong-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Phupong-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sadeghi_x002d_Bazargani-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Said-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:46:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Senthong-2009">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:50:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Subakir-2000">
<DESCRIPTION>
<P>B - Unclear; Moderate risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Tantiwattanakul-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Warner-2010">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Weisberg-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:53:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisberg-2009">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Witjaksono-1996">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-d_x0027_Arcangues-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-04-22 16:07:10 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-07 10:30:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abdel_x002d_Aleem-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-29 15:49:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abdel_x002d_Aleem-2012">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 16:07:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996">
<DESCRIPTION>
<P>C - inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:35:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Archer-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:35:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boonkasemsanti-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:36:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buasang-2009">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:36:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheng-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:33:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dempsey-2010">
<DESCRIPTION>
<P>C - High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:37:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diaz-1990">
<DESCRIPTION>
<P>A - Adequate </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:38:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Habashy-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:38:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gemzell_x002d_Danielsson-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:39:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldberg-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:40:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harel-2002">
<DESCRIPTION>
<P>B - Moderate risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:40:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jain-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:41:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johannisson-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:41:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaewrudee-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-07 21:51:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Madden-2012">
<DESCRIPTION>
<P>C-one arm is not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:41:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massai-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:42:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Monteil_x002d_Seurin-1985">
<DESCRIPTION>
<P>C - High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:42:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nathirojanakun-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:42:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parker-1980">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:43:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phaliwong-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:43:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phupong-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:44:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sadeghi_x002d_Bazargani-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:45:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Said-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:46:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Senthong-2009">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:50:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subakir-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:51:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tantiwattanakul-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:52:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Warner-2010">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:52:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisberg-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:53:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisberg-2009">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:53:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Witjaksono-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-14 13:31:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-d_x0027_Arcangues-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2013-04-22 16:07:33 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Drop outs (%) &gt; 10</NAME>
<DESCRIPTION>
<P>Greater than 10% drop out rates suggest bias</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-20 10:42:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abdel_x002d_Aleem-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-30 11:07:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abdel_x002d_Aleem-2012">
<DESCRIPTION>
<P>14.7 %</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 16:07:33 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996">
<DESCRIPTION>
<P>C - Drop out rate 10.66%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-04 19:23:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Archer-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boonkasemsanti-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:11:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buasang-2009">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-13 21:30:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheng-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-04 20:53:29 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dempsey-2010">
<DESCRIPTION>
<P>C - High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:16:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-1990">
<DESCRIPTION>
<P>C - High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:19:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Habashy-1970">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-30 10:05:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gemzell_x002d_Danielsson-2002">
<DESCRIPTION>
<P>C - High risk of bias, drop out rate 35%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:22:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goldberg-2002">
<DESCRIPTION>
<P>C - High risk of bias(38% drop out)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:40:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harel-2002">
<DESCRIPTION>
<P>B - Moderate risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:26:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jain-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:28:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johannisson-1982">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:30:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaewrudee-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:51:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Madden-2012">
<DESCRIPTION>
<P>C-drop out rate 17.8%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:32:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massai-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:32:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monteil_x002d_Seurin-1985">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:33:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nathirojanakun-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-30 11:17:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Parker-1980">
<DESCRIPTION>
<P>C - High risk of bias(23 % drop out)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:34:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phaliwong-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:34:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phupong-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:44:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sadeghi_x002d_Bazargani-2006">
<DESCRIPTION>
<P>B - Moderate risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:36:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Said-1996">
<DESCRIPTION>
<P>C - High risk of bias(44% drop out)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:36:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Senthong-2009">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subakir-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-30 09:45:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tantiwattanakul-2004">
<DESCRIPTION>
<P>B -drop out 11%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-30 11:21:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Warner-2010">
<DESCRIPTION>
<P>C - moderate risk of bias(drop out 14.7%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 21:37:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weisberg-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-04 20:39:00 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weisberg-2009">
<DESCRIPTION>
<P>C - High risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-14 13:54:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Witjaksono-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-30 11:10:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-d_x0027_Arcangues-2004">
<DESCRIPTION>
<P>C - High risk of bias(28.6%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-04-22 15:50:25 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-01-06 20:55:08 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Estrogen vs placebo (LNG subcutaneous implant/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.6487541424831609" CI_END="0.6138871955197773" CI_START="0.3005187375861191" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42951671098792715" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.2119114250544621" LOG_CI_START="-0.5221284442051468" LOG_EFFECT_SIZE="-0.3670199346298044" METHOD="MH" MODIFIED="2012-06-02 16:29:03 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4205587264176368" P_Q="1.0" P_Z="3.523173269085272E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="77" WEIGHT="100.0" Z="4.63769431768827">
<NAME>Continued irregular bleeding during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.600614622864824" CI_START="0.2455329082753775" EFFECT_SIZE="0.3840190816935003" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="39" LOG_CI_END="-0.2214040984570606" LOG_CI_START="-0.6098902920354866" LOG_EFFECT_SIZE="-0.41564719524627364" ORDER="2349" O_E="0.0" SE="0.22819871314563997" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="43" TOTAL_2="46" VAR="0.05207465268132608" WEIGHT="66.99876399865163"/>
<DICH_DATA CI_END="0.948744128454444" CI_START="0.28707898134497034" EFFECT_SIZE="0.5218855218855218" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="-0.022850898830561565" LOG_CI_START="-0.5419986034632803" LOG_EFFECT_SIZE="-0.2824247511469209" ORDER="2350" O_E="0.0" SE="0.3049499315238425" STUDY_ID="STD-Boonkasemsanti-1996" TOTAL_1="33" TOTAL_2="31" VAR="0.09299446073639622" WEIGHT="33.00123600134837"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.718535639144121" CI_START="-9.081464360855879" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-01-13 10:24:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="5.668189683520155E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="90" UNITS="" WEIGHT="100.0" Z="6.199391443654135">
<NAME>Bleeding during treatment (days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.718535639144121" CI_START="-9.081464360855879" EFFECT_SIZE="-6.9" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="12.3" ORDER="2351" SD_1="5.1" SD_2="5.4" SE="1.1130124727102089" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="43" TOTAL_2="46" WEIGHT="100.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="2.3" MEAN_2="2.2" MODIFIED="2011-01-13 10:24:35 +0100" MODIFIED_BY="[Empty name]" ORDER="82" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Archer-2008" TOTAL_1="20" TOTAL_2="44" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5756852763233747" CI_START="0.136185522236565" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.28" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.23981487788077438" LOG_CI_START="-0.8658690594347871" LOG_EFFECT_SIZE="-0.5528419686577808" METHOD="MH" MODIFIED="2013-01-06 14:47:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="5.371290292237265E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="3.4615225954464406">
<NAME>Unacceptable bleeding after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5756852763233747" CI_START="0.136185522236565" EFFECT_SIZE="0.28" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.23981487788077438" LOG_CI_START="-0.8658690594347871" LOG_EFFECT_SIZE="-0.5528419686577808" ORDER="2352" O_E="0.0" SE="0.36774732526300613" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="42" TOTAL_2="42" VAR="0.13523809523809524" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.808001290553363E-5" CI_END="3.1828103236489422" CI_START="0.03566863492584523" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33693693693693694" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.5028107580532676" LOG_CI_START="-1.447713511225622" LOG_EFFECT_SIZE="-0.47245137658617725" METHOD="MH" MODIFIED="2013-01-06 20:55:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9925118873256114" P_Q="0.9925118894460486" P_Z="0.3423787449514113" Q="8.807996302017249E-5" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="96" WEIGHT="200.0" Z="0.9494756841939896">
<NAME>Discontinuation of contraceptive method</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.146451329441078" CI_START="0.014238658560838814" DF="0" EFFECT_SIZE="0.34057971014492755" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.9109684671857773" LOG_CI_START="-1.846530924116815" LOG_EFFECT_SIZE="-0.467781228465519" MODIFIED="2013-01-06 20:55:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5060663569760352" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.00000000000001" Z="0.6649752042216946">
<NAME>Discontinuation of contraceptive method</NAME>
<DICH_DATA CI_END="8.146451329441069" CI_START="0.014238658560838814" EFFECT_SIZE="0.34057971014492755" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9109684671857768" LOG_CI_START="-1.846530924116815" LOG_EFFECT_SIZE="-0.467781228465519" ORDER="2353" O_E="0.0" SE="1.6197687922932713" STUDY_ID="STD-Diaz-1990" TOTAL_1="45" TOTAL_2="46" VAR="2.623650940487203" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.99146782835324" CI_START="0.013903717501920699" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.9026265554350377" LOG_CI_START="-1.8568690648743624" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-01-06 20:55:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.497922686342418" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.6777618841839292">
<NAME>Discontinuation of contraceptive method because of bleeding</NAME>
<DICH_DATA CI_END="7.99146782835324" CI_START="0.013903717501920699" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9026265554350377" LOG_CI_START="-1.8568690648743624" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="2354" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.99146782835324" CI_START="0.013903717501920699" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.9026265554350377" LOG_CI_START="-1.8568690648743624" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.497922686342418" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.6777618841839292">
<NAME>Discontinuation of treatment due to lack of improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.99146782835324" CI_START="0.013903717501920699" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9026265554350377" LOG_CI_START="-1.8568690648743624" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="2355" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1487772902183095" CI_END="63.40407592748297" CI_START="1.0354821851433615" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="8.102702702702702" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="1.8021171773756788" LOG_CI_START="0.015142631514852442" LOG_EFFECT_SIZE="0.9086299044452656" METHOD="MH" NO="6" P_CHI2="0.6997067226599007" P_Q="1.0" P_Z="0.04624162696306642" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="96" WEIGHT="100.0" Z="1.9931810356379758">
<NAME>Discontinuation of treatment due to side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="101.58460526662178" CI_START="0.24610028197072092" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.006827897373713" LOG_CI_START="-0.6088878887016753" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="2356" O_E="0.0" SE="1.5364844007426468" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.3607843137254902" WEIGHT="50.27027027027027"/>
<DICH_DATA CI_END="197.5080325690915" CI_START="0.6395590664692011" EFFECT_SIZE="11.23913043478261" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.2955847628966213" LOG_CI_START="-0.19411934007188417" LOG_EFFECT_SIZE="1.0507327114123683" ORDER="2357" O_E="0.0" SE="1.4624645143177724" STUDY_ID="STD-Diaz-1990" TOTAL_1="45" TOTAL_2="46" VAR="2.138802455638718" WEIGHT="49.729729729729726"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="37.05656932989878" CI_START="2.231266235000909" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.093023255813954" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="1.5688652101782385" LOG_CI_START="0.3485513934543221" LOG_EFFECT_SIZE="0.9587083018162803" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.002072850129809454" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="46" WEIGHT="100.0" Z="3.0795910322214732">
<NAME>Side-effects related to treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="37.05656932989878" CI_START="2.231266235000909" DF="0" EFFECT_SIZE="9.093023255813954" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="1.5688652101782385" LOG_CI_START="0.3485513934543221" LOG_EFFECT_SIZE="0.9587083018162803" NO="1" P_CHI2="1.0" P_Z="0.002072850129809454" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="46" WEIGHT="100.0" Z="3.0795910322214732">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="37.05656932989878" CI_START="2.231266235000909" EFFECT_SIZE="9.093023255813954" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" LOG_CI_END="1.5688652101782385" LOG_CI_START="0.3485513934543221" LOG_EFFECT_SIZE="0.9587083018162803" ORDER="2358" O_E="0.0" SE="0.7168183765944437" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="43" TOTAL_2="46" VAR="0.5138285850234937" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0267483554543388" CI_START="-1.6267483554543403" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2013-01-06 20:30:33 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.6576350768372163" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="44" UNITS="" WEIGHT="100.0" Z="0.44318064759210735">
<NAME>Bleeding/spotting after treatment (# days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0267483554543388" CI_START="-1.6267483554543403" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="6.4" MODIFIED="2011-01-25 11:03:48 +0100" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="2.6" SD_2="2.3" SE="0.6769248649054581" STUDY_ID="STD-Archer-2008" TOTAL_1="20" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-01-06 19:29:14 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Estrogen vs placebo (DMPA/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="9.175675692819372" CI_END="1.0167633649762808" CI_START="0.46126479501164364" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6848336623743996" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="50" I2="89.10162004981746" I2_Q="88.55403945730062" ID="CMP-002.01" LOG_CI_END="0.0072198897535875085" LOG_CI_START="-0.33604969066731444" LOG_EFFECT_SIZE="-0.1644149004568635" METHOD="MH" NO="1" P_CHI2="0.0024525370196027962" P_Q="0.0031186918935632857" P_Z="0.06044723209017886" Q="8.736706685904426" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="181" TOTAL_2="194" WEIGHT="200.0" Z="1.877517273870089">
<NAME>Continued irregular bleeding during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.60131176941229" CI_START="0.11127080467731307" DF="0" EFFECT_SIZE="0.25866666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="25" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.22090029567089847" LOG_CI_START="-0.9536187712520495" LOG_EFFECT_SIZE="-0.587259533461474" NO="1" P_CHI2="1.0" P_Z="0.0016794387111455046" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="97" WEIGHT="100.0" Z="3.1417456322481003">
<NAME>Estradiol</NAME>
<DICH_DATA CI_END="0.6013117694122901" CI_START="0.11127080467731307" EFFECT_SIZE="0.25866666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="25" LOG_CI_END="-0.2209002956708984" LOG_CI_START="-0.9536187712520495" LOG_EFFECT_SIZE="-0.587259533461474" ORDER="2359" O_E="0.0" SE="0.4304024595713181" STUDY_ID="STD-Said-1996" TOTAL_1="90" TOTAL_2="97" VAR="0.1852462772050401" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7712345358066524" CI_START="0.6938271512898322" DF="0" EFFECT_SIZE="1.1085714285714285" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.2482760715586046" LOG_CI_START="-0.1587487090707414" LOG_EFFECT_SIZE="0.0447636812439316" NO="2" P_CHI2="1.0" P_Z="0.6663920477813354" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="97" WEIGHT="99.99999999999999" Z="0.4311049706500914">
<NAME>Estrone sulfate</NAME>
<DICH_DATA CI_END="1.7712345358066524" CI_START="0.6938271512898322" EFFECT_SIZE="1.1085714285714285" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.2482760715586046" LOG_CI_START="-0.1587487090707414" LOG_EFFECT_SIZE="0.0447636812439316" ORDER="2360" O_E="0.0" SE="0.23908837094683635" STUDY_ID="STD-Said-1996" TOTAL_1="91" TOTAL_2="97" VAR="0.05716324912201202" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.3215239265231515" CI_END="1.1612305121093527" CI_START="0.23773927047341245" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5254237288135593" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" I2="76.86001473085578" I2_Q="71.74395041118402" ID="CMP-002.02" LOG_CI_END="0.0649184386879077" LOG_CI_START="-0.6238990743036509" LOG_EFFECT_SIZE="-0.2794903178078716" METHOD="MH" MODIFIED="2013-01-06 19:29:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03763339752371264" P_Q="0.059939378954974254" P_Z="0.11171637145935995" Q="3.539065136677172" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="144" TOTAL_2="146" WEIGHT="100.0" Z="1.5905256373404524">
<NAME>Continued irregular bleeding after treatment(3 months).</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0006942280148283" CI_START="0.003457807105893963" DF="0" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="3.0139478976993133E-4" LOG_CI_START="-2.461199237546318" LOG_EFFECT_SIZE="-1.2304489213782739" NO="1" P_CHI2="1.0" P_Z="0.05005613012926073" STUDIES="1" TAU2="0.0" TOTAL_1="73" TOTAL_2="73" WEIGHT="51.86440677966102" Z="1.9594840147806996">
<NAME>Estradiol</NAME>
<DICH_DATA CI_END="1.0006942280148283" CI_START="0.003457807105893963" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="3.0139478976993133E-4" LOG_CI_START="-2.461199237546318" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="2361" O_E="0.0" SE="1.445897656058859" STUDY_ID="STD-Said-1996" TOTAL_1="73" TOTAL_2="73" VAR="2.0906200317965022" WEIGHT="51.86440677966102"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5901202559886407" CI_START="0.4081399383211277" DF="0" EFFECT_SIZE="1.028169014084507" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.4133199282896914" LOG_CI_START="-0.3891909054869301" LOG_EFFECT_SIZE="0.012064511401380599" NO="2" P_CHI2="1.0" P_Z="0.9530078111706707" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="73" WEIGHT="48.13559322033898" Z="0.05893006509706681">
<NAME>Estrone sulphate</NAME>
<DICH_DATA CI_END="2.5901202559886403" CI_START="0.4081399383211277" EFFECT_SIZE="1.028169014084507" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.41331992828969133" LOG_CI_START="-0.3891909054869301" LOG_EFFECT_SIZE="0.012064511401380599" ORDER="2362" O_E="0.0" SE="0.47139883625308215" STUDY_ID="STD-Said-1996" TOTAL_1="71" TOTAL_2="73" VAR="0.22221686282076017" WEIGHT="48.13559322033898"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-01-06 20:55:17 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Estrogen vs placebo (DMPA/Prophylactic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9644794052230447" CI_START="0.21288403309920068" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.453125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.01570704152292814" LOG_CI_START="-0.671856910646934" LOG_EFFECT_SIZE="-0.3437819760849311" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.03999505559627151" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0" Z="2.0537999727410856">
<NAME>Unacceptable bleeding during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9644794052230447" CI_START="0.21288403309920068" EFFECT_SIZE="0.453125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="-0.01570704152292814" LOG_CI_START="-0.671856910646934" LOG_EFFECT_SIZE="-0.3437819760849311" ORDER="2363" O_E="0.0" SE="0.3854256811176762" STUDY_ID="STD-El_x002d_Habashy-1970" TOTAL_1="32" TOTAL_2="29" VAR="0.14855295566502463" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.6033915804337475" CI_START="-20.20339158043375" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2011-01-25 11:42:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1717368556615958" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="1.3666442006681991">
<NAME>Bleeding during treatment (days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.6033915804337475" CI_START="-20.20339158043375" EFFECT_SIZE="-8.3" ESTIMABLE="YES" MEAN_1="21.5" MEAN_2="29.8" MODIFIED="2011-01-25 11:42:26 +0100" MODIFIED_BY="[Empty name]" ORDER="110" SD_1="19.0" SD_2="23.0" SE="6.073270567380922" STUDY_ID="STD-Dempsey-2010" TOTAL_1="26" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5757363712460264" CI_END="1.2799747285475245" CI_START="0.7816323356732777" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0002347907753315" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.10720139514731743" LOG_CI_START="-0.10699748240853929" LOG_EFFECT_SIZE="1.0195636938907136E-4" METHOD="MH" MODIFIED="2013-01-06 20:55:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.44798852403402634" P_Q="1.0" P_Z="0.9985112729908884" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="69" WEIGHT="100.0" Z="0.0018658436895397082">
<NAME>Discontinuation of contraceptive method</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5757363712460264" CI_END="1.2799747285475245" CI_START="0.7816323356732777" DF="1" EFFECT_SIZE="1.0002347907753315" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.10720139514731743" LOG_CI_START="-0.10699748240853929" LOG_EFFECT_SIZE="1.0195636938907136E-4" MODIFIED="2013-01-06 20:55:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44798852403402634" P_Z="0.9985112729908884" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="69" WEIGHT="100.0" Z="0.0018658436895397082">
<NAME>Discontinuation of contraceptive method</NAME>
<DICH_DATA CI_END="1.9314341862619506" CI_START="0.29767028461594086" EFFECT_SIZE="0.7582417582417582" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.28587991412192704" LOG_CI_START="-0.5262645172896036" LOG_EFFECT_SIZE="-0.1201923015838383" MODIFIED="2011-01-25 11:46:41 +0100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.4770576591909052" STUDY_ID="STD-Dempsey-2010" TOTAL_1="26" TOTAL_2="23" VAR="0.22758401019270588" WEIGHT="19.466764061358656"/>
<DICH_DATA CI_END="1.3299105303681773" CI_START="0.8428458331662885" EFFECT_SIZE="1.0587301587301587" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.12382242482092633" LOG_CI_START="-0.07425185589499185" LOG_EFFECT_SIZE="0.024785284462967266" ORDER="2364" O_E="0.0" SE="0.11634981297603292" STUDY_ID="STD-Goldberg-2002" TOTAL_1="36" TOTAL_2="46" VAR="0.013537278979557837" WEIGHT="80.53323593864134"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-06 20:55:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Discontinuation of contraceptive method because of bleeding</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4533728700272606" CI_START="0.9303064853362789" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1627906976744187" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.1623770489992361" LOG_CI_START="-0.031373951486371524" LOG_EFFECT_SIZE="0.0655015487564323" METHOD="MH" MODIFIED="2013-01-06 20:08:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.1851005004616448" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="66" WEIGHT="100.0" Z="1.32521304326104">
<NAME>Non-compliance with treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4533728700272608" CI_START="0.9303064853362789" EFFECT_SIZE="1.1627906976744187" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="43" LOG_CI_END="0.1623770489992362" LOG_CI_START="-0.031373951486371524" LOG_EFFECT_SIZE="0.0655015487564323" ORDER="2365" O_E="0.0" SE="0.11381029676816624" STUDY_ID="STD-Goldberg-2002" TOTAL_1="66" TOTAL_2="66" VAR="0.012952783650458072" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-01-06 19:37:05 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Estrogen vs placebo (Minipill/Therapeutic)</NAME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-01-06 20:41:29 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Estrogen and progestin vs placebo (LNG subcutaneous implant/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.236236777390798" CI_START="0.026173175761108447" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.07863247863247863" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.6266524904035424" LOG_CI_START="-1.5821435783976705" LOG_EFFECT_SIZE="-1.1043980344006064" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="5.875442353464779E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.0" Z="4.53082273444568">
<NAME>Continued irregular bleeding during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.236236777390798" CI_START="0.026173175761108447" EFFECT_SIZE="0.07863247863247863" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="39" LOG_CI_END="-0.6266524904035424" LOG_CI_START="-1.5821435783976705" LOG_EFFECT_SIZE="-1.1043980344006064" ORDER="2366" O_E="0.0" SE="0.561260194844917" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="45" TOTAL_2="46" VAR="0.3150130063173542" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-8.086783422629887" CI_START="-11.313216577370115" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.700000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="4.667864950188791E-32" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="46" UNITS="" WEIGHT="100.0" Z="11.784933850005158">
<NAME>Bleeding during treatment (days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-8.086783422629887" CI_START="-11.313216577370115" EFFECT_SIZE="-9.700000000000001" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="12.3" ORDER="2367" SD_1="1.4" SD_2="5.4" SE="0.8230848067081645" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.29186412509510495" CI_START="0.0011510658761824952" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.018329070758738276" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="25" I2="0.0" I2_Q="100.0" ID="CMP-005.03" LOG_CI_END="-0.534819283671566" LOG_CI_START="-2.938899820728282" LOG_EFFECT_SIZE="-1.736859552199924" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.004625735185360757" Q="9.889337833218825E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="42" WEIGHT="100.0" Z="2.832003434197685">
<NAME>Unacceptable bleeding after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.29186412509510495" CI_START="0.0011510658761824952" EFFECT_SIZE="0.018329070758738276" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="25" LOG_CI_END="-0.534819283671566" LOG_CI_START="-2.938899820728282" LOG_EFFECT_SIZE="-1.736859552199924" ORDER="2368" O_E="0.0" SE="1.4121688078577004" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="45" TOTAL_2="42" VAR="1.9942207418862385" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.99146782835324" CI_START="0.013903717501920699" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.9026265554350377" LOG_CI_START="-1.8568690648743624" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.497922686342418" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.6777618841839292">
<NAME>Discontinuation of contraceptive method because of bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.99146782835324" CI_START="0.013903717501920699" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9026265554350377" LOG_CI_START="-1.8568690648743624" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="2369" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="71.92321045517915" CI_START="0.12513345751728625" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="1.8568690648743624" LOG_CI_START="-0.9026265554350377" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2013-01-06 20:41:29 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.497922686342418" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="0.6777618841839292">
<NAME>Discontinuation of treatment due to side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.92321045517915" CI_START="0.12513345751728625" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8568690648743624" LOG_CI_START="-0.9026265554350377" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="2371" O_E="0.0" SE="1.6209413870933633" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="50" TOTAL_2="50" VAR="2.627450980392157" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="29.70605485927295" CI_START="1.7236208426599242" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.155555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="1.4728449787435909" LOG_CI_START="0.2364417370973837" LOG_EFFECT_SIZE="0.8546433579204873" METHOD="MH" MODIFIED="2013-01-06 20:41:29 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.006736732189997527" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.0" Z="2.709585586204482">
<NAME>Side-effects related to treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.70605485927295" CI_START="1.7236208426599242" DF="0" EFFECT_SIZE="7.155555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="1.4728449787435909" LOG_CI_START="0.2364417370973837" LOG_EFFECT_SIZE="0.8546433579204873" NO="1" P_CHI2="1.0" P_Z="0.006736732189997527" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.0" Z="2.709585586204482">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="29.70605485927295" CI_START="1.7236208426599242" EFFECT_SIZE="7.155555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.4728449787435909" LOG_CI_START="0.2364417370973837" LOG_EFFECT_SIZE="0.8546433579204873" ORDER="2372" O_E="0.0" SE="0.726269384437735" STUDY_ID="STD-Alvarez_x002d_Sanchez-1996" TOTAL_1="45" TOTAL_2="46" VAR="0.5274672187715665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-01-06 20:06:20 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Estrogen and progestin vs placebo (DMPA /Therapeutic for amenorrhea)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7327631563622548" CI_START="0.19442740995095573" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37745098039215685" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.13503637529930462" LOG_CI_START="-0.7112425092075292" LOG_EFFECT_SIZE="-0.4231394422534169" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.003994244919670756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="22" WEIGHT="100.0" Z="2.8786158926491274">
<NAME>Continued amenorrhea during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7327631563622548" CI_START="0.1944274099509557" EFFECT_SIZE="0.37745098039215685" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.13503637529930462" LOG_CI_START="-0.7112425092075292" LOG_EFFECT_SIZE="-0.4231394422534169" ORDER="2373" O_E="0.0" SE="0.33846633532405473" STUDY_ID="STD-Sadeghi_x002d_Bazargani-2006" TOTAL_1="24" TOTAL_2="22" VAR="0.11455946014769545" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8809331408159415" CI_START="0.4030014817949583" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5958333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-0.05505705149323162" LOG_CI_START="-0.3946933569998568" LOG_EFFECT_SIZE="-0.22487520424654422" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.009447883959985248" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="22" WEIGHT="100.00000000000001" Z="2.5954074649461627">
<NAME>Discontinuation of the contraceptive method</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8809331408159415" CI_START="0.4030014817949583" EFFECT_SIZE="0.5958333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="-0.05505705149323162" LOG_CI_START="-0.3946933569998568" LOG_EFFECT_SIZE="-0.22487520424654422" ORDER="2374" O_E="0.0" SE="0.1995040470814184" STUDY_ID="STD-Sadeghi_x002d_Bazargani-2006" TOTAL_1="24" TOTAL_2="22" VAR="0.0398018648018648" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2013-01-06 20:50:51 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Progestin vs placebo (LNG subcutaneous implant/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="27.20691780840998" CI_START="0.3168714508215703" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="1.4346793446236137" LOG_CI_START="-0.4991168876925756" LOG_EFFECT_SIZE="0.46778122846551906" METHOD="MH" MODIFIED="2013-01-06 20:50:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.34301630590024257" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="0.9482223050338547">
<NAME>Discontinuation of contraceptive method</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.20691780840998" CI_START="0.3168714508215703" DF="0" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="1.4346793446236137" LOG_CI_START="-0.4991168876925756" LOG_EFFECT_SIZE="0.46778122846551906" NO="1" P_CHI2="1.0" P_Z="0.34301630590024257" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="0.9482223050338547">
<NAME>Discontinuation of contraceptive method</NAME>
<DICH_DATA CI_END="27.20691780840997" CI_START="0.3168714508215705" EFFECT_SIZE="2.9361702127659575" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4346793446236137" LOG_CI_START="-0.4991168876925754" LOG_EFFECT_SIZE="0.46778122846551906" ORDER="2375" O_E="0.0" SE="1.1359214793082617" STUDY_ID="STD-Diaz-1990" TOTAL_1="47" TOTAL_2="46" VAR="1.2903176071538698" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2013-01-06 19:54:05 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Antiprogestin vs placebo (LNG subcutaneous implant/Therapeutic)</NAME>
<CONT_OUTCOME CHI2="1.137373378354363" CI_END="-3.0300404997129147" CI_START="-10.08813970288172" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.5590901012973175" ESTIMABLE="YES" I2="12.078125000000004" I2_Q="12.078125000000004" ID="CMP-008.01" MODIFIED="2013-01-06 19:48:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2862080724189695" P_Q="0.2862080724189695" P_Z="2.697007104204223E-4" Q="1.137373378354363" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="3.6427882351453134">
<NAME>Bleeding during treatment (days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.879891953620163" CI_START="-9.879891953620163" DF="0" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.01" NO="1" P_CHI2="1.0" P_Z="0.18242243945826034" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="36.022747467567086" Z="1.3333333333333333">
<NAME>at 3 months</NAME>
<CONT_DATA CI_END="1.879891953620163" CI_START="-9.879891953620163" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="33.0" ORDER="2376" SD_1="15.0" SD_2="15.0" SE="3.0" STUDY_ID="STD-Cheng-2000" TOTAL_1="50" TOTAL_2="50" WEIGHT="36.022747467567086"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.5879038344719314" CI_START="-12.41209616552807" DF="0" EFFECT_SIZE="-8.0" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.02" NO="2" P_CHI2="1.0" P_Z="3.797063730271736E-4" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="63.977252532432914" Z="3.5538010251967806">
<NAME>at 6 months</NAME>
<CONT_DATA CI_END="-3.5879038344719314" CI_START="-12.41209616552807" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="31.0" ORDER="2377" SD_1="9.0" SD_2="13.0" SE="2.2511108368980857" STUDY_ID="STD-Cheng-2000" TOTAL_1="48" TOTAL_2="50" WEIGHT="63.977252532432914"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.7479988784823428" CI_START="-7.747998878482343" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2013-01-06 19:48:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.21557013489883148" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="47" UNITS="" WEIGHT="100.0" Z="1.2383937115628847">
<NAME>Bleeding after treatment (days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7479988784823428" CI_START="-7.747998878482343" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="29.0" ORDER="2378" SD_1="10.0" SD_2="13.0" SE="2.422492921264856" STUDY_ID="STD-Cheng-2000" TOTAL_1="44" TOTAL_2="47" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-01-06 19:48:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Discontinuation of contraceptive method because of bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2379" O_E="0.0" SE="0.0" STUDY_ID="STD-Cheng-2000" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9054656613258321" CI_START="0.23305730922584647" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.459375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="-0.04312801512295855" LOG_CI_START="-0.6325372720205011" LOG_EFFECT_SIZE="-0.3378326435717299" METHOD="MH" MODIFIED="2013-01-06 19:54:05 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.02465336392833206" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="49" WEIGHT="100.0" Z="2.246791364247772">
<NAME>Patient dissatisfaction with treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9054656613258321" CI_START="0.23305730922584647" EFFECT_SIZE="0.459375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.04312801512295855" LOG_CI_START="-0.6325372720205011" LOG_EFFECT_SIZE="-0.3378326435717299" ORDER="2380" O_E="0.0" SE="0.346221915124493" STUDY_ID="STD-Cheng-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.11986961451247163" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2013-01-06 20:28:30 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Antiprogestin vs placebo (LNG subcutaneous implant/Prophylactic)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-9.074314660544944" CI_START="-26.925685339455057" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2013-01-06 20:28:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="7.731790815664863E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="3.9525650277824944">
<NAME>Bleeding during treatment (days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-9.074314660544944" CI_START="-26.925685339455057" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="50.0" ORDER="2381" SD_1="15.0" SD_2="31.0" SE="4.554004772465067" STUDY_ID="STD-Massai-2004" TOTAL_1="58" TOTAL_2="57" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8296160027865884" CI_START="0.6508851390955015" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0912698412698412" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.26235995018391095" LOG_CI_START="-0.18649564408647404" LOG_EFFECT_SIZE="0.03793215304871851" METHOD="MH" MODIFIED="2013-01-06 20:28:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7404423760753815" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="55" WEIGHT="100.0" Z="0.3312675826282099">
<NAME>Unacceptable bleeding after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8296160027865884" CI_START="0.6508851390955015" EFFECT_SIZE="1.0912698412698412" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.26235995018391095" LOG_CI_START="-0.18649564408647404" LOG_EFFECT_SIZE="0.03793215304871851" ORDER="2382" O_E="0.0" SE="0.26365999794544964" STUDY_ID="STD-Massai-2004" TOTAL_1="56" TOTAL_2="55" VAR="0.0695165945165945" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.007329751896776" CI_START="0.00964621359876602" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19661016949152543" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.6028550807748148" LOG_CI_START="-2.0156431256052665" LOG_EFFECT_SIZE="-0.7063940224152256" METHOD="MH" MODIFIED="2013-01-06 20:28:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.29029186113576566" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="57" WEIGHT="100.00000000000001" Z="1.0574816048793259">
<NAME>Discontinuation of contraceptive method because of bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.007329751896776" CI_START="0.00964621359876602" EFFECT_SIZE="0.19661016949152543" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6028550807748148" LOG_CI_START="-2.0156431256052665" LOG_EFFECT_SIZE="-0.7063940224152256" ORDER="2383" O_E="0.0" SE="1.538118808202826" STUDY_ID="STD-Massai-2004" TOTAL_1="58" TOTAL_2="57" VAR="2.3658094681472823" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2013-02-07 21:57:13 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Antiprogestin vs placebo (Implanon/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.4651450251563293" CI_END="1.2790406103200644" CI_START="0.575252677871097" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8577712609970676" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.10688433381244529" LOG_CI_START="-0.24014135096104214" LOG_EFFECT_SIZE="-0.0666285085742984" METHOD="MH" MODIFIED="2013-02-07 21:57:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4952292375198407" P_Q="0.5069185304101385" P_Z="0.45167746446131685" Q="0.4404226996753927" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="90" WEIGHT="100.00000000000001" Z="0.7526213930503856">
<NAME>Side effects related to treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4226785066701044" CI_START="0.6129087502179873" DF="0" EFFECT_SIZE="0.9337944664031621" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="0.1531067703908498" LOG_CI_START="-0.2126041783798845" LOG_EFFECT_SIZE="-0.02974870399451734" NO="1" P_CHI2="1.0" P_Z="0.7498281499840096" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="45" WEIGHT="74.19354838709678" Z="0.31886597112819465">
<NAME>Any side effects</NAME>
<DICH_DATA CI_END="1.4226785066701044" CI_START="0.6129087502179873" EFFECT_SIZE="0.9337944664031621" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.1531067703908498" LOG_CI_START="-0.2126041783798845" LOG_EFFECT_SIZE="-0.02974870399451734" ORDER="2385" O_E="0.0" SE="0.21482042160632184" STUDY_ID="STD-Weisberg-2006" TOTAL_1="44" TOTAL_2="45" VAR="0.04614781353911787" WEIGHT="74.19354838709678"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8034080099923544" CI_START="0.2265612932103391" DF="0" EFFECT_SIZE="0.6392045454545454" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-010.01.02" LOG_CI_END="0.25609399429972873" LOG_CI_START="-0.6448142850332659" LOG_EFFECT_SIZE="-0.19436014536676857" NO="2" P_CHI2="1.0" P_Z="0.397732743390685" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="45" WEIGHT="25.806451612903228" Z="0.8456773984380997">
<NAME>Nausea/vomiting</NAME>
<DICH_DATA CI_END="1.8034080099923548" CI_START="0.22656129321033905" EFFECT_SIZE="0.6392045454545454" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.25609399429972884" LOG_CI_START="-0.644814285033266" LOG_EFFECT_SIZE="-0.19436014536676857" ORDER="2386" O_E="0.0" SE="0.5291979828481068" STUDY_ID="STD-Weisberg-2006" TOTAL_1="44" TOTAL_2="45" VAR="0.2800505050505051" WEIGHT="25.806451612903228"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2013-01-06 19:57:38 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Antiprogestin vs placebo (DMPA/Prophylactic)</NAME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2013-01-06 20:10:06 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Antiprogestin vs placebo (Minipill/Prophylactic)</NAME>
<DICH_OUTCOME CHI2="4.526572200243482" CI_END="1.2657405418070324" CI_START="0.710745841808939" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9484829080686388" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="83" I2="55.81645643711546" I2_Q="55.73813956878685" ID="CMP-012.01" LOG_CI_END="0.10234469082375183" LOG_CI_START="-0.14828567245315882" LOG_EFFECT_SIZE="-0.022970490814703468" METHOD="MH" NO="1" P_CHI2="0.1040082711946353" P_Q="0.10442562032344793" P_Z="0.7193969989575577" Q="4.518562890297341" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03627670758030955" TOTALS="YES" TOTAL_1="133" TOTAL_2="127" WEIGHT="100.0" Z="0.35926480826494944">
<NAME>Percentage of women with B/S episodes starting day 8-28</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1825018303873203" CI_START="0.5948692043601094" DF="0" EFFECT_SIZE="0.8387096774193549" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="31" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="0.07280182165213053" LOG_CI_START="-0.22557851337904" LOG_EFFECT_SIZE="-0.07638834586345469" NO="1" P_CHI2="1.0" P_Z="0.3156000582385936" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="32.35129606602616" Z="1.0035407106525303">
<NAME>Cycle 1</NAME>
<DICH_DATA CI_END="1.1825018303873203" CI_START="0.5948692043601094" EFFECT_SIZE="0.8387096774193549" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="31" LOG_CI_END="0.07280182165213053" LOG_CI_START="-0.22557851337904" LOG_EFFECT_SIZE="-0.07638834586345469" ORDER="2387" O_E="0.0" SE="0.1752700858037888" STUDY_ID="STD-Gemzell_x002d_Danielsson-2002" TOTAL_1="50" TOTAL_2="50" VAR="0.03071960297766749" WEIGHT="32.35129606602616"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0882134984419676" CI_START="0.6031904908672271" DF="0" EFFECT_SIZE="0.8101851851851852" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="36" I2="0.0" ID="CMP-012.01.02" LOG_CI_END="0.0367141086885239" LOG_CI_START="-0.21954551361779676" LOG_EFFECT_SIZE="-0.09141570246463643" NO="2" P_CHI2="1.0" P_Z="0.1620052656109175" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="50" WEIGHT="36.77613268590046" Z="1.398359076935997">
<NAME>Cycle 3</NAME>
<DICH_DATA CI_END="1.0882134984419676" CI_START="0.6031904908672271" EFFECT_SIZE="0.8101851851851852" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="36" LOG_CI_END="0.0367141086885239" LOG_CI_START="-0.21954551361779676" LOG_EFFECT_SIZE="-0.09141570246463643" ORDER="2388" O_E="0.0" SE="0.15052817064832136" STUDY_ID="STD-Gemzell_x002d_Danielsson-2002" TOTAL_1="48" TOTAL_2="50" VAR="0.02265873015873016" WEIGHT="36.77613268590046"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8677913361795513" CI_START="0.90729944672763" DF="0" EFFECT_SIZE="1.3017857142857143" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" I2="0.0" ID="CMP-012.01.03" LOG_CI_END="0.2713283565795224" LOG_CI_START="-0.04224935395597393" LOG_EFFECT_SIZE="0.11453950131177422" NO="3" P_CHI2="1.0" P_Z="0.1521955635491007" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="27" WEIGHT="30.87257124807339" Z="1.4318192258938862">
<NAME>Cycle 6</NAME>
<DICH_DATA CI_END="1.8677913361795513" CI_START="0.90729944672763" EFFECT_SIZE="1.3017857142857143" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.2713283565795224" LOG_CI_START="-0.04224935395597393" LOG_EFFECT_SIZE="0.11453950131177422" ORDER="2389" O_E="0.0" SE="0.18419709940325182" STUDY_ID="STD-Gemzell_x002d_Danielsson-2002" TOTAL_1="35" TOTAL_2="27" VAR="0.03392857142857143" WEIGHT="30.87257124807339"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.700002113150363" CI_START="0.14356835531972334" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="0.8260749396753634" LOG_CI_START="-0.842941274749089" LOG_EFFECT_SIZE="-0.008433167536862813" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9841977137011404" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="0.01980652375332767">
<NAME>Discontinuation of the contraceptive method because of bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.700002113150363" CI_START="0.14356835531972334" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8260749396753634" LOG_CI_START="-0.842941274749089" LOG_EFFECT_SIZE="-0.008433167536862813" ORDER="2390" O_E="0.0" SE="0.9803883861164288" STUDY_ID="STD-Gemzell_x002d_Danielsson-2002" TOTAL_1="52" TOTAL_2="51" VAR="0.9611613876319758" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4689289605328861" CI_START="0.7923521524460962" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0788461538461538" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="0.16700079320715433" LOG_CI_START="-0.10108175796442982" LOG_EFFECT_SIZE="0.032959517621362226" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6298506112066455" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="0.48193712871925676">
<NAME>Percentage of women having side effects related to treatment (headache,emotional lability,acne, breast pain).</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4689289605328861" CI_START="0.7923521524460962" EFFECT_SIZE="1.0788461538461538" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="30" LOG_CI_END="0.16700079320715433" LOG_CI_START="-0.10108175796442982" LOG_EFFECT_SIZE="0.032959517621362226" ORDER="2391" O_E="0.0" SE="0.15747301758821888" STUDY_ID="STD-Gemzell_x002d_Danielsson-2002" TOTAL_1="52" TOTAL_2="51" VAR="0.024797751268339496" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.124127432901127" CI_START="0.17319185000749543" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7355769230769231" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="0.4947287404027757" LOG_CI_START="-0.7614725486931011" LOG_EFFECT_SIZE="-0.13337190414516273" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6772768938925822" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.0" Z="0.4161819143844171">
<NAME>Discontinuation of the contraceptive because of side effects.</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.124127432901127" CI_START="0.17319185000749543" EFFECT_SIZE="0.7355769230769231" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4947287404027757" LOG_CI_START="-0.7614725486931011" LOG_EFFECT_SIZE="-0.13337190414516273" ORDER="2392" O_E="0.0" SE="0.7378988555115864" STUDY_ID="STD-Gemzell_x002d_Danielsson-2002" TOTAL_1="52" TOTAL_2="51" VAR="0.544494720965309" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2013-01-06 20:35:19 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Antiprogestin and estrogen vs placebo (Implanon/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6605612445507086" CI_START="0.0024582764343934966" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.04029692470837752" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="-0.18008691016551118" LOG_CI_START="-2.609369282075525" LOG_EFFECT_SIZE="-1.3947280961205182" METHOD="MH" MODIFIED="2011-02-01 10:55:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.024413734075171098" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="37" WEIGHT="99.99999999999999" Z="2.2505550348789125">
<NAME>Continued irregular bleeding during treatment (# women)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6605612445507086" CI_START="0.0024582764343934966" EFFECT_SIZE="0.04029692470837752" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="-0.18008691016551118" LOG_CI_START="-2.609369282075525" LOG_EFFECT_SIZE="-1.3947280961205182" MODIFIED="2011-02-01 10:55:15 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="1.426972490401622" STUDY_ID="STD-Weisberg-2009" TOTAL_1="40" TOTAL_2="37" VAR="2.0362504883630073" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.348968761642942" CI_END="1.3777796226990144" CI_START="0.6821544125604163" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9694629694629694" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="36" I2="10.420185629672597" I2_Q="32.69041303401845" ID="CMP-013.02" LOG_CI_END="0.13917975726703807" LOG_CI_START="-0.16611730726076696" LOG_EFFECT_SIZE="-0.01346877499686442" METHOD="MH" MODIFIED="2013-01-06 20:34:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.34088512974828966" P_Q="0.22635013855496589" P_Z="0.8627023142749012" Q="2.971344930419504" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="170" TOTAL_2="168" WEIGHT="300.0" Z="0.17293526192633019">
<NAME>Side effects related to treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7542897955576868" CI_START="0.8448100146592725" DF="0" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" I2="0.0" ID="CMP-013.02.01" LOG_CI_END="0.24410133715757326" LOG_CI_START="-0.07324094650832048" LOG_EFFECT_SIZE="0.08543019532462637" NO="1" P_CHI2="1.0" P_Z="0.29130414893364676" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="1.0552650223238145">
<NAME>Any side effects</NAME>
<DICH_DATA CI_END="1.7542897955576868" CI_START="0.8448100146592725" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.24410133715757326" LOG_CI_START="-0.07324094650832048" LOG_EFFECT_SIZE="0.08543019532462637" ORDER="2393" O_E="0.0" SE="0.18640842829498477" STUDY_ID="STD-Weisberg-2006" TOTAL_1="45" TOTAL_2="45" VAR="0.034748102139406475" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.606101216971189E-4" CI_END="1.3761853712497878" CI_START="0.1798312418844511" DF="1" EFFECT_SIZE="0.49747474747474746" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" ID="CMP-013.02.02" LOG_CI_END="0.138676937016215" LOG_CI_START="-0.7451348565440539" LOG_EFFECT_SIZE="-0.3032289597639194" MODIFIED="2011-02-01 11:19:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9848492925360743" P_Z="0.1786585537605211" STUDIES="2" TAU2="0.0" TOTAL_1="85" TOTAL_2="84" WEIGHT="100.0" Z="1.3448968310611247">
<NAME>Nausea/Vomiting</NAME>
<DICH_DATA CI_END="1.5429771261836058" CI_START="0.1620244368873757" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.18835948792583612" LOG_CI_START="-0.7904194792537986" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="2394" O_E="0.0" SE="0.5749396103553447" STUDY_ID="STD-Weisberg-2006" TOTAL_1="45" TOTAL_2="45" VAR="0.3305555555555556" WEIGHT="79.79797979797979"/>
<DICH_DATA CI_END="5.160959111254101" CI_START="0.04604885349348369" EFFECT_SIZE="0.4875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7127304182974155" LOG_CI_START="-1.3367811782283043" LOG_EFFECT_SIZE="-0.3120253799654444" MODIFIED="2011-02-01 11:19:49 +0100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="1.203893257045231" STUDY_ID="STD-Weisberg-2009" TOTAL_1="40" TOTAL_2="39" VAR="1.4493589743589745" WEIGHT="20.2020202020202"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6810397269294155" CI_START="0.11477735404731247" DF="0" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-013.02.03" LOG_CI_END="0.5659705045135308" LOG_CI_START="-0.9401437912278198" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2011-02-01 11:20:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6263107951756626" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="100.0" Z="0.48692597103064">
<NAME>Headache</NAME>
<DICH_DATA CI_END="3.6810397269294155" CI_START="0.11477735404731253" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5659705045135308" LOG_CI_START="-0.9401437912278195" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2011-02-01 11:20:13 +0100" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.884698992704472" STUDY_ID="STD-Weisberg-2009" TOTAL_1="40" TOTAL_2="39" VAR="0.7826923076923076" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-013.03" MODIFIED="2013-01-06 20:35:19 +0100" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Number of days to stop bleeding/spotting following initiation of treatment</NAME>
<TR>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>Lower 95% CI</P>
</TH>
<TH>
<P>Upper 95% CI</P>
</TH>
<TH>
<P>Total</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-01-25 12:12:31 +0100" MODIFIED_BY="[Empty name]" ORDER="200" STUDY_ID="STD-Weisberg-2009">
<TR>
<TD>
<P>Antiprogestin + EE</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>4.6</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>6.4</P>
</TD>
<TD>
<P>5.1</P>
</TD>
<TD>
<P>8.0</P>
</TD>
<TD>
<P>37</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0017973192342815789" CI_END="1.5968733998790956" CI_START="0.3526915688946133" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7504690431519699" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-013.04" LOG_CI_END="0.20327048663733369" LOG_CI_START="-0.45260492203455344" LOG_EFFECT_SIZE="-0.1246672176986099" METHOD="MH" MODIFIED="2013-01-06 20:35:19 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.966183979330804" P_Q="0.9662445368656231" P_Z="0.45621703857472906" Q="0.0017908838940968734" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="80" WEIGHT="200.0" Z="0.7450904653884552">
<NAME>Discontinuation of contraceptive method</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.064237081107419" CI_START="0.17472394716433787" DF="0" EFFECT_SIZE="0.7317073170731707" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-013.04.01" LOG_CI_END="0.48632236377827853" LOG_CI_START="-0.7576475677784247" LOG_EFFECT_SIZE="-0.13566260200007307" MODIFIED="2011-02-01 11:41:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6690207579414529" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.42749234884865">
<NAME>Discontinuation of method at 90 days following initiation of treatment</NAME>
<DICH_DATA CI_END="3.064237081107418" CI_START="0.1747239471643379" EFFECT_SIZE="0.7317073170731707" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4863223637782784" LOG_CI_START="-0.7576475677784247" LOG_EFFECT_SIZE="-0.13566260200007307" MODIFIED="2011-02-01 11:41:29 +0100" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.7307140955468795" STUDY_ID="STD-Weisberg-2009" TOTAL_1="41" TOTAL_2="40" VAR="0.5339430894308942" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.841334467421066" CI_START="0.3127019919026299" DF="0" EFFECT_SIZE="0.7588075880758808" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-013.04.02" LOG_CI_END="0.2651326826713045" LOG_CI_START="-0.5048693523049868" LOG_EFFECT_SIZE="-0.11986833481684114" MODIFIED="2011-02-01 11:41:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5417121324216281" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.6102259694288499">
<NAME>Discontinuation of method at 180 days following initiation of treatment</NAME>
<DICH_DATA CI_END="1.841334467421066" CI_START="0.3127019919026299" EFFECT_SIZE="0.7588075880758808" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.2651326826713045" LOG_CI_START="-0.5048693523049868" LOG_EFFECT_SIZE="-0.11986833481684114" MODIFIED="2011-02-01 11:41:46 +0100" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.45230300691661884" STUDY_ID="STD-Weisberg-2009" TOTAL_1="41" TOTAL_2="40" VAR="0.20457801006581494" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2013-01-06 19:51:20 +0100" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Venotonic vs placebo (Minipill/Therapeutic)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.22463666230687" CI_START="-2.77536333769313" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.01" MODIFIED="2013-01-06 19:49:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="4.29036613020848E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="5.055601391655587">
<NAME>Bleeding during treatment (days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.22463666230687" CI_START="-2.77536333769313" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="6.2" ORDER="2395" SD_1="1.2" SD_2="1.3" SE="0.3956008088970496" STUDY_ID="STD-Monteil_x002d_Seurin-1985" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2013-01-06 20:45:15 +0100" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Vitamin E vs placebo (LNG subcutaneous implant/Therapeutic)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.776236020168181" CI_START="-5.023763979831818" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.3999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.01" MODIFIED="2013-01-06 20:45:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.7889468781257822E-43" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="34" UNITS="" WEIGHT="100.0" Z="13.825488182728066">
<NAME>Bleeding during treatment (days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.776236020168181" CI_START="-5.023763979831818" EFFECT_SIZE="-4.3999999999999995" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="12.1" ORDER="2396" SD_1="1.4" SD_2="1.3" SE="0.31825277645507233" STUDY_ID="STD-Subakir-2000" TOTAL_1="38" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6094936568126323" CI_START="0.8305952041375018" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7314814814814814" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="0.5574462829373654" LOG_CI_START="-0.08061058083826686" LOG_EFFECT_SIZE="0.23841785104954924" METHOD="MH" MODIFIED="2013-01-06 20:45:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.14299469389215091" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="108" TOTAL_2="110" WEIGHT="100.0" Z="1.464729643572554">
<NAME>Discontinuation of treatment due to lack of improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6094936568126323" CI_START="0.8305952041375018" EFFECT_SIZE="1.7314814814814814" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.5574462829373654" LOG_CI_START="-0.08061058083826686" LOG_EFFECT_SIZE="0.23841785104954924" ORDER="2397" O_E="0.0" SE="0.37479776021422057" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="108" TOTAL_2="110" VAR="0.14047336106159636" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.077354055844882" CI_START="0.06452429727937857" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="1.206214575911225" LOG_CI_START="-1.1902767165686743" LOG_EFFECT_SIZE="0.007968929671275373" METHOD="MH" MODIFIED="2013-01-06 20:45:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9896000802299567" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="108" TOTAL_2="110" WEIGHT="100.0" Z="0.013034735573664389">
<NAME>Discontinuation of treatment because of side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.077354055844882" CI_START="0.06452429727937857" EFFECT_SIZE="1.0185185185185186" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.206214575911225" LOG_CI_START="-1.1902767165686743" LOG_EFFECT_SIZE="0.007968929671275373" ORDER="2398" O_E="0.0" SE="1.4077108480259117" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="108" TOTAL_2="110" VAR="1.9816498316498317" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3355716486593779" CI_END="1.0847121426623834" CI_START="0.3783495864789422" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.640625" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-015.04" LOG_CI_END="0.03531450183445595" LOG_CI_START="-0.4221067363627592" LOG_EFFECT_SIZE="-0.19339611726415168" METHOD="MH" MODIFIED="2013-01-06 20:45:15 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5623967363211053" P_Q="0.5630477436737663" P_Z="0.09745237387768611" Q="0.33445489909258896" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="240" TOTAL_2="246" WEIGHT="200.0" Z="1.6573319860771167">
<NAME>Side-effects related to treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.353932339004194" CI_START="0.38023041120255374" DF="0" EFFECT_SIZE="0.7175" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" I2="0.0" ID="CMP-015.04.01" LOG_CI_END="0.13159696159333542" LOG_CI_START="-0.4199531507812755" LOG_EFFECT_SIZE="-0.14417809459397005" NO="1" P_CHI2="1.0" P_Z="0.30550961635614593" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="123" WEIGHT="100.0" Z="1.024689747762613">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.353932339004194" CI_START="0.38023041120255374" EFFECT_SIZE="0.7175" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.13159696159333542" LOG_CI_START="-0.4199531507812755" LOG_EFFECT_SIZE="-0.14417809459397005" ORDER="2399" O_E="0.0" SE="0.32398326622593504" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="120" TOTAL_2="123" VAR="0.10496515679442509" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.321424394099223" CI_START="0.19876752024019137" DF="0" EFFECT_SIZE="0.5125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" I2="0.0" ID="CMP-015.04.02" LOG_CI_END="0.12104231982124403" LOG_CI_START="-0.7016545803656603" LOG_EFFECT_SIZE="-0.29030613027220814" NO="2" P_CHI2="1.0" P_Z="0.1665943215991121" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="123" WEIGHT="100.0" Z="1.383230105025205">
<NAME>Gastrointestinal discomfort</NAME>
<DICH_DATA CI_END="1.3214243940992232" CI_START="0.19876752024019137" EFFECT_SIZE="0.5125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.1210423198212441" LOG_CI_START="-0.7016545803656603" LOG_EFFECT_SIZE="-0.29030613027220814" ORDER="2400" O_E="0.0" SE="0.48325623158512265" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="120" TOTAL_2="123" VAR="0.23353658536585367" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2013-01-06 19:34:04 +0100" MODIFIED_BY="[Empty name]" NO="16">
<NAME>NSAIDs vs placebo (LNG sub-cutaneous implant/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.0019106964543557437" CI_END="0.5055340932236424" CI_START="0.20329164196742008" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3205789386125437" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="-0.2962495502616809" LOG_CI_START="-0.6918804763646466" LOG_EFFECT_SIZE="-0.4940650133131637" METHOD="MH" MODIFIED="2011-01-25 10:54:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9651343696447928" P_Q="1.0" P_Z="9.81972744931538E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="53" WEIGHT="100.0" Z="4.895217073414952">
<NAME>Continued irregular bleeding during treatment (# women)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6026981703607218" CI_START="0.166808861453299" EFFECT_SIZE="0.3170731707317073" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" LOG_CI_END="-0.2199001269383411" LOG_CI_START="-0.7777808818874562" LOG_EFFECT_SIZE="-0.49884050441289873" MODIFIED="2011-01-25 10:54:08 +0100" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.327701917011385" STUDY_ID="STD-Buasang-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.10738854641293666" WEIGHT="45.69955082349027"/>
<DICH_DATA CI_END="0.6141669460010752" CI_START="0.17042805862208243" EFFECT_SIZE="0.3235294117647059" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="24" LOG_CI_END="-0.2117135606634206" LOG_CI_START="-0.7684589031046397" LOG_EFFECT_SIZE="-0.49008623188403005" ORDER="2401" O_E="0.0" SE="0.3270349700838643" STUDY_ID="STD-Kaewrudee-1999" TOTAL_1="34" TOTAL_2="33" VAR="0.106951871657754" WEIGHT="54.30044917650973"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.1606169652305782" CI_START="-10.039383034769422" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.02" MODIFIED="2013-01-06 14:41:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.01342204455923952" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="33" UNITS="" WEIGHT="100.00000000000001" Z="2.4723701981697506">
<NAME>Bleeding during treatment (days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.1606169652305782" CI_START="-10.039383034769422" EFFECT_SIZE="-5.6" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="17.2" ORDER="2402" SD_1="8.2" SD_2="10.2" SE="2.2650329647823675" STUDY_ID="STD-Kaewrudee-1999" TOTAL_1="34" TOTAL_2="33" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.65323868772056" CI_END="0.595195288223532" CI_START="0.24667513342916994" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3831708197905381" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="41" I2="39.512666414867624" I2_Q="0.0" ID="CMP-016.03" LOG_CI_END="-0.22534051547733164" LOG_CI_START="-0.607874628211136" LOG_EFFECT_SIZE="-0.41660757184423386" METHOD="MH" MODIFIED="2013-01-06 14:42:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.19851876960621484" P_Q="1.0" P_Z="1.9627409753828216E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="53" WEIGHT="100.0" Z="4.269087693465852">
<NAME>Unacceptable bleeding after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5659324581067751" CI_START="0.1223680963519873" EFFECT_SIZE="0.2631578947368421" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" LOG_CI_END="-0.2472353971188853" LOG_CI_START="-0.912331796114735" LOG_EFFECT_SIZE="-0.5797835966168102" MODIFIED="2011-01-25 10:46:37 +0100" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.39068091705043445" STUDY_ID="STD-Buasang-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.15263157894736845" WEIGHT="45.97327555074034"/>
<DICH_DATA CI_END="0.8349580602411466" CI_START="0.28206252725414604" EFFECT_SIZE="0.4852941176470588" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.0783353384844009" LOG_CI_START="-0.5496546071722969" LOG_EFFECT_SIZE="-0.3139949728283488" ORDER="2403" O_E="0.0" SE="0.2768552714952773" STUDY_ID="STD-Kaewrudee-1999" TOTAL_1="34" TOTAL_2="33" VAR="0.07664884135472369" WEIGHT="54.02672444925966"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.146451329441078" CI_START="0.014238658560838814" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.34057971014492755" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-016.04" LOG_CI_END="0.9109684671857773" LOG_CI_START="-1.846530924116815" LOG_EFFECT_SIZE="-0.467781228465519" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5060663569760352" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.00000000000001" Z="0.6649752042216946">
<NAME>Discontinuation of contraceptive method</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.146451329441078" CI_START="0.014238658560838814" DF="0" EFFECT_SIZE="0.34057971014492755" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-016.04.01" LOG_CI_END="0.9109684671857773" LOG_CI_START="-1.846530924116815" LOG_EFFECT_SIZE="-0.467781228465519" NO="1" P_CHI2="1.0" P_Z="0.5060663569760352" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="46" WEIGHT="100.00000000000001" Z="0.6649752042216946">
<NAME>Discontinuation of contraceptive method</NAME>
<DICH_DATA CI_END="8.146451329441069" CI_START="0.014238658560838814" EFFECT_SIZE="0.34057971014492755" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9109684671857768" LOG_CI_START="-1.846530924116815" LOG_EFFECT_SIZE="-0.467781228465519" ORDER="2404" O_E="0.0" SE="1.6197687922932713" STUDY_ID="STD-Diaz-1990" TOTAL_1="45" TOTAL_2="46" VAR="2.623650940487203" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-016.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Discontinuation of contraceptive method because of bleeding</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.988852318876937" CI_START="0.6440076515405959" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3873873873873874" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-016.05" LOG_CI_END="0.4755044567986219" LOG_CI_START="-0.19110897269901064" LOG_EFFECT_SIZE="0.14219774204980565" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.4030569565362663" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="111" TOTAL_2="110" WEIGHT="100.0" Z="0.8361741326170679">
<NAME>Discontinuation of treatment due to lack of improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.988852318876937" CI_START="0.6440076515405959" EFFECT_SIZE="1.3873873873873874" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.4755044567986219" LOG_CI_START="-0.19110897269901064" LOG_EFFECT_SIZE="0.14219774204980565" ORDER="2405" O_E="0.0" SE="0.3915720282766037" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="111" TOTAL_2="110" VAR="0.15332865332865334" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6319859587461818" CI_END="15.605037965599463" CI_START="0.3537631048682347" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3495715954822796" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-016.06" LOG_CI_END="1.193264829600537" LOG_CI_START="-0.4512874630816662" LOG_EFFECT_SIZE="0.3709886832594354" METHOD="MH" NO="6" P_CHI2="0.4266280132484994" P_Q="1.0" P_Z="0.37654370846368534" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="190" TOTAL_2="189" WEIGHT="99.99999999999999" Z="0.8842825626110293">
<NAME>Discontinuation of treatment due to side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.645556300322859" CI_START="0.06276946152467848" EFFECT_SIZE="0.990990990990991" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.19439100972352" LOG_CI_START="-1.2022515969803846" LOG_EFFECT_SIZE="-0.003930293628432402" ORDER="2406" O_E="0.0" SE="1.40779973075011" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="111" TOTAL_2="110" VAR="1.981900081900082" WEIGHT="67.00636115799038"/>
<DICH_DATA CI_END="103.54160722303256" CI_START="0.25206071227311444" EFFECT_SIZE="5.108695652173913" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0151149020276877" LOG_CI_START="-0.5984948408473633" LOG_EFFECT_SIZE="0.7083100305901622" ORDER="2407" O_E="0.0" SE="1.5352473005416867" STUDY_ID="STD-Diaz-1990" TOTAL_1="45" TOTAL_2="46" VAR="2.356984273820536" WEIGHT="32.9936388420096"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2408" O_E="0.0" SE="0.0" STUDY_ID="STD-Kaewrudee-1999" TOTAL_1="34" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6419122938348352" CI_END="1.3544859055509897" CI_START="0.5534316233841914" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.865803288027997" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-016.07" LOG_CI_END="0.13177449023055426" LOG_CI_START="-0.25693602866296383" LOG_EFFECT_SIZE="-0.06258076921620478" METHOD="MH" NO="7" P_CHI2="0.44001096200030254" P_Q="0.9276812131164414" P_Z="0.527980360534761" Q="0.008237853098101178" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="278" TOTAL_2="279" WEIGHT="100.0" Z="0.631092022607056">
<NAME>Side-effects related to treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6172399072007115" CI_END="1.5064254209634207" CI_START="0.5124096268768454" DF="1" EFFECT_SIZE="0.8785823170731706" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" I2="38.16625501587425" ID="CMP-016.07.01" LOG_CI_END="0.17794763579975686" LOG_CI_START="-0.29038271955924544" LOG_EFFECT_SIZE="-0.05621754187974428" NO="1" P_CHI2="0.20347712956037678" P_Z="0.6379684269038102" STUDIES="2" TAU2="0.0" TOTAL_1="156" TOTAL_2="156" WEIGHT="66.73720192072923" Z="0.47054117301112486">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.7773238175294193" CI_START="0.5719051412230252" EFFECT_SIZE="1.0081967213114753" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.24976656081274776" LOG_CI_START="-0.24267599928344838" LOG_EFFECT_SIZE="0.0035452807646496587" ORDER="2409" O_E="0.0" SE="0.28926319743049167" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="122" TOTAL_2="123" VAR="0.08367319738771159" WEIGHT="55.43799679878463"/>
<DICH_DATA CI_END="2.0589109129385186" CI_START="0.02859647534320855" EFFECT_SIZE="0.2426470588235294" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31363755552709505" LOG_CI_START="-1.543687492511755" LOG_EFFECT_SIZE="-0.61502496849233" ORDER="2410" O_E="0.0" SE="1.0910019271252858" STUDY_ID="STD-Kaewrudee-1999" TOTAL_1="34" TOTAL_2="33" VAR="1.1902852049910875" WEIGHT="11.299205121944604"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8716288847478748" CI_START="0.37714497914774886" DF="0" EFFECT_SIZE="0.8401639344262295" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" ID="CMP-016.07.02" LOG_CI_END="0.2722197390152343" LOG_CI_START="-0.4234916695811845" LOG_EFFECT_SIZE="-0.07563596528297513" NO="2" P_CHI2="1.0" P_Z="0.6699879519006695" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="123" WEIGHT="33.26279807927077" Z="0.4261645448351391">
<NAME>Gastrointestinal discomfort</NAME>
<DICH_DATA CI_END="1.8716288847478748" CI_START="0.37714497914774886" EFFECT_SIZE="0.8401639344262295" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.2722197390152343" LOG_CI_START="-0.4234916695811845" LOG_EFFECT_SIZE="-0.07563596528297513" ORDER="2411" O_E="0.0" SE="0.4086643252365503" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="122" TOTAL_2="123" VAR="0.16700653072104493" WEIGHT="33.26279807927077"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7185798489085987" CI_START="0.11360275853158236" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-016.08" LOG_CI_END="-0.14352496585459193" LOG_CI_START="-0.9446111228459594" LOG_EFFECT_SIZE="-0.5440680443502757" METHOD="MH" MODIFIED="2011-01-25 10:48:11 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.007761562112288585" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.6622698763653014">
<NAME>Patient dissatisfaction with treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7185798489085986" CI_START="0.11360275853158236" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.14352496585459198" LOG_CI_START="-0.9446111228459594" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2011-01-25 10:48:11 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.4705619740571601" STUDY_ID="STD-Buasang-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.22142857142857142" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8392978691537019" CI_START="-1.2392978691537022" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.09" MODIFIED="2013-01-06 19:34:04 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.706046688069136" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="44" UNITS="" WEIGHT="100.0" Z="0.37717078860866915">
<NAME>Bleeding/spotting after treatment (# days)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8392978691537019" CI_START="-1.2392978691537022" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="6.4" MODIFIED="2011-01-25 11:06:20 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="2.6" SD_2="2.3" SE="0.5302637585953369" STUDY_ID="STD-Archer-2008" TOTAL_1="42" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2013-01-06 20:13:08 +0100" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Vitamin E + NSAID vs placebo (LNG subcutaneous implant/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.074495231629322" CI_START="0.9817166968190235" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="0.6100738138867022" LOG_CI_START="-0.008013822558739852" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2013-01-06 20:12:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.05624401942448368" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" WEIGHT="100.0" Z="1.909140112106841">
<NAME>Discontinuation of treatment due to lack of improvement</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.074495231629322" CI_START="0.9817166968190234" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.6100738138867022" LOG_CI_START="-0.0080138225587399" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="2412" O_E="0.0" SE="0.36306773723119745" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="110" TOTAL_2="110" VAR="0.13181818181818183" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.736881949124992" CI_START="0.18401903315121143" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="1.3371972467692281" LOG_CI_START="-0.7351372554412657" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2013-01-06 20:12:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5690753448577124" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" WEIGHT="100.0" Z="0.5694138172561514">
<NAME>Discontinuation of treatment due to side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.736881949124992" CI_START="0.18401903315121143" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3371972467692281" LOG_CI_START="-0.7351372554412657" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="2413" O_E="0.0" SE="1.2172995448196726" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="110" TOTAL_2="110" VAR="1.481818181818182" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.16034803118353322" CI_END="2.0329963186465085" CI_START="0.8755914541910141" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3341942148760333" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="0.30813659221750006" LOG_CI_START="-0.05769848581561528" LOG_EFFECT_SIZE="0.12521905320094243" METHOD="MH" MODIFIED="2013-01-06 20:12:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6888365042949918" P_Q="0.6891070189837427" P_Z="0.17968553362366205" Q="0.16005399329516737" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="246" WEIGHT="100.0" Z="1.3417239034133097">
<NAME>Side-effects related to treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3842818242072856" CI_START="0.8494502832743481" DF="0" EFFECT_SIZE="1.4231404958677687" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" I2="0.0" ID="CMP-017.03.01" LOG_CI_END="0.3773575880917833" LOG_CI_START="-0.07086203448941156" LOG_EFFECT_SIZE="0.1532477768011859" NO="1" P_CHI2="1.0" P_Z="0.18016850607792803" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="123" WEIGHT="62.5" Z="1.3402363846163252">
<NAME>Headache</NAME>
<DICH_DATA CI_END="2.3842818242072856" CI_START="0.8494502832743481" EFFECT_SIZE="1.4231404958677687" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.3773575880917833" LOG_CI_START="-0.07086203448941156" LOG_EFFECT_SIZE="0.1532477768011859" ORDER="2414" O_E="0.0" SE="0.26328642502710875" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="121" TOTAL_2="123" VAR="0.06931974160355535" WEIGHT="62.5"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.458637307681302" CI_START="0.5720560646460551" DF="0" EFFECT_SIZE="1.1859504132231404" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-017.03.02" LOG_CI_END="0.39069446737629066" LOG_CI_START="-0.24256140586916852" LOG_EFFECT_SIZE="0.07406653075356102" NO="2" P_CHI2="1.0" P_Z="0.6466072748306397" STUDIES="1" TAU2="0.0" TOTAL_1="121" TOTAL_2="123" WEIGHT="37.5" Z="0.458480493809929">
<NAME>Gastrointestinal discomfort</NAME>
<DICH_DATA CI_END="2.458637307681302" CI_START="0.5720560646460551" EFFECT_SIZE="1.1859504132231404" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.39069446737629066" LOG_CI_START="-0.24256140586916852" LOG_EFFECT_SIZE="0.07406653075356102" ORDER="2415" O_E="0.0" SE="0.3719776346115105" STUDY_ID="STD-d_x0027_Arcangues-2004" TOTAL_1="121" TOTAL_2="123" VAR="0.13836736065117441" WEIGHT="37.5"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2013-01-06 20:03:24 +0100" MODIFIED_BY="[Empty name]" NO="18">
<NAME>NSAID vs placebo (DMPA/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.5288429195973008" CI_END="0.7165286306787222" CI_START="0.247917369330891" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4214734786058719" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="-0.14476645160667814" LOG_CI_START="-0.6056930450744333" LOG_EFFECT_SIZE="-0.3752297483405558" METHOD="MH" NO="1" P_CHI2="0.4670938014114754" P_Q="1.0" P_Z="0.001417207922516896" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="49" WEIGHT="100.0" Z="3.1911232855648457">
<NAME>Continued irregular bleeding during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.774652449539806" CI_START="0.15002729073341786" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.11089310149586547" LOG_CI_START="-0.823829733365147" LOG_EFFECT_SIZE="-0.46736141743050624" ORDER="2416" O_E="0.0" SE="0.41878250665326017" STUDY_ID="STD-Nathirojanakun-2006" TOTAL_1="22" TOTAL_2="24" VAR="0.17537878787878788" WEIGHT="51.565647317341146"/>
<DICH_DATA CI_END="1.0172322857751412" CI_START="0.25294014984239865" EFFECT_SIZE="0.5072463768115942" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.007420135726510275" LOG_CI_START="-0.5969822285004694" LOG_EFFECT_SIZE="-0.29478104638697966" ORDER="2417" O_E="0.0" SE="0.35502894058688267" STUDY_ID="STD-Tantiwattanakul-2004" TOTAL_1="23" TOTAL_2="25" VAR="0.12604554865424428" WEIGHT="48.434352682658854"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="236.84844663428143" CI_START="0.8374143068965777" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="14.083333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-018.02" LOG_CI_END="2.374470540761792" LOG_CI_START="-0.0770596236296943" LOG_EFFECT_SIZE="1.1487054585660488" METHOD="MH" MODIFIED="2013-01-06 20:03:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.06624713403763932" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="1.8367478078270896">
<NAME>Side-effects related to treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-018.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Headache</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="236.84844663428143" CI_START="0.8374143068965777" DF="0" EFFECT_SIZE="14.083333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-018.02.02" LOG_CI_END="2.374470540761792" LOG_CI_START="-0.0770596236296943" LOG_EFFECT_SIZE="1.1487054585660488" NO="2" P_CHI2="1.0" P_Z="0.06624713403763932" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="1.8367478078270896">
<NAME>Gastrointestinal discomfort</NAME>
<DICH_DATA CI_END="236.84844663428143" CI_START="0.8374143068965777" EFFECT_SIZE="14.083333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.374470540761792" LOG_CI_START="-0.0770596236296943" LOG_EFFECT_SIZE="1.1487054585660488" ORDER="2418" O_E="0.0" SE="1.4400409538335877" STUDY_ID="STD-Tantiwattanakul-2004" TOTAL_1="23" TOTAL_2="25" VAR="2.073717948717949" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2013-01-06 20:54:30 +0100" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Selective estrogen receptor modulator vs placebo (LNG subcutaneous implant/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7987936732574388" CI_START="0.20951013697737492" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="-0.09756538356130501" LOG_CI_START="-0.6787949592044576" LOG_EFFECT_SIZE="-0.38818017138288136" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.008845604472706933" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.00000000000001" Z="2.617964354553561">
<NAME>Continued irregular bleeding during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7987936732574389" CI_START="0.20951013697737486" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="22" LOG_CI_END="-0.09756538356130495" LOG_CI_START="-0.6787949592044578" LOG_EFFECT_SIZE="-0.38818017138288136" ORDER="2419" O_E="0.0" SE="0.3414171298655892" STUDY_ID="STD-Abdel_x002d_Aleem-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.11656565656565658" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8795223129592193" CI_START="0.1598879277170997" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" I2="0.0" I2_Q="100.00000000000001" ID="CMP-019.02" LOG_CI_END="-0.05575313827344083" LOG_CI_START="-0.7961843262711215" LOG_EFFECT_SIZE="-0.42596873227228116" METHOD="MH" MODIFIED="2013-01-06 20:38:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.02412532580514851" Q="6.515921573962101E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="2.2551275184709563">
<NAME>Unacceptable bleeding after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8795223129592193" CI_START="0.1598879277170997" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.05575313827344083" LOG_CI_START="-0.7961843262711215" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="2420" O_E="0.0" SE="0.43493294502332963" STUDY_ID="STD-Abdel_x002d_Aleem-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.18916666666666668" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.009816774315104845" CI_END="0.596803779829787" CI_START="0.07426449217954009" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-019.03" LOG_CI_END="-0.22416843494218944" LOG_CI_START="-1.1292187843075439" LOG_EFFECT_SIZE="-0.6766936096248666" METHOD="MH" MODIFIED="2013-01-06 20:54:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9210750411656735" P_Q="0.9210857547622104" P_Z="0.003380078411064352" Q="0.009814100622509547" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="100" WEIGHT="200.0" Z="2.9308758443398855">
<NAME>Discontinuation of contraceptive method</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8669836432287152" CI_START="0.0461369719168367" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" ID="CMP-019.03.01" LOG_CI_END="-0.06198909597537003" LOG_CI_START="-1.3359509126966675" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2013-01-06 20:54:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.03149973818288508" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="2.150701876290387">
<NAME>Discontinuation of contraceptive method</NAME>
<DICH_DATA CI_END="0.8669836432287152" CI_START="0.0461369719168367" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.06198909597537003" LOG_CI_START="-1.3359509126966675" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="2421" O_E="0.0" SE="0.7483314773547882" STUDY_ID="STD-Abdel_x002d_Aleem-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.5599999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9773646143707243" CI_START="0.05052640061168752" DF="0" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" ID="CMP-019.03.02" LOG_CI_END="-0.00994338871865748" LOG_CI_START="-1.29648163883203" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2013-01-06 20:54:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.04656226894797846" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="1.990260299120881">
<NAME>Discontinuation of contraceptive method because of bleeding</NAME>
<DICH_DATA CI_END="0.9773646143707243" CI_START="0.05052640061168752" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.00994338871865748" LOG_CI_START="-1.29648163883203" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="2422" O_E="0.0" SE="0.7557189365836423" STUDY_ID="STD-Abdel_x002d_Aleem-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.5711111111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1183228290321168" CI_END="2.257065097044571" CI_START="0.5199722031269067" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="52.792842229014255" I2_Q="52.62899359181789" ID="CMP-019.04" LOG_CI_END="0.3535440849437562" LOG_CI_START="-0.28401987242533233" LOG_EFFECT_SIZE="0.03476210625921191" METHOD="MH" MODIFIED="2013-01-06 20:38:27 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.14554590996158867" P_Q="0.1462441732803924" P_Z="0.830759562750013" Q="2.110995893528823" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="0.21372750296600457">
<NAME>Side-effects related to treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.237422252194887" CI_START="0.6555348068838204" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" ID="CMP-019.04.01" LOG_CI_END="0.6271017428919642" LOG_CI_START="-0.1834042436592514" LOG_EFFECT_SIZE="0.2218487496163564" NO="1" P_CHI2="1.0" P_Z="0.28329427518042527" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="50.0" Z="1.0729484210560531">
<NAME>Headache</NAME>
<DICH_DATA CI_END="4.237422252194887" CI_START="0.6555348068838203" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6271017428919642" LOG_CI_START="-0.18340424365925145" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="2423" O_E="0.0" SE="0.47609522856952335" STUDY_ID="STD-Abdel_x002d_Aleem-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.22666666666666668" WEIGHT="50.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8892219341538161" CI_START="0.13232960907368208" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-019.04.02" LOG_CI_END="0.27628297915888045" LOG_CI_START="-0.8783429704868428" LOG_EFFECT_SIZE="-0.3010299956639812" NO="2" P_CHI2="1.0" P_Z="0.3067857602346794" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="50.0" Z="1.0219897620501002">
<NAME>Gastrointestinal discomfort</NAME>
<DICH_DATA CI_END="1.8892219341538161" CI_START="0.13232960907368208" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27628297915888045" LOG_CI_START="-0.8783429704868428" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="2424" O_E="0.0" SE="0.6782329983125268" STUDY_ID="STD-Abdel_x002d_Aleem-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.45999999999999996" WEIGHT="50.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.4483978612757049" CI_START="0.10671675008409032" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.21875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-019.05" LOG_CI_END="-0.3483364675274989" LOG_CI_START="-0.9717674090837994" LOG_EFFECT_SIZE="-0.6600519383056491" METHOD="MH" MODIFIED="2013-01-06 20:38:27 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="3.3220127967812335E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="4.150188708232722">
<NAME>Patient dissatisfaction with treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4483978612757049" CI_START="0.10671675008409032" EFFECT_SIZE="0.21875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="32" LOG_CI_END="-0.3483364675274989" LOG_CI_START="-0.9717674090837994" LOG_EFFECT_SIZE="-0.6600519383056491" ORDER="2425" O_E="0.0" SE="0.36620642110310253" STUDY_ID="STD-Abdel_x002d_Aleem-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.13410714285714287" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2013-01-06 19:46:00 +0100" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Antifibrinolytic vs placebo (LNG subcutaneous implant/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9160263562288572" CI_START="0.32479486985709954" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="-0.03809203048052791" LOG_CI_START="-0.48839083906863495" LOG_EFFECT_SIZE="-0.26324143477458145" METHOD="MH" MODIFIED="2011-01-18 11:14:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.021930952883684733" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="34" WEIGHT="100.00000000000001" Z="2.2915616100098037">
<NAME>Continued irregular bleeding during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9160263562288572" CI_START="0.32479486985709954" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.03809203048052791" LOG_CI_START="-0.48839083906863495" LOG_EFFECT_SIZE="-0.26324143477458145" ORDER="2426" O_E="0.0" SE="0.26450774917970565" STUDY_ID="STD-Phupong-2006" TOTAL_1="34" TOTAL_2="34" VAR="0.06996434937611407" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6207002211498174" CI_START="0.8458308650108152" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-020.02" LOG_CI_END="0.5587925685369879" LOG_CI_START="-0.07271647116439901" LOG_EFFECT_SIZE="0.24303804868629444" METHOD="MH" MODIFIED="2013-01-06 19:43:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1314022054714323" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="34" WEIGHT="100.0" Z="1.5085954193886835">
<NAME>Unacceptable bleeding after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6207002211498174" CI_START="0.8458308650108153" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.5587925685369879" LOG_CI_START="-0.07271647116439896" LOG_EFFECT_SIZE="0.24303804868629444" ORDER="2427" O_E="0.0" SE="0.37095153594075697" STUDY_ID="STD-Phupong-2006" TOTAL_1="34" TOTAL_2="34" VAR="0.1376050420168067" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2013-02-07 21:58:06 +0100" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Matrix metalloproteinase inhibitor vs placebo (Implanon/Therapeutic).</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3026909476259916" CI_START="0.5805877092965168" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.15625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="0.36223565366231913" LOG_CI_START="-0.23613216216814106" LOG_EFFECT_SIZE="0.06305174574708902" METHOD="MH" MODIFIED="2011-02-01 10:56:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6795669514764531" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="37" WEIGHT="100.0" Z="0.413054136794301">
<NAME>Continued irregular bleeding during treatment (# women)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3026909476259916" CI_START="0.5805877092965168" EFFECT_SIZE="1.15625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.36223565366231913" LOG_CI_START="-0.23613216216814106" LOG_EFFECT_SIZE="0.06305174574708902" MODIFIED="2011-02-01 10:56:06 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.3514842169872707" STUDY_ID="STD-Weisberg-2009" TOTAL_1="32" TOTAL_2="37" VAR="0.1235411547911548" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.421249791312229" CI_END="1.0302942771056687" CI_START="0.44758981494739886" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6790796896028406" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="36" I2="32.145883141572085" I2_Q="0.0" ID="CMP-021.02" LOG_CI_END="0.012961287491184517" LOG_CI_START="-0.3491198045441995" LOG_EFFECT_SIZE="-0.16807925852650749" METHOD="MH" MODIFIED="2013-02-07 21:58:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21942335833556303" P_Q="0.40552244226674383" P_Z="0.06881327860439988" Q="1.8051583398498015" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="162" TOTAL_2="168" WEIGHT="300.0" Z="1.8196437235002503">
<NAME>Side effects related to treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2897456536577745" CI_START="0.5291118119297228" DF="0" EFFECT_SIZE="0.8260869565217391" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" I2="0.0" ID="CMP-021.02.01" LOG_CI_END="0.11050407300929202" LOG_CI_START="-0.27645254313881984" LOG_EFFECT_SIZE="-0.08297423506476391" NO="1" P_CHI2="1.0" P_Z="0.40060495265312424" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="0.8405413195439497">
<NAME>Any side effect</NAME>
<DICH_DATA CI_END="1.2897456536577743" CI_START="0.5291118119297228" EFFECT_SIZE="0.8260869565217391" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.11050407300929194" LOG_CI_START="-0.27645254313881984" LOG_EFFECT_SIZE="-0.08297423506476391" ORDER="2428" O_E="0.0" SE="0.22730023179154302" STUDY_ID="STD-Weisberg-2006" TOTAL_1="45" TOTAL_2="45" VAR="0.05166539537248918" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.591710187800897" CI_END="1.442210751532835" CI_START="0.18470891141015133" DF="1" EFFECT_SIZE="0.5161290322580645" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="61.4154389365381" ID="CMP-021.02.02" LOG_CI_END="0.15902872885767286" LOG_CI_START="-0.7335121512143686" LOG_EFFECT_SIZE="-0.2872417111783479" MODIFIED="2011-02-01 11:18:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10742468182403953" P_Z="0.20711809573151108" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="84" WEIGHT="100.0" Z="1.2615296875181268">
<NAME>Nausea/Vomiting</NAME>
<DICH_DATA CI_END="1.1130282406367542" CI_START="0.056153112489081405" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.04650618373912067" LOG_CI_START="-1.2506261663950453" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="2429" O_E="0.0" SE="0.7619419633774973" STUDY_ID="STD-Weisberg-2006" TOTAL_1="45" TOTAL_2="45" VAR="0.5805555555555555" WEIGHT="80.64516129032258"/>
<DICH_DATA CI_END="9.174301831949997" CI_START="0.2878284417026571" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9625730241973164" LOG_CI_START="-0.5408662935675301" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2011-02-01 11:18:30 +0100" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.8831276973997191" STUDY_ID="STD-Weisberg-2009" TOTAL_1="36" TOTAL_2="39" VAR="0.7799145299145298" WEIGHT="19.354838709677416"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2072833331774998E-32" CI_END="2.8901850179430086" CI_START="0.008252676266543812" DF="0" EFFECT_SIZE="0.15444015444015446" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="100.0" ID="CMP-021.02.03" LOG_CI_END="0.46092564542081543" LOG_CI_START="-2.0834051909273943" LOG_EFFECT_SIZE="-0.8112397727532894" MODIFIED="2011-02-01 11:19:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.21135873995237275" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="39" WEIGHT="100.0" Z="1.2498380436287746">
<NAME>Headache</NAME>
<DICH_DATA CI_END="2.8901850179430064" CI_START="0.008252676266543812" EFFECT_SIZE="0.15444015444015444" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4609256454208151" LOG_CI_START="-2.0834051909273943" LOG_EFFECT_SIZE="-0.8112397727532894" MODIFIED="2011-02-01 11:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="1.4945525279117018" STUDY_ID="STD-Weisberg-2009" TOTAL_1="36" TOTAL_2="39" VAR="2.2336872586872585" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-021.03" MODIFIED="2013-01-06 19:40:12 +0100" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Number of days to stop bleeding/spotting following initiation of treatment</NAME>
<TR>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>Lower 95% CI</P>
</TH>
<TH>
<P>Upper 95% CI</P>
</TH>
<TH>
<P>Total</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-01-25 12:19:36 +0100" MODIFIED_BY="[Empty name]" ORDER="245" STUDY_ID="STD-Weisberg-2009">
<TR>
<TD>
<P>Matrix metalloproteinase inhibitor</P>
</TD>
<TD>
<P>6.4</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>9.2</P>
</TD>
<TD>
<P>31</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>6.4</P>
</TD>
<TD>
<P>5.1</P>
</TD>
<TD>
<P>8.0</P>
</TD>
<TD>
<P>37</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.09663642313815558" CI_END="1.7212228775586043" CI_START="0.3959258201873461" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.825515947467167" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-021.04" LOG_CI_END="0.23583710985499365" LOG_CI_START="-0.4023861749357633" LOG_EFFECT_SIZE="-0.08327453254038479" METHOD="MH" MODIFIED="2013-01-06 19:40:12 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7559040393875479" P_Q="0.756195497038254" P_Z="0.6090240697628582" Q="0.09639823135282642" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="80" WEIGHT="200.0" Z="0.5114670319873191">
<NAME>Discontinuation of contraceptive method</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6363545103743022" CI_START="0.26174961585215983" DF="0" EFFECT_SIZE="0.975609756097561" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-021.04.01" LOG_CI_END="0.560666216242497" LOG_CI_START="-0.5821139470260432" LOG_EFFECT_SIZE="-0.010723865391773113" MODIFIED="2011-02-01 11:40:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9706567052279426" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.0367846601096308">
<NAME>Discontinuation of method at 90 days following initiation of treatment</NAME>
<DICH_DATA CI_END="3.6363545103743022" CI_START="0.26174961585215983" EFFECT_SIZE="0.975609756097561" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.560666216242497" LOG_CI_START="-0.5821139470260432" LOG_EFFECT_SIZE="-0.010723865391773113" MODIFIED="2011-02-01 11:40:01 +0100" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.6712747247569812" STUDY_ID="STD-Weisberg-2009" TOTAL_1="41" TOTAL_2="40" VAR="0.45060975609756093" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.841334467421066" CI_START="0.3127019919026299" DF="0" EFFECT_SIZE="0.7588075880758808" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-021.04.02" LOG_CI_END="0.2651326826713045" LOG_CI_START="-0.5048693523049868" LOG_EFFECT_SIZE="-0.11986833481684114" MODIFIED="2011-02-01 11:40:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5417121324216281" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.6102259694288499">
<NAME>Discontinuation of method at 180 days following initiation of treatment</NAME>
<DICH_DATA CI_END="1.841334467421066" CI_START="0.3127019919026299" EFFECT_SIZE="0.7588075880758808" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.2651326826713045" LOG_CI_START="-0.5048693523049868" LOG_EFFECT_SIZE="-0.11986833481684114" MODIFIED="2011-02-01 11:40:22 +0100" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.45230300691661884" STUDY_ID="STD-Weisberg-2009" TOTAL_1="41" TOTAL_2="40" VAR="0.20457801006581494" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2012-05-30 16:05:53 +0200" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Matrix metalloproteinase inhibitor vs placebo (DMPA/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-05-29 22:26:09 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Women who stopped bleeding within10 days of starting treatment.</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2116867425411804" CI_START="0.6391090805994202" EFFECT_SIZE="0.88" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.08339035615844047" LOG_CI_START="-0.19442501185810315" LOG_EFFECT_SIZE="-0.05551732784983137" MODIFIED="2012-05-29 22:26:09 +0200" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.16319012238116848" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="34" TOTAL_2="34" VAR="0.026631016042780745" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.20603659229271337" CI_END="1.1145683584449213" CI_START="-1.511472416019395" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19845202878723686" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-022.02" MODIFIED="2012-05-29 22:39:38 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9021105569322283" P_Q="0.9021105569322283" P_Z="0.767052811824763" Q="0.20603659229271337" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="90" UNITS="" WEIGHT="300.0" Z="0.2962321323142697">
<NAME>Number of bleeding days in the first 3 months after treatment.</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5963895586980432" CI_START="-2.7563895586980434" DF="0" EFFECT_SIZE="-0.5800000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-022.02.01" MODIFIED="2012-05-29 22:29:31 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.60144520804849" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.5223233618678423">
<NAME>Number of bleeding days in the first month</NAME>
<CONT_DATA CI_END="1.5963895586980432" CI_START="-2.7563895586980434" EFFECT_SIZE="-0.5800000000000001" ESTIMABLE="YES" MEAN_1="5.76" MEAN_2="6.34" MODIFIED="2012-05-29 22:29:31 +0200" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="4.65" SD_2="4.3" SE="1.1104232403580505" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.4693906036194213" CI_START="-2.189390603619422" DF="0" EFFECT_SIZE="0.13999999999999968" ESTIMABLE="YES" I2="0.0" ID="CMP-022.02.02" MODIFIED="2012-05-29 22:31:25 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9062285975260325" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.11779688533526768">
<NAME>Number of bleeding days in the second month</NAME>
<CONT_DATA CI_END="2.4693906036194213" CI_START="-2.189390603619422" EFFECT_SIZE="0.13999999999999968" ESTIMABLE="YES" MEAN_1="6.93" MEAN_2="6.79" MODIFIED="2012-05-29 22:31:25 +0200" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="4.45" SD_2="4.6" SE="1.1884864324004714" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.227316899680792" CI_START="-2.4273168996807915" DF="0" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-022.02.03" MODIFIED="2012-05-29 22:33:42 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9328850120494878" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.08421560402061579">
<NAME>Number of bleeding days in the third month</NAME>
<CONT_DATA CI_END="2.227316899680792" CI_START="-2.4273168996807915" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="7.28" MEAN_2="7.38" MODIFIED="2012-05-29 22:33:42 +0200" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="4.4" SD_2="4.64" SE="1.1874284007453046" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8591628334716876" CI_END="1.2224341629156321" CI_START="-1.0992742364901937" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.061579963212719274" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-022.03" MODIFIED="2012-05-30 15:42:44 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6507814635922164" P_Q="0.6507814635922164" P_Z="0.9171928149820521" Q="0.8591628334716876" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="90" UNITS="" WEIGHT="300.0" Z="0.1039704297896493">
<NAME>Number of spotting days in the first three months after treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.6780885351981247" CI_START="-1.7780885351981244" DF="0" EFFECT_SIZE="0.9500000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-022.03.01" MODIFIED="2012-05-30 15:38:42 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4949123373286678" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.6825166270411487">
<NAME>Number of spotting days in the first month</NAME>
<CONT_DATA CI_END="3.6780885351981247" CI_START="-1.7780885351981244" EFFECT_SIZE="0.9500000000000002" ESTIMABLE="YES" MEAN_1="6.36" MEAN_2="5.41" MODIFIED="2012-05-30 15:38:42 +0200" MODIFIED_BY="[Empty name]" ORDER="139" SD_1="5.8" SD_2="5.42" SE="1.3919074823399504" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9614823525393055" CI_START="-3.821482352539305" DF="0" EFFECT_SIZE="-0.9299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-022.03.02" MODIFIED="2012-05-30 15:40:30 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5284383367707015" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.6303917103355284">
<NAME>Number of spotting days in the second month</NAME>
<CONT_DATA CI_END="1.9614823525393055" CI_START="-3.821482352539305" EFFECT_SIZE="-0.9299999999999997" ESTIMABLE="YES" MEAN_1="4.45" MEAN_2="5.38" MODIFIED="2012-05-30 15:40:30 +0200" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="4.98" SD_2="6.19" SE="1.4752732067257097" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4913522301529125" CI_START="-1.3713522301529124" DF="0" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-022.03.03" MODIFIED="2012-05-30 15:42:44 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9345206257748491" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.08215856069182935">
<NAME>Number of spotting days in the third month</NAME>
<CONT_DATA CI_END="1.4913522301529125" CI_START="-1.3713522301529124" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" MEAN_1="3.72" MEAN_2="3.66" MODIFIED="2012-05-30 15:42:44 +0200" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="2.85" SD_2="2.71" SE="0.7302951694231303" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.44120180988566465" CI_END="1.1399544133661728" CI_START="0.7516806144615773" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.925679012345679" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-022.04" LOG_CI_END="0.056887484301933404" LOG_CI_START="-0.1239666498881692" LOG_EFFECT_SIZE="-0.033539582793117896" METHOD="MH" MODIFIED="2012-05-30 15:51:40 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8020368378531593" P_Q="0.8025530864412498" P_Z="0.46725376023050347" Q="0.43991487441657773" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="90" WEIGHT="300.0" Z="0.7269546214731524">
<NAME>Women with bleeding-free interval equal to or less than15 days in the first 3 months after start of treatment.</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.477329912769921" CI_START="0.7017350734693255" DF="0" EFFECT_SIZE="1.018181818181818" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="0.0" ID="CMP-022.04.01" LOG_CI_END="0.16947749145003307" LOG_CI_START="-0.15382681642612003" LOG_EFFECT_SIZE="0.007825337511956526" MODIFIED="2012-05-30 15:49:28 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9244110106572763" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.09487890706473541">
<NAME>First month</NAME>
<DICH_DATA CI_END="1.477329912769921" CI_START="0.7017350734693255" EFFECT_SIZE="1.018181818181818" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.16947749145003307" LOG_CI_START="-0.15382681642612003" LOG_EFFECT_SIZE="0.007825337511956526" MODIFIED="2012-05-30 15:49:28 +0200" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="0.18991055082858696" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="33" TOTAL_2="32" VAR="0.036066017316017315" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2316544507923461" CI_START="0.5965097410871841" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="0.0" ID="CMP-022.04.02" LOG_CI_END="0.09048888058510479" LOG_CI_START="-0.2243824598463312" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2012-05-30 15:50:03 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.40459623195947947" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.8334407086830661">
<NAME>Second month</NAME>
<DICH_DATA CI_END="1.2316544507923461" CI_START="0.5965097410871841" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.09048888058510479" LOG_CI_START="-0.2243824598463312" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2012-05-30 15:50:03 +0200" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.18495698400769803" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="29" TOTAL_2="29" VAR="0.03420908593322386" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.279650604563686" CI_START="0.6397012601635121" DF="0" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" I2="0.0" ID="CMP-022.04.03" LOG_CI_END="0.10709140619185194" LOG_CI_START="-0.19402279375403253" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2012-05-30 15:50:55 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5715027131120045" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.5658397670338629">
<NAME>Third month</NAME>
<DICH_DATA CI_END="1.2796506045636857" CI_START="0.6397012601635121" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.10709140619185187" LOG_CI_START="-0.19402279375403253" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2012-05-30 15:50:55 +0200" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.17687597158754131" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="29" TOTAL_2="29" VAR="0.031285109325036725" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-022.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2012-05-30 15:59:53 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Women who discontinued DMPA</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9846285256319316" CI_START="0.10718084397988621" EFFECT_SIZE="0.6535104041433158" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6003878397125335" LOG_CI_START="-0.9698828274905381" LOG_EFFECT_SIZE="-0.18474749388900236" MODIFIED="2012-05-30 15:59:53 +0200" MODIFIED_BY="[Empty name]" ORDER="144" O_E="-0.5" SE="0.9223847628802477" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="34" TOTAL_2="34" VAR="1.1753731343283582" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-022.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2012-05-30 16:05:53 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Women who lost to follow up</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.330025430548599" CI_START="0.25096442330001334" EFFECT_SIZE="1.530197520437178" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9698828274905381" LOG_CI_START="-0.6003878397125334" LOG_EFFECT_SIZE="0.18474749388900238" MODIFIED="2012-05-30 16:05:53 +0200" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.5" SE="0.9223847628802477" STUDY_ID="STD-Abdel_x002d_Aleem-2012" TOTAL_1="34" TOTAL_2="34" VAR="1.1753731343283582" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2012-05-29 21:04:38 +0200" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Antifibrinolytic vs placebo (DMPA/Therapeutic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.27807374009255326" CI_START="0.06140018029784112" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13066666666666665" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="-0.5558400218204009" LOG_CI_START="-1.2118303535780093" LOG_EFFECT_SIZE="-0.8838351876992052" METHOD="MH" MODIFIED="2011-01-18 11:32:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.2817598472814437E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="49" WEIGHT="100.0" Z="5.28143496114735">
<NAME>Continued irregular bleeding during treatment (# of women)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.27807374009255326" CI_START="0.06140018029784112" EFFECT_SIZE="0.13066666666666665" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="45" LOG_CI_END="-0.5558400218204009" LOG_CI_START="-1.2118303535780093" LOG_EFFECT_SIZE="-0.8838351876992052" MODIFIED="2011-01-18 11:32:36 +0100" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.3853319680789316" STUDY_ID="STD-Senthong-2009" TOTAL_1="50" TOTAL_2="49" VAR="0.14848072562358278" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-9.668266200801899" CI_START="-13.931733799198103" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-023.02" MODIFIED="2011-01-18 11:35:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="2.012107565617109E-27" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="10.849185309287956">
<NAME>Unacceptable bleeding after treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-9.668266200801899" CI_START="-13.931733799198103" EFFECT_SIZE="-11.8" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="17.5" MODIFIED="2011-01-18 11:35:30 +0100" MODIFIED_BY="[Empty name]" ORDER="88" SD_1="2.5" SD_2="7.2" SE="1.0876392709319893" STUDY_ID="STD-Senthong-2009" TOTAL_1="50" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2012-05-29 21:04:33 +0200" MODIFIED_BY="[Empty name]" NO="24">
<NAME>NSAID vs Placebo (Implanon/Therapeutic)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-024.01" MODIFIED="2011-01-18 11:48:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Unaccetable bleeding after treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="10.5" MEAN_2="16.8" MODIFIED="2011-01-18 11:48:22 +0100" MODIFIED_BY="[Empty name]" ORDER="89" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Phaliwong-2004" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8095314666659231" CI_START="0.24400640658363407" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-024.02" LOG_CI_END="-0.09176626546060801" LOG_CI_START="-0.612598770762117" LOG_EFFECT_SIZE="-0.35218251811136253" METHOD="MH" MODIFIED="2011-01-18 11:47:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.008034370182833697" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="2.6506220117091295">
<NAME>Continued irregular bleeding during treatment (# of women)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8095314666659231" CI_START="0.24400640658363407" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.09176626546060801" LOG_CI_START="-0.612598770762117" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2011-01-18 11:47:54 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.3059395917765877" STUDY_ID="STD-Phaliwong-2004" TOTAL_1="23" TOTAL_2="23" VAR="0.09359903381642512" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8232760104861434" CI_END="4.540694966078105" CI_START="0.34411032048461176" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="29.160309067492925" I2_Q="28.878798687892605" ID="CMP-024.03" LOG_CI_END="0.6571223279307734" LOG_CI_START="-0.4633023019146606" LOG_EFFECT_SIZE="0.09691001300805642" METHOD="MH" MODIFIED="2011-01-18 11:55:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24374400908294702" P_Q="0.24510973095967725" P_Z="0.7345718630553815" Q="2.81210098128577" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="69" WEIGHT="100.0" Z="0.339050267510277">
<NAME>Side effects related to treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="128.32668192868655" CI_START="0.38183797214697845" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-024.03.01" LOG_CI_END="2.1083169651015954" LOG_CI_START="-0.41812088507308187" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-01-18 11:54:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18978243043445164" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="12.5" Z="1.311223010468128">
<NAME>Abdominal discomfort</NAME>
<DICH_DATA CI_END="128.32668192868655" CI_START="0.38183797214697845" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1083169651015954" LOG_CI_START="-0.41812088507308187" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2011-01-18 11:54:56 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="1.4840420992616592" STUDY_ID="STD-Phaliwong-2004" TOTAL_1="23" TOTAL_2="23" VAR="2.2023809523809526" WEIGHT="12.5"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.042527544933725" CI_START="0.06647818971997141" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-024.03.02" LOG_CI_END="1.1773208154172596" LOG_CI_START="-1.1773208154172596" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-18 11:55:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="25.0" Z="0.0">
<NAME>Headache</NAME>
<DICH_DATA CI_END="15.042527544933725" CI_START="0.06647818971997141" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1773208154172596" LOG_CI_START="-1.1773208154172596" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-18 11:55:22 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="1.3831281496162493" STUDY_ID="STD-Phaliwong-2004" TOTAL_1="23" TOTAL_2="23" VAR="1.9130434782608696" WEIGHT="25.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9501157596592686" CI_START="0.010126285515098515" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-024.03.03" LOG_CI_END="0.596609822979522" LOG_CI_START="-1.9945498316515593" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-01-18 11:54:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2903255922645326" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="62.5" Z="1.0574076609474308">
<NAME>Breast tenderness</NAME>
<DICH_DATA CI_END="3.9501157596592686" CI_START="0.010126285515098515" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.596609822979522" LOG_CI_START="-1.9945498316515593" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-01-18 11:54:21 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="1.52206000757745" STUDY_ID="STD-Phaliwong-2004" TOTAL_1="23" TOTAL_2="23" VAR="2.316666666666667" WEIGHT="62.5"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2012-05-29 21:04:29 +0200" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Antiprogestin vs Placebo (LNG-IUS/Prophylactic)</NAME>
<CONT_OUTCOME CHI2="12.035136028661036" CI_END="3.7779678673887203" CI_START="-5.483759744909052" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.852895938760166" ESTIMABLE="YES" I2="83.3819909036582" I2_Q="83.3819909036582" ID="CMP-025.01" MODIFIED="2011-01-25 11:11:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0024355919366910728" P_Q="0.0024355919366910728" P_Z="0.7181150275139189" Q="12.035136028661036" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="187" TOTAL_2="177" UNITS="" WEIGHT="300.0" Z="0.3609791590741203">
<NAME>Unacceptable bleeding after treatment (% days)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.522061358455181" CI_START="-18.677938641544806" DF="0" EFFECT_SIZE="-10.599999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.01" MODIFIED="2011-01-18 12:26:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.010114326434726453" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="2.5718960192734843">
<NAME>Treatment cycle 1 (28 days)</NAME>
<CONT_DATA CI_END="-2.522061358455181" CI_START="-18.677938641544806" EFFECT_SIZE="-10.599999999999994" ESTIMABLE="YES" MEAN_1="46.7" MEAN_2="57.3" MODIFIED="2011-01-18 12:26:27 +0100" MODIFIED_BY="[Empty name]" ORDER="94" SD_1="20.6" SD_2="24.8" SE="4.121472999127822" STUDY_ID="STD-Warner-2010" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.370221843038654" CI_START="-9.570221843038656" DF="0" EFFECT_SIZE="-1.6000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.02" MODIFIED="2011-01-18 12:27:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6939817188108666" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0" Z="0.3934573512534136">
<NAME>Post treatment cycle 2 (28 days)</NAME>
<CONT_DATA CI_END="6.370221843038654" CI_START="-9.570221843038656" EFFECT_SIZE="-1.6000000000000014" ESTIMABLE="YES" MEAN_1="39.6" MEAN_2="41.2" MODIFIED="2011-01-18 12:27:23 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="19.9" SD_2="24.8" SE="4.0665144389931385" STUDY_ID="STD-Warner-2010" TOTAL_1="63" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="17.515606028235243" CI_START="1.4843939717647636" DF="0" EFFECT_SIZE="9.500000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-025.01.03" MODIFIED="2011-01-18 12:28:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.020183140152214462" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="57" WEIGHT="100.0" Z="2.322925775985266">
<NAME>Post treatment cycle 3 (28 days)</NAME>
<CONT_DATA CI_END="17.515606028235243" CI_START="1.4843939717647636" EFFECT_SIZE="9.500000000000004" ESTIMABLE="YES" MEAN_1="38.2" MEAN_2="28.7" MODIFIED="2011-01-18 12:28:25 +0100" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="23.7" SD_2="20.7" SE="4.089670061011997" STUDY_ID="STD-Warner-2010" TOTAL_1="61" TOTAL_2="57" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.0344773124331743" CI_START="0.03452431096432087" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.32367149758454106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="0.4820838947933952" LOG_CI_START="-1.461874980305578" LOG_EFFECT_SIZE="-0.4898955427560913" METHOD="MH" MODIFIED="2011-01-18 12:32:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.32322223210298495" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="67" WEIGHT="100.0" Z="0.9878579555236277">
<NAME>Discontinuation of the contraceptive method</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.034477312433173" CI_START="0.03452431096432088" EFFECT_SIZE="0.32367149758454106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.482083894793395" LOG_CI_START="-1.4618749803055777" LOG_EFFECT_SIZE="-0.4898955427560913" MODIFIED="2011-01-18 12:32:48 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.141891065984762" STUDY_ID="STD-Warner-2010" TOTAL_1="69" TOTAL_2="67" VAR="1.3039152065758164" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="26.534358997979872" CI_START="1.5012505805019842" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.311475409836065" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-025.03" LOG_CI_END="1.4238086006519421" LOG_CI_START="0.17645318834352516" LOG_EFFECT_SIZE="0.8001308944977337" METHOD="MH" MODIFIED="2011-01-18 12:38:49 +0100" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;The authors advise interpretation of the data with caution, due to the &amp;quot;difficulty of differentiating effects due to the LNG-IUS that all women received, to the intermittent intervention administered to half the women, and to individual participant characteristics (in terms of susceptibilities to/tolerance of symptoms.)&amp;quot; &lt;/p&gt;" NOTES_MODIFIED="2011-01-18 12:38:49 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="1.0" P_Q="1.0" P_Z="0.011920664490117385" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="55" WEIGHT="100.0" Z="2.514484196979812">
<NAME>Side effects related to treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.534358997979872" CI_START="1.5012505805019842" DF="0" EFFECT_SIZE="6.311475409836065" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="0.0" ID="CMP-025.03.01" LOG_CI_END="1.4238086006519421" LOG_CI_START="0.17645318834352516" LOG_EFFECT_SIZE="0.8001308944977337" MODIFIED="2011-01-18 12:35:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.011920664490117385" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="55" WEIGHT="100.0" Z="2.514484196979812">
<NAME>Tendency to gain weight</NAME>
<DICH_DATA CI_END="26.534358997979872" CI_START="1.5012505805019842" EFFECT_SIZE="6.311475409836065" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.4238086006519421" LOG_CI_START="0.17645318834352516" LOG_EFFECT_SIZE="0.8001308944977337" MODIFIED="2011-01-18 12:35:04 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.7327027436988361" STUDY_ID="STD-Warner-2010" TOTAL_1="61" TOTAL_2="55" VAR="0.5368533106238024" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.67300756534436" CI_START="0.10992472329414438" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6354166666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="100.0" ID="CMP-025.04" LOG_CI_END="0.5650218228685514" LOG_CI_START="-0.9589046189261543" LOG_EFFECT_SIZE="-0.1969413980288014" METHOD="MH" MODIFIED="2012-05-02 14:02:31 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.6124470421703735" Q="3.845539308882397E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="61" WEIGHT="100.00000000000001" Z="0.5065835680977281">
<NAME>Patient dissatisfaction with treatment (number of women non-compliant)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.67300756534436" CI_START="0.10992472329414438" EFFECT_SIZE="0.6354166666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5650218228685514" LOG_CI_START="-0.9589046189261543" LOG_EFFECT_SIZE="-0.1969413980288014" MODIFIED="2011-01-18 12:41:34 +0100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.8951619354677579" STUDY_ID="STD-Warner-2010" TOTAL_1="64" TOTAL_2="61" VAR="0.8013148907103824" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2404123431872664E-30" CI_END="1.0799028651017644" CI_START="0.8479861470381335" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9569444444444444" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="48" I2="100.0" I2_Q="0.0" ID="CMP-025.05" LOG_CI_END="0.033384693405951515" LOG_CI_START="-0.07161124245323683" LOG_EFFECT_SIZE="-0.019113274523642677" METHOD="MH" MODIFIED="2011-01-18 12:46:22 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.4754889396031352" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="52" WEIGHT="100.0" Z="0.7135767567843114">
<NAME>Blood loss during treatment (perceived improvement)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0799028651017644" CI_START="0.8479861470381336" EFFECT_SIZE="0.9569444444444445" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="48" LOG_CI_END="0.033384693405951515" LOG_CI_START="-0.07161124245323677" LOG_EFFECT_SIZE="-0.019113274523642625" MODIFIED="2011-01-18 12:46:22 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.061675132461951956" STUDY_ID="STD-Warner-2010" TOTAL_1="60" TOTAL_2="52" VAR="0.00380382196419932" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2011-01-25 11:33:25 +0100" MODIFIED_BY="[Empty name]" NO="26">
<NAME>Vitamin C vs Placebo (DMPA/Prophylactic)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.155172412370676" CI_START="-3.1551724123706757" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-026.01" MODIFIED="2011-01-25 11:33:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6371462375881785" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.4716925773536853">
<NAME>Bleeding during treatment (# days)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.155172412370676" CI_START="-3.1551724123706757" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-026.01.01" MODIFIED="2011-01-25 11:33:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6371462375881785" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="14" WEIGHT="100.0" Z="0.4716925773536853">
<NAME>First treatment cycle</NAME>
<CONT_DATA CI_END="5.155172412370676" CI_START="-3.1551724123706757" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="14.0" MODIFIED="2011-01-25 11:33:25 +0100" MODIFIED_BY="[Empty name]" ORDER="108" SD_1="5.0" SD_2="6.0" SE="2.120024880633596" STUDY_ID="STD-Harel-2002" TOTAL_1="13" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2013-04-22 15:49:25 +0200" MODIFIED_BY="[Empty name]" NO="27">
<NAME>Antiprogestin and matrix metalloproteinase inhibitor vs Placebo (Implanon/Therapeutic)</NAME>
<OTHER_OUTCOME COLS="5" ID="CMP-027.01" MODIFIED="2011-01-25 12:25:44 +0100" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Number of days to stop bleeding/spotting following initiation of treatment</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>Lower 95% CI</P>
</TH>
<TH>
<P>Upper 95% CI</P>
</TH>
<TH>
<P>Total</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-01-25 12:25:44 +0100" MODIFIED_BY="[Empty name]" ORDER="275" STUDY_ID="STD-Weisberg-2009">
<TR>
<TD>
<P>Antiprogestin + matrix metalloproteinase inhibitor</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>3.8</P>
</TD>
<TD>
<P>5.2</P>
</TD>
<TD>
<P>35</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>6.4</P>
</TD>
<TD>
<P>5.1</P>
</TD>
<TD>
<P>8.0</P>
</TD>
<TD>
<P>37</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7060580339772582" CI_START="0.013081019409016369" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.09610389610389611" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-027.02" LOG_CI_END="-0.15115960093084305" LOG_CI_START="-1.8833584099521685" LOG_EFFECT_SIZE="-1.0172590054415056" METHOD="MH" MODIFIED="2011-02-01 10:56:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.02133320687016399" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="37" WEIGHT="100.0" Z="2.3020348510005704">
<NAME>Continued irregular bleeding during treatment (# women)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7060580339772582" CI_START="0.013081019409016369" EFFECT_SIZE="0.09610389610389611" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.15115960093084305" LOG_CI_START="-1.8833584099521685" LOG_EFFECT_SIZE="-1.0172590054415056" MODIFIED="2011-02-01 10:56:56 +0100" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="1.0175021549415193" STUDY_ID="STD-Weisberg-2009" TOTAL_1="35" TOTAL_2="37" VAR="1.0353106353106354" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6302014509765268" CI_END="3.4199351546751666" CI_START="0.30799534262603256" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="38.65788799286261" I2_Q="38.34355617034005" ID="CMP-027.03" LOG_CI_END="0.534017871484866" LOG_CI_START="-0.5114558506654879" LOG_EFFECT_SIZE="0.011281010409689084" METHOD="MH" MODIFIED="2011-02-01 11:17:27 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.20167524799342185" P_Q="0.20282844488506868" P_Z="0.9662616728230695" Q="1.6218904917103703" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="76" TOTAL_2="78" WEIGHT="200.0" Z="0.04229733114044211">
<NAME>Side effects related to treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.555558146898951" CI_START="0.39915429769384236" DF="0" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-027.03.01" LOG_CI_END="1.0234812024669333" LOG_CI_START="-0.3988591903195928" LOG_EFFECT_SIZE="0.3123110060736703" MODIFIED="2011-02-01 11:16:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.38939235180041776" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="0.8607198768793378">
<NAME>Nausea/Vomiting</NAME>
<DICH_DATA CI_END="10.555558146898951" CI_START="0.39915429769384236" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0234812024669333" LOG_CI_START="-0.3988591903195928" LOG_EFFECT_SIZE="0.3123110060736703" MODIFIED="2011-02-01 11:16:29 +0100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.8354897874213006" STUDY_ID="STD-Weisberg-2009" TOTAL_1="38" TOTAL_2="39" VAR="0.6980431848852902" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1455895298957213" CI_START="0.03720638372172236" DF="0" EFFECT_SIZE="0.34210526315789475" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-027.03.02" LOG_CI_END="0.4977020506039488" LOG_CI_START="-1.4293825392238955" LOG_EFFECT_SIZE="-0.4658402443099734" MODIFIED="2011-02-01 11:17:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.34334507100308576" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="0.9475765684768961">
<NAME>Headache</NAME>
<DICH_DATA CI_END="3.1455895298957213" CI_START="0.03720638372172236" EFFECT_SIZE="0.34210526315789475" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4977020506039488" LOG_CI_START="-1.4293825392238955" LOG_EFFECT_SIZE="-0.4658402443099734" MODIFIED="2011-02-01 11:17:08 +0100" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="1.131979027287442" STUDY_ID="STD-Weisberg-2009" TOTAL_1="38" TOTAL_2="39" VAR="1.2813765182186234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.15008569012894438" CI_END="1.0004213276184084" CI_START="0.14074164783906343" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37523452157598497" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-027.04" LOG_CI_END="1.829417232536287E-4" LOG_CI_START="-0.8515773684484358" LOG_EFFECT_SIZE="-0.4256972133625911" METHOD="MH" MODIFIED="2011-02-01 11:38:29 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6984536393037477" P_Q="0.6984898497870518" P_Z="0.050098493974065995" Q="0.15004778873751679" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="80" WEIGHT="200.0" Z="1.9591220594478311">
<NAME>Discontinuation of contraceptive method</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.516069041765822" CI_START="0.094573557044041" DF="0" EFFECT_SIZE="0.4878048780487805" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-027.04.01" LOG_CI_END="0.4007225541208155" LOG_CI_START="-1.0242302762323243" LOG_EFFECT_SIZE="-0.3117538610557543" MODIFIED="2011-02-01 11:38:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3911082932728569" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.8576092158210665">
<NAME>Discontinuation of method at 90 days following initiation of treatment</NAME>
<DICH_DATA CI_END="2.516069041765822" CI_START="0.094573557044041" EFFECT_SIZE="0.4878048780487805" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4007225541208155" LOG_CI_START="-1.0242302762323243" LOG_EFFECT_SIZE="-0.3117538610557543" MODIFIED="2011-02-01 11:38:03 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.837024346179704" STUDY_ID="STD-Weisberg-2009" TOTAL_1="41" TOTAL_2="40" VAR="0.7006097560975609" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1147140027429412" CI_START="0.09487380159600906" DF="0" EFFECT_SIZE="0.3252032520325203" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-027.04.02" LOG_CI_END="0.047163456655172555" LOG_CI_START="-1.0228536968780437" LOG_EFFECT_SIZE="-0.48784512011143555" MODIFIED="2011-02-01 11:38:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07390772509042208" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="1.7871841816643341">
<NAME>Discontinuation of method at 180 days following initiation of treatment</NAME>
<DICH_DATA CI_END="1.1147140027429412" CI_START="0.09487380159600906" EFFECT_SIZE="0.3252032520325203" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.047163456655172555" LOG_CI_START="-1.0228536968780437" LOG_EFFECT_SIZE="-0.48784512011143555" MODIFIED="2011-02-01 11:38:29 +0100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.6285333726557448" STUDY_ID="STD-Weisberg-2009" TOTAL_1="41" TOTAL_2="40" VAR="0.39505420054200535" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2013-04-22 15:50:25 +0200" MODIFIED_BY="[Empty name]" NO="28">
<NAME>Estrogen and matrix metalloproteinase inhibitor vs Placebo (Implanon/Therapeutic)</NAME>
<OTHER_OUTCOME COLS="5" ID="CMP-028.01" MODIFIED="2011-01-25 12:28:48 +0100" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Number of days to stop bleeding/spotting following initiation of treatment</NAME>
<TR>
<TH>
<P>Treatment group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>Lower 95% CI</P>
</TH>
<TH>
<P>Upper 95% CI</P>
</TH>
<TH>
<P>Total</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2011-01-25 12:28:48 +0100" MODIFIED_BY="[Empty name]" ORDER="281" STUDY_ID="STD-Weisberg-2009">
<TR>
<TD>
<P>Estrogen + matrix metalloproteinase inhibitor</P>
</TD>
<TD>
<P>6.4</P>
</TD>
<TD>
<P>4.8</P>
</TD>
<TD>
<P>8.6</P>
</TD>
<TD>
<P>35</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>6.4</P>
</TD>
<TD>
<P>5.1</P>
</TD>
<TD>
<P>8.0</P>
</TD>
<TD>
<P>37</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5524944312675033" CI_START="0.7092073979512562" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3454545454545455" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-028.02" LOG_CI_END="0.4069648032672994" LOG_CI_START="-0.1492267427938347" LOG_EFFECT_SIZE="0.12886903023673235" METHOD="MH" MODIFIED="2011-02-01 10:57:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.36374963487101175" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="37" WEIGHT="100.0" Z="0.9082434271981414">
<NAME>Continued irregular bleeding during treatment (# women)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5524944312675033" CI_START="0.7092073979512562" EFFECT_SIZE="1.3454545454545455" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.4069648032672994" LOG_CI_START="-0.1492267427938347" LOG_EFFECT_SIZE="0.12886903023673235" MODIFIED="2011-02-01 10:57:21 +0100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.3267096673488661" STUDY_ID="STD-Weisberg-2009" TOTAL_1="35" TOTAL_2="37" VAR="0.10673920673920673" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1046438588749243" CI_END="3.0319080385736883" CI_START="0.2345253082312779" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8432432432432433" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="9.473085649659405" I2_Q="8.881350839338204" ID="CMP-028.03" LOG_CI_END="0.48171602448452844" LOG_CI_START="-0.6298102845816329" LOG_EFFECT_SIZE="-0.07404713004855218" METHOD="MH" MODIFIED="2011-02-01 11:12:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.29324973638335383" P_Q="0.2948224538944888" P_Z="0.7939877127941902" Q="1.097470176754689" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="78" WEIGHT="200.0" Z="0.26113589371653345">
<NAME>Side effects related to treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.933785460996226" CI_START="0.2798161424254484" DF="0" EFFECT_SIZE="1.5810810810810811" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-028.03.01" LOG_CI_END="0.9510355189636429" LOG_CI_START="-0.553127234933272" LOG_EFFECT_SIZE="0.19895414201518546" MODIFIED="2011-02-01 11:10:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6041198878344687" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="39" WEIGHT="100.0" Z="0.5184850534486174">
<NAME>Nausea/Vomiting</NAME>
<DICH_DATA CI_END="8.933785460996226" CI_START="0.2798161424254484" EFFECT_SIZE="1.5810810810810811" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9510355189636429" LOG_CI_START="-0.553127234933272" LOG_EFFECT_SIZE="0.19895414201518546" MODIFIED="2011-02-01 11:10:47 +0100" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.8835526473647627" STUDY_ID="STD-Weisberg-2009" TOTAL_1="37" TOTAL_2="39" VAR="0.7806652806652806" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.228616600094923" CI_START="0.03823550064532015" DF="0" EFFECT_SIZE="0.35135135135135137" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-028.03.02" LOG_CI_END="0.5090164753828386" LOG_CI_START="-1.4175332189031549" LOG_EFFECT_SIZE="-0.4542583717601582" MODIFIED="2011-02-01 11:10:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3553436045806566" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="39" WEIGHT="100.0" Z="0.9242741580623342">
<NAME>Headache</NAME>
<DICH_DATA CI_END="3.2286166000949237" CI_START="0.038235500645320136" EFFECT_SIZE="0.35135135135135137" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5090164753828387" LOG_CI_START="-1.417533218903155" LOG_EFFECT_SIZE="-0.4542583717601582" MODIFIED="2011-02-01 11:10:02 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="1.1316648269983833" STUDY_ID="STD-Weisberg-2009" TOTAL_1="37" TOTAL_2="39" VAR="1.2806652806652807" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17123998926076842" CI_END="2.316159117311251" CI_START="0.6224968216264377" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2007504690431519" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-028.04" LOG_CI_END="0.36476839158239543" LOG_CI_START="-0.20586286166776574" LOG_EFFECT_SIZE="0.07945276495731486" METHOD="MH" MODIFIED="2011-02-01 11:36:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6790124132553998" P_Q="0.6798883520343457" P_Z="0.5852051393787454" Q="0.170251848387347" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="80" WEIGHT="200.0" Z="0.5457975072395642">
<NAME>Discontinuation of contraceptive method</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.799808576850949" CI_START="0.44618079182622666" DF="0" EFFECT_SIZE="1.4634146341463414" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-028.04.01" LOG_CI_END="0.6812239174432809" LOG_CI_START="-0.35048913011546456" LOG_EFFECT_SIZE="0.16536739366390812" MODIFIED="2011-02-01 11:34:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5298055537271458" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.6283028727133785">
<NAME>Discontinuation of method at 90 days following initiation of treatment</NAME>
<DICH_DATA CI_END="4.799808576850949" CI_START="0.44618079182622666" EFFECT_SIZE="1.4634146341463414" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6812239174432809" LOG_CI_START="-0.35048913011546456" LOG_EFFECT_SIZE="0.16536739366390812" MODIFIED="2011-02-01 11:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.6060333511979581" STUDY_ID="STD-Weisberg-2009" TOTAL_1="41" TOTAL_2="40" VAR="0.36727642276422756" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3841871968514323" CI_START="0.4928637747171599" DF="0" EFFECT_SIZE="1.084010840108401" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" ID="CMP-028.04.02" LOG_CI_END="0.37734035147419887" LOG_CI_START="-0.3072731011363949" LOG_EFFECT_SIZE="0.03503362516890198" MODIFIED="2011-02-01 11:33:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8410161229634121" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.20059390687427847">
<NAME>Discontinuation of method at 180 days following initiation of treatment</NAME>
<DICH_DATA CI_END="2.3841871968514323" CI_START="0.4928637747171599" EFFECT_SIZE="1.084010840108401" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.37734035147419887" LOG_CI_START="-0.3072731011363949" LOG_EFFECT_SIZE="0.03503362516890198" MODIFIED="2011-02-01 11:33:17 +0100" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.40214533095470856" STUDY_ID="STD-Weisberg-2009" TOTAL_1="41" TOTAL_2="40" VAR="0.1617208672086721" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" MODIFIED="2013-04-22 15:50:25 +0200" MODIFIED_BY="[Empty name]" NO="29">
<NAME>Estrogen vs placebo (LNG-IUS/Prophylactic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-029.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-01-02 09:58:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Discontiuation of the contraceptive method</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.131350376360228" CI_START="0.06311809321150688" EFFECT_SIZE="0.9772727272727273" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1798776877609272" LOG_CI_START="-1.1998461295741287" LOG_EFFECT_SIZE="-0.009984220906600895" MODIFIED="2013-01-02 09:57:00 +0100" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="1.3978615501254903" STUDY_ID="STD-Madden-2012" TOTAL_1="44" TOTAL_2="43" VAR="1.9540169133192389" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-029.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-01-02 09:49:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Side effects related to treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.08142337334066" CI_START="0.12277782085855314" EFFECT_SIZE="2.933333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.845602913892187" LOG_CI_START="-0.910880079031175" LOG_EFFECT_SIZE="0.46736141743050613" MODIFIED="2013-01-02 09:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="1.6191717548540585" STUDY_ID="STD-Madden-2012" TOTAL_1="44" TOTAL_2="43" VAR="2.6217171717171714" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-029.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-01-02 09:54:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="44" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Discontinuation of treatment because of side effects</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.08142337334066" CI_START="0.12277782085855314" EFFECT_SIZE="2.933333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.845602913892187" LOG_CI_START="-0.910880079031175" LOG_EFFECT_SIZE="0.46736141743050613" MODIFIED="2013-01-02 09:52:59 +0100" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="1.6191717548540585" STUDY_ID="STD-Madden-2012" TOTAL_1="44" TOTAL_2="43" VAR="2.6217171717171714" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5446809334984344" CI_END="9.376769763786745" CI_START="1.663444461154725" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.9493968814357165" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-029.04" LOG_CI_END="0.9720532525181517" LOG_CI_START="0.22100830528497906" LOG_EFFECT_SIZE="0.5965307789015654" METHOD="MH" MODIFIED="2013-01-02 10:08:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4604993337465645" P_Q="0.47201513981964427" P_Z="0.0018489982766525083" Q="0.5172547681113089" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="87" TOTAL_2="82" WEIGHT="200.0" Z="3.11347236040643">
<NAME>Patient dissatisfaction with treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.207169638909296" CI_START="1.3452282595188163" DF="0" EFFECT_SIZE="3.3227272727272728" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" I2="0.0" ID="CMP-029.04.01" LOG_CI_END="0.914193410209017" LOG_CI_START="0.12879598206229162" LOG_EFFECT_SIZE="0.5214946961356542" MODIFIED="2013-01-02 10:01:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.009246957920290108" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="100.0" Z="2.6027862733555946">
<NAME>At 4 weeks</NAME>
<DICH_DATA CI_END="8.207169638909296" CI_START="1.3452282595188163" EFFECT_SIZE="3.3227272727272728" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.914193410209017" LOG_CI_START="0.12879598206229162" LOG_EFFECT_SIZE="0.5214946961356542" MODIFIED="2013-01-02 10:01:34 +0100" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.4613463370733571" STUDY_ID="STD-Madden-2012" TOTAL_1="44" TOTAL_2="43" VAR="0.2128404427310036" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="175.17824030469552" CI_START="0.5708471544528901" DF="0" EFFECT_SIZE="10.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-029.04.02" LOG_CI_END="2.24348015946622" LOG_CI_START="-0.2434801594662199" LOG_EFFECT_SIZE="1.0" MODIFIED="2013-01-02 10:08:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.11498146807203513" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="39" WEIGHT="100.0" Z="1.576192406142929">
<NAME>At 12 weeks</NAME>
<DICH_DATA CI_END="175.17824030469552" CI_START="0.5708471544528901" EFFECT_SIZE="10.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.24348015946622" LOG_CI_START="-0.2434801594662199" LOG_EFFECT_SIZE="1.0" MODIFIED="2013-01-02 10:08:20 +0100" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="1.4608528019930376" STUDY_ID="STD-Madden-2012" TOTAL_1="43" TOTAL_2="39" VAR="2.134090909090909" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" MODIFIED="2013-01-02 10:24:44 +0100" MODIFIED_BY="[Empty name]" NO="30">
<NAME>NSAIDs VS Placebo (LNG IUS/prophylactic)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-01-02 10:17:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Discontinuation of the contraceptive method</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.740436467838126" CI_START="0.19285462692411448" EFFECT_SIZE="2.0476190476190474" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3372682588703688" LOG_CI_START="-0.7147699371790345" LOG_EFFECT_SIZE="0.3112491608456672" MODIFIED="2013-01-02 10:17:13 +0100" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="1.205377394112312" STUDY_ID="STD-Madden-2012" TOTAL_1="42" TOTAL_2="43" VAR="1.4529346622369879" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-030.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-01-02 10:19:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Side effects related to treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.29515452401557" CI_START="0.12856882843488493" EFFECT_SIZE="3.0697674418604652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.865075264777015" LOG_CI_START="-0.8908643135244886" LOG_EFFECT_SIZE="0.4871054756262634" MODIFIED="2013-01-02 10:19:10 +0100" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="1.6188525504152331" STUDY_ID="STD-Madden-2012" TOTAL_1="42" TOTAL_2="43" VAR="2.620683579985905" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-030.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-01-02 10:20:56 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Discontinuation of treatment due to side effects</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.29515452401557" CI_START="0.12856882843488493" EFFECT_SIZE="3.0697674418604652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.865075264777015" LOG_CI_START="-0.8908643135244886" LOG_EFFECT_SIZE="0.4871054756262634" MODIFIED="2013-01-02 10:20:56 +0100" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="1.6188525504152331" STUDY_ID="STD-Madden-2012" TOTAL_1="42" TOTAL_2="43" VAR="2.620683579985905" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6838885964770673" CI_END="4.506368944540788" CI_START="0.5839471431563679" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6221841052029728" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="62.740629349794084" I2_Q="58.91421612705063" ID="CMP-030.04" LOG_CI_END="0.6538267453147607" LOG_CI_START="-0.23362646191912723" LOG_EFFECT_SIZE="0.2101001416978167" METHOD="MH" MODIFIED="2013-01-02 10:24:44 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.10136799116975281" P_Q="0.1187349639353582" P_Z="0.353395396334901" Q="2.433931899881297" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="82" WEIGHT="200.0" Z="0.9280234890535611">
<NAME>Patient dissatisfaction with treatment</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.842022434336398" CI_START="0.2360428243502631" DF="0" EFFECT_SIZE="0.819047619047619" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-030.04.01" LOG_CI_END="0.453627501835662" LOG_CI_START="-0.6270091974884028" LOG_EFFECT_SIZE="-0.08669084782637036" MODIFIED="2013-01-02 10:22:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.753168275446496" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="43" WEIGHT="100.0" Z="0.3144644997439143">
<NAME>At 4 weeks</NAME>
<DICH_DATA CI_END="2.842022434336399" CI_START="0.23604282435026305" EFFECT_SIZE="0.819047619047619" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4536275018356621" LOG_CI_START="-0.6270091974884029" LOG_EFFECT_SIZE="-0.08669084782637036" MODIFIED="2013-01-02 10:22:58 +0100" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.6347713464208887" STUDY_ID="STD-Madden-2012" TOTAL_1="42" TOTAL_2="43" VAR="0.4029346622369879" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="179.3649796098149" CI_START="0.557522433964183" DF="0" EFFECT_SIZE="10.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-030.04.02" LOG_CI_END="2.253737652493564" LOG_CI_START="-0.25373765249356384" LOG_EFFECT_SIZE="1.0" MODIFIED="2013-01-02 10:24:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1179828148168029" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="39" WEIGHT="100.0" Z="1.5632967396662882">
<NAME>At 12 weeks</NAME>
<DICH_DATA CI_END="179.3649796098149" CI_START="0.5575224339641828" EFFECT_SIZE="10.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.253737652493564" LOG_CI_START="-0.253737652493564" LOG_EFFECT_SIZE="1.0" MODIFIED="2013-01-02 10:24:44 +0100" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="1.4729034063523803" STUDY_ID="STD-Madden-2012" TOTAL_1="35" TOTAL_2="39" VAR="2.1694444444444447" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-04-22 16:07:34 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-04-22 16:07:34 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAACcCAMAAACa91sKAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-04-22 16:07:34 +0200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAQMAAAT4CAIAAACT3jDhAAA6MklEQVR42u2dvW5TTdeGt4SEKFyk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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-01-06 10:32:52 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-01-06 10:32:52 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-01-06 10:32:20 +0100" MODIFIED_BY="[Empty name]">Appendix A: Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-06 10:32:52 +0100" MODIFIED_BY="[Empty name]">
<P>Pubmed</P>
<P>(progestational hormones, synthetic or progesterone or contraceptives, oral, synthetic or contraceptives, oral , hormonal or progestational hormones or gestagen or progestogen only contracept* or progestin only contracept*) and (uterine, hemorrhage or amenorrhea or (vagina* near (bleed* or haemorrhag* or hemorrhag* or blood loss)) or ((uterus or uterine) near (bleed* or haemorrhag* or hemorrhag* or blood loss)) or spotting or ((irregular or prolonged or frequent or persistent or unpredictable or unscheduled or abnormal or breakthrough) near (bleed* or menstrual* or menses or blood loss or period or periods or haemorrhag* or hemorrhag*)) or menstrual disturbance* or menstrual disorder)</P>
<P>limited to Publication date From 2009/05/27 to 2012/05/24</P>
<P>
<BR/>
</P>
<P>Pubmed</P>
<P>(progestational hormones, synthetic or progesterone or progestin or contraceptives, oral, synthetic or contraceptives, oral , hormonal</P>
<P>or "progestational hormones" or gestagen or "progestogen only "contracept* or "progestin only" contracept* or progestogen*</P>
<P>or norgestrienone or norgestrel or ogyline or microlut or microval or mirena or norplant or levonova or microlutin or follistrel</P>
<P>or neogest or norgeston or postinor-2 or ovrette or velonorgestrel or norgestimate or "nomegestrol acetate" or "norethisterone acetate"</P>
<P>or "norethiserone enanthate" or "norethisterone enantate" or micronovum or primolut-nor or ocilan or micronor or noriday or norlutate</P>
<P>or milligynon or norfor or noristerat or norluten or gestakadin or sovel or conludag or nur-isterate or mini-pe or menzol or primolut-N</P>
<P>or sh420 or utovlan or aygestin or nor-qd or medroxyprogesterone acetate or depo-provera or depocon or farlutal or prodafem</P>
<P>or provera or depo-ralovera or ralovera or depo-prodasone or gestoral or prodasone or clinofem or clinovir or depo-clinovir or</P>
<P>g-farlutal or lutoral or perlutex or petogen or depo-progevera or progevera or cykrina or gestapuran or prodafem or amen or</P>
<P>curretab or cycrin or lynoestrenol or lynestrenol or orgametril or exluton or exlutona or exlutena or gestodene or etonogestrel or</P>
<P>implanon or ethynodiol diacetate or etynodiol or lutometrodiol or luteonorm or femulen or drospirenone or desogestrel or</P>
<P>dienogest or demegestone or lutionex or c"yproterone acetate" or andro-diane or androcur or cyprone or cyprostat or</P>
<P>chlormadinone or luteran or gestafortin or prostal or algestone or acetophenide or neolution depositum</P>
<P>or levonorgestrel OR Intrauterine devices, medicated OR levonorgestrel intrauterine device OR levonorgestrel intrauterine system OR levonorgestrel releasing intrauterine device OR levonorgestrel releasing intrauterine system) and (uterine, hemorrhage or amenorrhea or (vagina* near(bleed* or haemorrhag* or hemorrhag* or blood loss)) or ((uterus or uterine) near (bleed* or haemorrhag* or hemorrhag* or blood loss)) or spotting or ((irregular or prolonged or frequent or persistent or unpredictable or unscheduled or abnormal or breakthrough) near (bleed* or menstrual* or menses or blood loss or period or periods or haemorrhag* or hemorrhag*)) or menstrual disturbance* or menstrual disorder)</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>Popline</P>
<P>
<BR/>
</P>
<P>title/keyword- (progestin only contracept*/ progesterone only contracept*/oral contraceptives low dose/ progestins low dose/(contraceptive agents &amp; (progestin*/progesterone*))/progestogne*/norgestrienone/norgestrel/ogyline/microlut/microval/mirena/norplant/levonova/microlutin/follistrel/neogest/norgeston/postinor-2/ovrette/velonorgestrel/norgestimate/nomegestrol acetate/norethisterone acetate/norethiserone enanthate/norethisterone enantate/micronovum/primolut-nor/ocilan/micronor/noriday/norlutate/milligynon/norfor/noristerat/norluten/gestakadin/sovel/conludag/nur-isterate/mini-pe/menzol/primolut-N/sh420/utovlan/aygestin/nor-qd/medroxyprogesterone acetate/depo-provera/depocon/farlutal/prodafem/provera/depo-ralovera/ralovera/depo-prodasone/gestoral/prodasone/clinofem/clinovir/depo-clinovir/g-farlutal/lutoral/perlutex/petogen/depo-progevera/progevera/cykrina/gestapuran/prodafem/amen/curretab/cycrin/lynoestrenol/lynestrenol/orgametril/exluton/exlutona/exlutona/exlutena/gestodene/etonogestrel/implanon/ethynodiol diacetate/etynodiol/lutometrodiol/luteonorm/femulen/drospirenone/desogestrel/dienogest/demegestone/lutionex/cyproterone acetate/andro-diane/androcur/cyprone/cyprostat/chlormadinone/luteran/gestafortin/gestafortin/prostal/algestone/acetophenide/neolution depositum) &amp; (bleed*/ menstruation disorders/haemorrhage/hemorrhage/spotting) &amp; treat*</P>
<P>OR</P>
<P>abstract - (progestin only contracept*/ progesterone only contracept*/oral contraceptives low dose/ progestins low dose/(contraceptive agents &amp; (progestin*/progesterone*))/progestogne*/norgestrienone/norgestrel/ogyline/microlut/microval/mirena/norplant/levonova/microlutin/follistrel/neogest/norgeston/postinor-2/ovrette/velonorgestrel/norgestimate/nomegestrol acetate/norethisterone acetate/norethiserone enanthate/norethisterone enantate/micronovum/primolut-nor/ocilan/micronor/noriday/norlutate/milligynon/norfor/noristerat/norluten/gestakadin/sovel/conludag/nur-isterate/mini-pe/menzol/primolut-N/sh420/utovlan/aygestin/nor-qd/medroxyprogesterone acetate/depo-provera/depocon/farlutal/prodafem/provera/depo-ralovera/ralovera/depo-prodasone/gestoral/prodasone/clinofem/clinovir/depo-clinovir/g-farlutal/lutoral/perlutex/petogen/depo-progevera/progevera/cykrina/gestapuran/prodafem/amen/curretab/cycrin/lynoestrenol/lynestrenol/orgametril/exluton/exlutona/exlutona/exlutena/gestodene/etonogestrel/implanon/ethynodiol diacetate/etynodiol/lutometrodiol/luteonorm/femulen/drospirenone/desogestrel/dienogest/demegestone/lutionex/cyproterone acetate/andro-diane/androcur/cyprone/cyprostat/chlormadinone/luteran/gestafortin/gestafortin/prostal/algestone/acetophenide/neolution depositum) &amp; (bleed*/ menstruation disorders/haemorrhage/hemorrhage/spotting) &amp; treat*</P>
<P>disorders/haemorrhage/hemorrhage/spotting) &amp; treat*</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>
<BR/>
</P>
<P>Embase</P>
<P>
<BR/>
</P>
<P>s gestagen</P>
<P>s progestational hormones, synthetic</P>
<P>s progesterone</P>
<P>s low dose oral contraceptive</P>
<P>s progestin(n)only or progesterone(n)only or progestogen(n)only and contracep?</P>
<P>s progestin(n)only or progesterone(n)only or progestogen(n)only) and oral contraceptive agent</P>
<P>s (progestin(n)only or progesterone(n)only or progestogen(n)only) and oral contraceptive agent</P>
<P>s s1 or s2 or s3 or s4 or s6</P>
<P>s uterus bleeding</P>
<P>s amenorrhea</P>
<P>s (uterus or uterine)(n)(bleed? or haemorrhag? or hemorrhag? or "blood loss)</P>
<P>s (uterus or uterine)(n)(bleed? or haemorrhag? or hemorrhag? or "blood loss")</P>
<P>s spotting</P>
<P>s (irregular or prolonged or frequent or persistent or unpredictable or unscheduled or abnormal or breakthrough)(n)(bleed? or menstrual? or menses or "blood loss" or period or periods or haemorrhag? or hemorrhag?)</P>
<P>s menstrual disorder</P>
<P>s menstruation disorder</P>
<P>s menstrual irregularity</P>
<P>s s8 or s9 or s11 or s12 or s13 or s14 or s15 or s16</P>
<P>s levonorgestrel</P>
<P>s lng ius</P>
<P>s s7 or s18 or s19</P>
<P>s s17 and s20</P>
<P>e clinical trial</P>
<P>e e3</P>
<P>s r1, r3:r10</P>
<P>s random? or allocat?</P>
<P>s s22 or s23</P>
<P>s s21 and s24</P>
<P>s s25 and pd=20090706:20120613</P>
<P>
<BR/>
</P>
<P>Central</P>
<P>(progest* only contracept* or oral contraceptives low dose or progestins low dose or levonorgestrel or "LNG IUS" or levonorgestrel IUS or levonorgestrel NEAR/1 releasing or levonorgestrel IUD) AND (bleed* or menstruation disorders or haemorrhage or hemorrhage or spotting) AND treat*</P>
<P>
<BR/>
</P>
<P>LILACS</P>
<P>progest* or progestinas or progestogens or progesterona or gestagen or levonorgestrel or levanogestrel [Words] and bleeding or sangria or sangramento or haemorrhage or hemorrhage or hemorragia or hemorragia uterina or menstrual or amenorrhea or amenorrea or amenorreia [Words]</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>